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Abstract 
Title: Outcomes of infants starting Antiretroviral Therapy (ART) in Southern Africa. 
Background and Rationale: Within the global burden of the Human Immune 
Deficiency Virus (HIV) stands a distinct group – HIV infected infants. They are a 
physically, physiologically, developmentally and socially vulnerable group who 
differ considerably from their adult and child HIV infected counterparts. 
Distinguished in part by their multiple age-specific complexities in testing, treatment 
and monitoring these infants ultimately experience accelerated disease progression 
and an increased risk of morbidity and mortality. Advances in evidence gained from 
trials of the benefits of early initiation of ART in infants have resulted in 
international treatment guidelines changes and an increase in velocity and coverage 
of infant ART provision. However, there is limited published data on the outcomes 
of infants starting ART in routine care in Southern Africa.  
Objectives: To describe the baseline characteristics of infants starting first line ART 
in routine care setting in Southern Africa. To describe and examine the outcomes of 
these infants including clinical, immunological and virological responses and to 
identify the determinants for these outcomes.   
Method: A retrospective analysis was performed of prospectively collected cohort 
data of infants that initiated ART in routine care settings at the International 
Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) 
collaborative sites. A description of demographic, clinical, laboratory and program 
baseline characteristics is provided and longitudinal profiles of response variables are 
described. The Kaplan-Meier method was used to assess time to outcomes of 
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mortality and virological outcome. Cox Proportional Hazards models identified those 
baseline characteristics associated with each of these outcomes. Competing Risk 
Analysis provides Cumulative Incidence Functions for mortality and programmatic 
outcomes.  Multiple imputation was conducted and Rubin’s Rules provided pooled 
estimates from Survival Analysis. 
Part A: The study protocol as submitted for Departmental and Ethical Approval is 
presented here. It includes the background, rationale and methodology of the 
research done for this mini-dissertation.  
Part B: A structured literature review is presented of articles pertaining to 
observational research conducted in Sub-Saharan Africa on the outcomes of infants 
initiating antiretroviral therapy.  
Part C: Here a journal-ready manuscript according to the requirements of the 
Pediatric Infectious Disease Journal (author’s information included as Appendix F) 
is presented.  
Appendices: Includes all additional documentation necessary as addendums in the 
presentation of the above parts of the mini-dissertation.   
Results: 4945 infants initiated ART at a median (IQR) age of 5.9 months (3.7-8.7) 
and were followed for a median (IQR) of 11.2 months (2.8-20.0). At initiation of 
ART 77% of infants were classified as World Health Organisation (WHO) clinical 
stage 3 or 4 and 87% met the 2006 WHO definition of severe immunosuppression.  
3-year mortality probability was over 15% and Loss to Follow-up (LTFU) 29%. 
Severe immune suppression (adjusted Hazard ratio (aHR) 2.19, 95%CI 1.44-3.33), 
WHO stage 3/4 (aHR 1.36, 95% CI 1.04-1.78), lower weight-for-age z-score (WAZ 
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<-3 compared to >-2 aHR 2.34, 95%CI 1.78-2.80) and initiation of ART in 2010 or 
after (aHR 0.75, 95%CI 0.59-0.94) were each found to be independently associated 
with mortality.  The proportion of infants attaining virological suppression by 12 
months was 56.1% (95% Confidence Interval (CI) 53.2-59.1). A viral load of 1 
million copies/ml or above was found to be associated with a longer time to 
virological suppression (aHR 0.78, 95% CI 0.68-0.89).  
Conclusion: Amongst infants initiating ART in Southern Africa between 2004 and 
2012 there was a predominance of severe baseline disease severity. Infant 
immunological and virological responses were suboptimal and high levels of loss to 
follow up and mortality were seen. 
The Vancouver referencing style has been used for Part A and B of this mini-
dissertation however, in keeping with the instructions for authors as stipulated by the 
Pediatric Infectious Disease Journal, Part C: the Journal Ready Manuscript includes 
references in the style of the United Stated National Library of Medicine.  
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Introduction  
Background  
Epidemiology of Infant HIV 
Of the 34 million people worldwide estimated to be living with Human Immune 
Deficiency Virus (HIV), 90% are living in Sub-Saharan Arica and 10% are children 
less than 15 years of age (1, 2). Despite advances in Prevention of Mother to Child 
Transmission (PMTCT) programs, including possible reduction of infection to as low 
as 1% (7) and a global coverage of 56% (8), over 900 infants are infected with HIV 
every day (9).  HIV infected infants form a distinct group whose risks and 
management needs distinguish them from their adult and child counterparts (1-3). 
Within this period of rapid physical growth (especially of their developing brain), 
establishment of a functioning immune system and a rapidly changing physiology, 
these infants are severely vulnerable to the multiple insults of HIV and its 
complications (10). The natural history of the disease itself differs significantly in 
infancy where there is a far more rapid progression to severe disease stages and death 
(4).  Untreated HIV infection in infancy is associated with serious morbidity from 
opportunistic infections and associated organ damage including HIV encephalopathy 
and its adverse permanent neurodevelopmental effects (11). 
In Southern Africa HIV related illnesses account for between 10 and 28% of under-5 
mortality (1, 9, 12). Furthermore in low and middle income countries, such as within 
this region, without antiretroviral therapy (ART) this infant group has up to a 30% 
risk of death in their first year of life and 50% by the age of two years (13).  This 
increased risk and vulnerability of the infant subgroup occurs within an environment 
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that is complicated by concerns relating to PMTCT ART exposure and the provision, 
administration and monitoring of ART. Additionally these factors interact in an age 
group known for their unpredictable, variable and rapidly changing physiology (3, 4, 
14-18). 
Support from Literature 
The uniqueness, vulnerability and need for research of infants infected with HIV 
have been noted by several studies. A 2003 Meta-Analysis of trials in Europe and 
United States of America (USA) of prognostic markers in HIV Paediatric care 
highlighted the need to view infants as a distinct group with regards to HIV and its 
care and management. In this study it was found that when comparing infants to 5 
year olds with similar T cell cluster of differentiation 4 (CD4) levels infants had a 6 
fold increase in the risk of death (5, 16). Soon followed by several observational 
studies, this evidence contributed to an emerging understanding of the possible 
inappropriateness of applying standardised childhood clinical, immunological and 
virological markers of disease progression to the infant subgroup and in doing so 
emphasised a need for an improved strategy for treatment initiation (19, 20). In 2004 
results from a small  open-label phase 1-2  trial by Luzuriaga et al provided evidence 
of  the long term virological benefits of early initiation of infants under 3 months of 
age (21). In addition to these improved physiological outcomes, early initiation of 
ART in infants was supported by observational evidence that showed that in keeping 
with the 2006 World Health Organisation (WHO) immunological criteria for 
initiation, 85% of HIV positive infants would require ART by 6 months of age (21, 
22). The practical and programmatic benefits of early initiation included  economic 
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viability in view of monitoring costs, minimization of loss to follow up and 
prevention of immunological decline  (22).   
Amongst this resounding call for definitive evidence and guideline amendment  in 
2008 a randomised control trial in South Africa - the Children with Human Immune 
Deficiency Virus Early Antiretroviral Therapy Trial (CHER) reported compelling 
evidence in support of early treatment of infants (5). This trial quantified the benefits 
of early initiation of ART before 12 weeks of age compared to deferring ART until 
WHO 2006 treatment initiation criteria were met and showed a 76% reduction in 
mortality and 75% reduction in disease progression in the early treatment group. 
Subsequent substudy analyses have shown specific benefits of early initiation 
regarding short-term neurodevelopmental outcomes, (23) nutrition and growth (24). 
These findings resulted in with rapid changes to national and global infant ART 
guidelines in 2008  calling for all HIV infected infants under the age of 12 months to 
be commenced on ART regardless of clinical or immunological factors (25). 
Subsequently 2010 and 2013 guidelines amended this guideline to all children under 
2 and under 5 years of age respectively (26, 27). 
What further evidence is required? 
The CHER trial was successful in quantifying the impact of early initiation of ART 
in a controlled trial environment with an average age of commencement of ART of 7 
weeks, complete availability of appropriate laboratory testing and drug regimens that 
were all protease inhibitor based, minimisation of loss to follow up and the exclusion 
of those with comorbid conditions. The possible  impact of these highly favourable 
conditions on the magnitude of the beneficial association of early initiation on infant 
outcomes leads to a concern about the generalizability of these outcomes to infants 
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receiving care in routine settings particularly those within resource-scarce regions 
such as Southern Africa (28). This ‘routine-setting’ is  characterised by concerns of 
delayed HIV diagnostic and missed testing, poor follow up, non-adherence, limited 
resources and restricted laboratory access further complicated by the social, 
diagnostic, monitoring and treatment needs of infants (3, 17, 18, 29, 30). Early 
initiation cannot occur without early testing and across sub-Saharan Africa only an 
estimated 28% of HIV exposed infants receive testing prior to 2 months of age, 
highlighting the need for better access to Polymerase Chain Reaction (PCR) HIV 
testing and PMTCT linkages (30-33). With HIV-related infant mortality peaking at 
2-3 months of age these testing delays, coupled with an average test-to-start interval 
of 33 days, have the potential to result in poor outcomes (34-36).  
In 2010 in light of insufficient treatment options,  a paucity of policy and research 
and a widening gap in coverage rates of ART for children and adults – 28% 
compared to 56% -  (9, 15, 29) the Drugs for Neglected Disease Initiative (DNDi) 
recognised paediatric HIV as a  neglected disease (3).This extremely high risk 
population, (17, 37) with a severe imbalance between needs and provision of care, 
not only require evidence based management to save lives but also to “build them a 
body that lasts a lifetime” as each life saved adds to the evolution of HIV into a 
chronic disease (10, 38). 
Problem Statement and Research Question 
Within the context of a severe burden of HIV and the rapid escalation of coverage of 
ART provision in Southern Africa evidence is needed regarding the routine care 
practices and outcomes of infants initiating ART.  Such evidence is necessary not 
only to monitor the implementation of guidelines and evaluate their impact but also 
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to identify predictors of these outcomes in order to inform program development and 
improvement (39-41).  There is however limited data on the outcomes of infants 
starting ART in routine care in resource scarce settings. Previously published studies, 
including those discussed here, lack power due to very small sample sizes, an often 
limited observational period and having been designed for other specific outcomes 
such as resistance (18, 19, 42-45). 
This problem leads to the question: “What are the outcomes of infants starting ART 
in routine care in Southern Africa?” and “What are the predictors of these 
outcomes?”  
Rationale for proposed study 
Funded by the National Institutes of Allergy and Infectious Diseases (NIAID), the 
International Epidemiology Databases to evaluate AIDS (IeDEA) is an international 
initiative that pools several large data sets each comprised of HIV infected 
individuals enrolled in standard care at participating sites (40, 46, 47).  With data 
collected from routine clinical records in a region that is home to over a third of all 
people living with HIV (1) the IeDEA-Southern Africa (IeDEA-SA)  database offers 
the opportunity to review the extent of implementation of the WHO 2010 guidelines 
with respect to immediate infant ART initiation and to examine the outcomes and 
their determinants for infants starting ART in these routine settings. The use of the 
IeDEA-SA infant ART cohort for this study will thus add to the current limited 
evidence and knowledge of the outcomes of infants starting ART in routine settings 
in Southern Africa. Further information including other research objectives of 
IeDEA-SA can be found on their website at www.iedea-hiv.org.  
Outcomes of Infants starting ART in Southern Africa                                                                 Protocol                   
 
 
8 
 
Study Objectives 
The following objectives have been identified for purposes of the study: 
1 To describe the baseline characteristics of infants commencing ART in IeDEA 
sites in Southern Africa. These characteristics include demographic, 
programmatic and both clinical and chemical markers of HIV disease severity 
(Virological, Immunological markers where available). 
2 To describe and examine the outcomes of infants starting ART in Southern 
Africa. These outcomes include repeated measures and their change over time as 
well as final outcomes of death, Loss to Follow Up and Transfer Out.  
3 To identify and examine predictors for these outcomes. 
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Methodology 
Study design 
This study will be a retrospective analysis of prospectively collected cohort data of 
infants that initiated ART in routine care settings at the IeDEA-SA collaborative 
sites. Data for this cohort is collected through routine clinical follow up of these 
infants within the standard treatment and monitoring of HIV and ART.  
Population and sampling  
Characteristics of study population 
The IeDEA-SA collaboration includes sites from South Africa, Zimbabwe, 
Mozambique, Malawi, Botswana and Zambia (39).  There are approximately 5000 
infants who have initiated ART before the age of 12 months amongst 11 participating 
sites.  Data recorded between 2004 and end of 2012 will be included in the analysis.  
Inclusion and Exclusion Criteria 
IeDEA requires participating sites to be facilities that treat those living with HIV and 
prospectively collect data in an electronic format (39). Data are captured for all those 
attending the facility with a documented HIV-1 infection and for whom the date of 
first visit at the facility is known exactly as per the IeDEA-SA Data Transfer 
Protocol (DTP) (Appendix A). 
 
 
Outcomes of Infants starting ART in Southern Africa                                                                 Protocol                   
 
 
10 
 
For purposes of this study sites and participants included in this study are required to 
meet the following eligibility criteria:  
 Sites included require provision of ART for infants (<1 year old) (at least a 
portion of  which  initiated ART since 1 January 2010 as this would ensure that 
each cohort captured a portion of infants initiated after the release of the WHO 
2010 guidelines) 
 Infants who are HIV infected (recorded PCR diagnosis or presumptive diagnosis) 
and ART naïve at their first visit (except for PMTCT exposure).  
 Infants who initiated a minimum of three antiretroviral drugs on a recorded date 
before their first birthday.  
Exclusion criteria for infants 
All infants with missing information on key variables e.g. date of birth, gender and 
date of initiation will be excluded from the analysis. 
Infants identified as being virologically suppressed (HIV-RNA <400 copies/ml) at 
initiation will be excluded from analysis as this suggests that they may be non-naïve 
to ART.  
Sampling  
All infants meeting eligibility criteria will be included in the study therefore no 
sample size calculation has been done. 
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Measurement 
Research Procedures and Data Collection Methods 
Data routinely recorded from participants at every clinic visit are collected on site by 
site investigators. Data includes baseline and follow up visit data. Data from each site 
is anonymised and transferred to IeDEA-SA using a Data Transfer Protocol 
(Appendix A).  The anonymised data from each of the sites are converted to 
Structured Query Language (SQL) format, stored, cleaned, merged and analysed (46, 
48).  
Variables for inclusion 
Infant characteristics at baseline initiation of ART 
This shall include demographic data of the individual as well as information of 
PMTCT exposure, anthropometric measures, clinical, immunological and virological 
markers of disease severity and details of treatment timing and medications. Table 1. 
Outcomes  
The primary outcomes of this study are death, loss to follow up (LTFU) and transfer 
out (TFO).  Dates of these outcomes shall be recorded. Table 2. Longitudinal 
response variables as recorded at subsequent dated follow up visits shall include 
immunological, virological and growth characteristics of those remaining in care. 
Table 3. 
Third Variables 
Potential confounders for the different predictor-response relationships such as age 
and gender will be included in the IeDEA database data extraction process.   
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Dummy Tables 
Table 1: Infant and program characteristics at initiation of ART 
Variable Format Description 
Patient Identifier Text and numeric 
Unique, anonymous, patient 
identifier 
Cohort Categorical* Treatment site 
Age at initiation of ART Numerical Age in months at ART initiation 
Gender Categorical, binary Male or Female gender 
PMTCT exposure Categorical 
Mother or infant exposed to MTCT 
drugs (peri/post-natally) 
Date of first visit at facility dd-mm-yy  
Date of ART initiation dd-mm-yy  
First line regimen used Categorical 
Names of each antiretroviral 
prescribed 
Weight Numerical Weight in Kilograms (kg) 
Height Numerical Height in centimetres (cm) 
Weight-for-Age Numerical Weight for age Z scores (WAZ) 
Height-for-Age Numerical Height for age Z scores (HAZ) 
BMI-for- Age Numerical 
Body Mass index for age Z-score 
(BAZ) 
Weight-for-Height Numerical 
Weight for Height Z scores 
(WFHZ) 
CD4 count Numerical CD4 absolute cell count (cells/μl) 
CD4 percentage Numerical CD4 percentage (%) 
Viral load Numerical 
HIV-RNA measurement value 
(copies/ml) 
Haemoglobin Numerical Blood Haemoglobin count (g/dl) 
WHO Stage Categorical, ordinal Clinical WHO stage (I to IV) 
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Table 2: Primary outcomes 
Variable Format Description 
Outcome Categorical 
Defined as died, lost to follow-up, 
transferred out 
Date of Outcome dd-mm-yy Date of event as stated above 
 
Table 3: Longitudinal Response Variables  
Variable Format Description 
Date of each visit dd-mm-yy Each date to be recorded with data as below 
Height Numerical Height in centimetres (cm) 
Weight Numerical Weight in kilos (kg) 
Weight-for-Age Numerical Weight for age Z scores (WAZ) 
Height-for-Age Numerical Height for age Z scores (HAZ) 
Body Mass Index for 
Age 
Numerical Body Mass index for age Z-score (BAZ) 
Weight-for-Height Numerical Weight for height Z scores (WFHZ) 
CD4 count Numeric al CD4 absolute cell count (cells/μl) 
CD4 percentage Numerical CD4 percentage (%) 
Viral load Numerical HIV-RNA measurement value (copies/ml) 
Haemoglobin Numerical Blood Haemoglobin count (g/dl) 
* Use of categorical variables as per Data Transfer Protocol Lists and coding see Appendix A for 
further details 
Validity and reliability of measuring instruments 
The validity of data in the IeDEA-SA database is dependent upon the recording of 
information at the participating sites. The data collated centrally is assessed through a 
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Data Quality Report and deficiencies in the data are reported to the sites and 
improvements made where feasible.   
Potential Bias and Confounding 
Survival Bias 
The study of outcomes of HIV positive infants is particularly vulnerable to the effect 
of Selection Bias through the unintentional selection of a group of “survivors”. This 
Survival Bias arises where death due to HIV occurring prior to initiation of ART 
naturally precludes inclusion within the observed cohort. Baseline characteristics and 
outcomes thus will reflect the characteristics of this population of “survivors”.  This 
will be addressed in the results section in the restriction of inference of the study 
results upon the general HIV positive infant population. However as this study aims 
to address outcomes in routine care setting this bias will at least partly reflect 
guideline changes (i.e earlier infant ART initiation recommended in later years). The 
bias is therefore indicative of the current programmatic characteristics of infant HIV 
testing and ART initiation.  
Loss to Follow Up 
LTFU shall be defined where the last visit recorded is more than 9 months prior to 
site database closure with the date of LTFU being the date of the last visit. 
Ascertainment bias may occur, as unidentified death may be the reason for the 
program attrition.  
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Confounders 
Assessment of potential confounders will be made in the analysis. Adjustment for 
confounders will be done by use of multivariate regression methods in the data 
analysis where appropriate. This is a retrospective analysis of prospectively collected 
cohort data and thus assessment and adjustment of confounders is limited to those 
confounders measured in the primary data capturing. This may result in residual 
confounding. Time based confounding will not be assessed for purposes of the 
dissertation.  
Missing data 
Patterns of missingness will be assessed and if appropriate methods of multiple 
imputation shall be used according to this pattern so as to minimize bias associated 
with complete case analysis (49, 50).  
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Data Analysis 
Analysis of pooled cohort data from infant ART sites that has been merged using the 
agreed IeDEA-SA format. For all analyses, techniques will be used that account for 
between cohort variation. The data shall be analysed using STATA statistical 
software version 12 (51).  
Key components of the analysis plan will be: 
Descriptive analysis 
The baseline characteristics of infants starting ARV’s will be described using means 
and standard deviations for normally distributed continuous variables and medians 
Interquartile Ranges for non-normally distributed continuous variables. Frequency 
and proportions shall be used to describe categorical variables. Longitudinal profiles 
of response variable will be represented graphically and with summary statistics. 
These will include both mean profiles over time for numerical variables (such as 
CD4 count and percentage) and changes in proportions for categorical variables 
(such as proportion with HIV-RNA <400 copies/ml) and those numerical variables 
where categorisation is appropriate.  
Survival analysis 
Estimation of median time from ART start in an HIV-infected infant to death, LTFU, 
TFO and virological suppression will be done using the Kaplan-Meier method. 
Crude and adjusted associations between baseline characteristics and ART outcomes 
will be done using Cox Proportional Hazards models for survival analysis of 
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Mortality and time to virological suppression. Competing risk analysis shall 
additionally provide cumulative incidence functions for death, LTFU and TFO.  
Additional Analytic Procedures 
Multiple imputation of baseline characteristics as a method for managing missing 
information shall be done if and where found appropriate and will use the STATA 
12.0 (51) ICE program and Rubin’s Rules to attain pooled estimates of imputed data 
sets. A post-imputation model selection method of assessing variable importance 
(VI) will provide a model and estimates in addition to those from an a priori model.  
The detailed analysis plan for the infant epidemiology concept has been circulated to 
the working group of IeDEA-SA (Appendix B).   
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Ethics  
Ethical Approval 
The parent protocol: The IeDEA –SA (previously known as The Observational 
Antiretroviral Studies in Southern Africa (OASIS) Collaboration) collaboration has 
received University of Cape Town (Appendix D and Appendix E FHS017) and 
University of Bern, Switzerland approval (HREC Reference 084/2006). The data to 
be used for this analysis are obtained from individual IeDEA sites each of which has 
existing local institutional review board or Human Research Ethics Committee 
approval for collection of data and contribution of data to IeDEA-SA collaborative 
analyses (46).  
Risk classification 
As a project involving the secondary analysis of data already collected at the primary 
sites and collated the proposed analysis is classified as having minimal risk.  
Potential risks and discomforts 
Use of this anonymised data for secondary data analysis holds no foreseen direct risk 
or harm to those whose information has routinely been collected for primary 
purposes, as all data is anonymised prior to transfer to the IeDEA-SA Data Centres 
and the analyses require no direct contact with participants at individual cohorts.  
Potential Benefits 
The potential benefit of the proposed research is the opportunity to gain an 
understanding of the individual and programmatic characteristics of routine care in 
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Southern Africa and thus to provide the evidence necessary to advise optimal infant 
care and management in this setting. It thus additionally offers the possibility of a 
societal benefit and a benefit to future infants initiating ART in this setting.  
Consent, Privacy and Confidentiality 
Data used for this study is fully anonymised and stripped of identifiers at the site 
level and due to this individual consent is not required  where de-identified data is 
used (46). Password protected encryption and compression is used for the transfer 
and storage of data. The encryption password (minimum of 10 characters long, 
including upper/lower case, numbers and special characters) is communicated to the 
relevant data centre contact person by fax or by telephone, and not by email.  
Importation and merging of data is done by a dedicated IeDEA-SA data manager into 
a secure instance on an enterprise SQL Server database.  Security is ensured through 
user level and network access control.   
Involvement of vulnerable persons 
The inclusion of individuals under the age of 18 years, as will be done in the study, 
constitutes the involvement of vulnerable persons.  The inclusion of this age group in 
the study is necessitated, as they themselves are the group for whom this evidence is 
needed. Use of other age groups for inference upon this group cannot be made as 
described earlier in the background section. Further support for the inclusion of this 
age group is, as highlighted earlier, in the paucity of literature and research attention 
as described by the DNDi (3). The anonymisation and protection of data shall ensure 
the protection of these participants and the minimisation of harm including 
stigmatisation and discrimination associated with HIV infection.  
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Stakeholders 
Stakeholders include members of the IeDEA international and Southern African 
groups, Site Investigators, Facility Managers at participating sites as well as infants 
and caregivers attending those sites, policy makers in the relevant settings and 
members of the academic community.  
Dissemination of Results 
The findings of this study shall be disseminated to the stakeholder’s through internal 
reports, reports back to participating sites, submission of abstracts to appropriate 
academic meetings and conferences as well as to relevant peer-reviewed journals for 
publication. 
Logistics 
Timetable    
Table 4 below describes the proposed study time and outlines the expected time 
requirements for completion of necessary tasks related to the research and 
development of the final dissertation.   
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Table 4. Timetable for completion of mini-dissertation 
Task Expected date of completion 
1 Protocol Development  
 1.1 Draft Protocol  August 2013 
 1.2 Draft to Supervisors September 2013 
 1.3 Feedback for Revision October 2013 
 1.4 Submission for expedited Review April 2014 
 1.4 Submission for Departmental Approval April 2014 
2 Literature Review 
 2.1 Systematic Search June 2013 
 2.2 Write Up August 2013 
3 Data Management and Analysis 
 2.1 Data Cleaning January 2014 
 2.2 Data Analysis April 2014 
4 Write-Up 
 4.1 Draft Manuscript May 2014 
 4.2 Draft dissertation to UCT Supervisors May 2014 
 4.3 Feedback for Revision June 2014 
 4.4 Finalise Dissertation June 2014 
5 Submissions 
 5.1 UCT Submission June 2014 
 5.2 Journal Submission July 2014 
6 Results Dissemination 
 6.1 Communication to stakeholder June 2014 
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Budget 
There are no foreseeable budgetary requirements as a retrospective secondary data 
analysis shall be conducted and the questionnaire forms part of routine IeDEA site 
survey data. The IeDEA-SA project is already funded and Mireille Porter’s time 
working on the analysis will be funded by the IeDEA-SA project. 
Contact Details 
Author: Mireille Porter 
CIDER, School of Public Health and Family Medicine  
Tel: 021 406 6808 
Email: mireilleporter@gmail.com 
Address: CIDER Room 5.53 School of Public Health and Family Medicine, 
Falmouth Building, Faculty of Health Sciences, University of Cape Town 
Supervisor: Dr Mary- Ann Davies 
CIDER, School of Public Health and Family Medicine, University of Cape Town  
Tel: 021 406 6051 
Fax: 021 406 6764 
Email: mary-ann.davies@uct.ac.za  
Address: CIDER Room 5.39 School of Public Health and Family Medicine, 
Falmouth Building, Faculty of Health Sciences, University of Cape Town 
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Co-Supervisor: Professor Brian Eley 
School of Child and Adolescent Health, University of Cape Town 
Email: brian.eley@uct.ac.za 
Red Cross Children’s Hospital 
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Introduction  
Background 
The expansion of programs providing antiretroviral therapy (ART) to those living 
with the Human Immunodeficiency Virus (HIV) in Sub-Saharan Africa is said to be 
“one of the largest pharmacologic interventions to promote health to date” (1, 2).  
The call for an increases velocity and coverage of ART provision for infants living 
with HIV was formalised in the 2008 World Health Organisation (WHO) infant and 
children ART guidelines with recommendation for the initiation of ART for all HIV 
positive infants immediately upon diagnosis regardless of the immunological and 
clinical disease criteria previously used (3). Although catalysed by experimental 
evidence from The Children with Human Immune Deficiency Virus Early 
Antiretroviral Therapy Trial (CHER) (4) these changes occurred upon a background 
of observational studies whose contribution of evidence for the early initiation of 
ART in infancy is not insignificant (5-9).  
The CHER study, a South African trial looking at early versus deferred ART 
initiation in infancy, provided evidence in support of early diagnosis and treatment of 
HIV infected infants from a sample of infants with an average age at commencement 
of ART of seven weeks, complete availability of appropriate laboratory testing and 
drug regimens including protease inhibitors, minimisation of loss to follow up 
(LTFU) and the exclusion of those with comorbid conditions or severe 
immunosuppression (4). 
Within Sub-Saharan Africa, and with Southern Africa in particular considered as the 
epicentre of the global HIV burden (10), both the short term impact and long term 
outcomes of policies and programs for ART roll-out are met with obstacles and trials 
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pertaining to the resource-scarce setting of this area (11, 12). In a  region where the 
‘routine-setting’ is  characterised by concerns of delayed and missed testing, poor 
follow up, non-adherence, limited resources and restricted laboratory access further 
complicated by the social, diagnostic, monitoring and treatment needs of infants 
there exists a severe contrast between that setting within which experimental  
evidence forming these policies was gained and the setting which these infants in 
reality exists (13-18) . 
Examination of literature describing findings from observational studies in Sub-
Saharan Africa which involve an HIV infected infant population group on 
antiretroviral therapy may provide us with opportunity to gain insight into the 
characteristics of these infants, their outcomes and the predictors of these outcomes 
within routine care settings of resource scarce environments.   
Aim and Objectives 
The aim of this literature review is to review current literature so as to place the 
proposed study within a context of up-to-date academic evidence appropriate to the 
objectives and methods of the mini-dissertation. Furthermore the aim is to critically 
assess those studies identified regarding their availability and quality – specifically 
their ability to provide valid conclusions- and in doing so to identify areas where 
further research, including the proposed study, might be justified.  
This review seeks to address the objectives of the mini-dissertation. These objectives 
are as follows: 
1. To describe the baseline characteristics of infants commencing ART in the 
International Epidemiologic Databases to Evaluate AIDS in Southern Africa 
(IeDEA-SA) sites. 
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2. To describe and examine the outcomes of infants starting ART in Southern 
Africa.  
3. To identify and examine predictors for these outcomes. 
The Objectives of the structured review therefore stand as follows: 
1. To identify all published literature pertaining to studies assessing the 
outcomes (and where available the predictors of these outcomes) of infants 
initiated on ART in routine care in Sub-Saharan Africa, 
2. To consider the evidence provided by the literature regarding all three 
objectives of the mini-dissertation, 
3. To review and report on the quality and results of the studies by critically 
reading and synthesising the findings and evidence regarding the outcomes of 
these infants, and 
4. To synthesise this information and to identify areas where further research 
would be useful.   
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Review Process 
Structure of the Review 
The review shall present the process of the identification of literature and the 
assessment of the quality and comparability of the identified literature. Following 
this a discussion of the findings of these studies – in categories of baseline 
characteristics, outcomes and predictors of the outcomes-   shall be presented with 
further discussion of resulting issues of validity therein. The review shall conclude, 
in keeping with the above review objectives, with a summary of the information 
gained from these studies and propose a way forwards regarding the study of the 
mini-dissertation. 
Search Strategy 
The online PubMed Interface (19) was used to search the Medline bibliographic 
database using the following  key word search:  
(infant OR “under 1 year old*” OR “under-1” OR “young children”) AND  
(antiretroviral* OR ART OR HAART OR ARV*) AND  
(HIV OR AIDS OR human immunodeficiency virus OR acquired immune deficiency 
syndrome) AND  
(outcome* OR response OR mortality OR survival OR benefit OR effect OR 
effectiveness OR health OR suppression) 
NOT pregnancy NOT pregnant NOT maternal NOT maternity NOT PMTCT NOT 
cure   
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(HAART: Highly active antiretroviral therapy, PMTCT: Prevention of Mother to Child transmission 
of HIV, ARV: Antitretroviral) 
Inclusion Criteria 
 Articles from Sub-Saharan Africa reporting on outcomes of starting first-line 
ART (minimum of three antiretroviral agents) in infancy. A cut-off of group 
definition of below 18 months was used. This age inclusion criteria was set in 
view of the severe paucity of literature pertaining to predictors of infants ART 
outcomes for a population initiating under 12 months of age.  
 The outcomes included were survival/mortality, immunological, virological and 
clinical disease status, growth or nutrition and opportunistic infections as well as 
loss to follow up, transfer out, adherence, regimen change and resistance.   
 Those studies where the study design is observational were included and priority 
given to cohort, case-control and cross-sectional designs. Both descriptive and 
analytic studies were included.  
 Priority was given to literature published in the past 10 years (January 2004 up to 
August 2013)  
Exclusion criteria  
 Studies which included infants as part of a wider spectrum of ages but did not 
provide a separate description and/or analysis of the outcomes of these infants 
(allowed categorisation < 18 months) were excluded.  
 Those studies including less than 25 infants were excluded from the review.  
 Studies where the majority of participants were either on regimens using less 
than three ART medicines or second-line therapy were excluded.  
 Those studies only observing highly specific outcomes not directly pertaining to 
our study objectives were excluded. This included studies investigating malaria, 
lipid profile responses, genetic mutations and nephrotoxicity.  
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 No quality criteria besides number of infants were used to determine exclusion. 
Included studies were however assessed for quality as discussed in the next 
section.   
Titles, published abstracts, methodology, results sections and, where necessary for 
clarity, the full text of identified articles were read by the author and the above 
inclusion and exclusion criteria applied. In addition the bibliographies of reviews of 
the initiation of ART in infancy (from original PubMed search) were examined and 
studies found to be in agreement with the above criteria were added. 
Articles Published 
The search as described above yielded 998 published articles, 18 of which satisfied 
the inclusion and non-exclusion criteria (Figure 1). A further article (20), meeting 
the same inclusion criteria, was identified through examining bibliographies of 
reviews and articles identified. A study done by Kay et al (2012) was further 
included despite its inclusion of one child of 19 months of age (21). This was done in 
view of the severe paucity of literature pertaining to the outcome virological 
suppression and the importance of the contribution of evidence as provided by this 
study. 
Figure 1. Flow chart showing the identification of published articles and 
inclusion in the review. 
Published Articles 
identified through 
initial search strategy 
998 
Providing Infant 
Analytic component 
6 
Purely Descriptive 
13 
Satisfied Inclusion 
Criteria 
17 
Additional Articles 
2 
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Quality and Comparability of Studies 
The key features regarding quality and comparability of the studies are shown in 
Tables 1a and 1b collated as per inclusion of analytic and descriptive information 
respectively. Quality criteria assessed for purposes of this review included primary 
aim and focus of the study (with reference to population group), study design, sample 
size (including proportion of infants) and inclusion and exclusion criteria. 
Comparability criteria include the year of study, presiding guidelines used for ART 
initiation, definition of infant subgroup and follow up time. Furthermore this section 
will include a review of the variables measured and the management of incomplete 
and missing outcomes.  
Primary aims and focus of the study 
Of the 19 studies included in this review only three were entirely comprised of an 
infant cohort (16, 21, 22). In keeping with the inclusion criteria all studies identified 
outcomes (one or more) of children initiating ART and the vast majority (16 of 19) 
of studies provided a minimum of one baseline measure at ART initiation for their 
infant participants.  The six analytic studies looked at the predictive ability of one or 
more of these baseline characteristics for the outcomes assessed. Two of the six 
analytic articles were however presentations of different aspects of the same study 
but both were included as they each presented different outcome measures (23, 24). 
Two further studies (Davies et al (2009) and Fenner et al (2010) overlapped 
regarding the study population and outcomes observed as both provide descriptive 
information on mortality in infants from the IeDEA-SA cohorts in similar time 
periods(25, 26). The remaining 13 studies, although almost all analytic in their 
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overall design for the total paediatric cohort, provided only outcome information of a 
descriptive nature for the infant subgroup (Figure 1).   
Study Designs 
All studies as per inclusion criteria were observational studies and the vast majority 
of these were cohort studies (prospective and/or retrospective).   
Infant subgroup definition 
A threshold of less than 18 months for classification as an infant was used in over 
half of the studies. Only one study, having initially been designed to include only 
those up to 18 months, included infants up to 20 months due to delays in initiation 
processes (21). The possible implications of the age of cohorts are considered in the 
section on quality and comparability of results.  The remaining studies used a 
threshold of less than 12 months with one of these being further subdivided into less 
than six months and six-12 months (27).  
Sample Size  
None of the studies included the use of sample size calculations but rather aimed to 
include as many participants as could be identified and who met inclusion criteria. 
The range of infant group sample sizes was 34 – 2151. The proportion of infants in 
the studies involving a total cohort of a wider age range were a minimum of 2% 
(n=36) (28) and a maximum of 44.7% (29) of all children in the study. 
Follow Up 
Follow up time was only specified for the infant subgroup in two studies with 
medians of 12.3 months (approximately 370 days) (30) and 752 days (16).  In those 
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studies reporting an overall  cohort median follow up time, this ranged from 196 days 
to 820 days (27, 31).  
Study Population and Inclusion Criteria  
All studies, as per inclusion criteria, were conducted within Sub-Saharan Africa. The 
study by Sauvageot et al (2010), although being conducted in Asia concurrently, 
provided separate result pertaining specifically to the African cohort (32). In keeping 
with the inclusion criteria all studies only included infants non-exposed to ART 
beyond Prevention of Mother to Child transmission of HIV (PMTCT) who were 
initiating a first line regimen of a minimum of three ART drugs.  
Despite the observational nature of all studies and an often stated benefit of capturing 
routine setting/standard care outcomes there was significant variation in the inclusion 
criteria beyond programmatic requirements of age and drug experience. These were 
largely for analysis purposes and related to risk of program attrition such as 
geographical proximity, caregivers, minimum follow up times and site sizes. 
Feinstein et al (2012) only included those who were defined as stunted or 
underweight at baseline and Kay et al (2012) only included those who had 
experienced nevirapine exposure (maternal or infant) prior to initiation of ART and 
had at least 1 viral load measurement after ART initiation (21). Further inclusion 
criteria were full attendance of visits as well as a 95% adherence at six weeks (33), 
having completed six months of ART (22) and identification of a parent or guardian 
as well as proximity to the facility, willingness to be visited at home and being over 
the age of six weeks (16).  
All sites included in the studies, including non-governmental, provided free routine 
care. This is important in decreasing the risk of selection bias resulting from 
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preferentially providing access to those of higher socioeconomic status.  The 
exclusion of orphans in the Tukei et al (2013) study not only decreases the external 
validity of these findings in areas where orphanhood is prevalent but also runs the 
risk of introducing selection bias as these infants have been shown in other studies to 
be at greater risk of delayed initiation, increased severity of clinical stage and at 
higher risk of worse outcomes (34). The exclusion of those living beyond 20km of 
the facility in this study may also result in selection bias as children from rural areas 
have been shown to have delayed initiation, lower baseline immunological status and 
poorer outcomes including higher loss to follow up (35). The effect of population 
selection on the interpretation of any characteristics or outcomes observed in the 
study is of concern as these criteria reduce the comparability of the populations and 
the ability to compare the outcomes reported. In particular the implication of 
selecting a population which is more likely to remain in care when assessing 
outcomes of death and programmatic end through loss to follow-up is of concern. 
Infant initiation guidelines  
Due to the length of observation periods almost all studies were affected at a point by 
changes to WHO and/or national guidelines. Guidelines used were largely those of 
the WHO or largely comparable National Guidelines. The majority of studies 
included at least a portion of their infants initiated as per WHO 2006 guidelines and 
the four most recent studies (16, 27, 29, 36) all included a portion of participants 
initiating ART in accordance with the 2010 WHO guidelines for early initiation 
regardless of immunological and clinical criteria under 24 months of age (37).  
The study of outcomes of HIV infected infants is particularly vulnerable to the effect 
of selection bias through the unintentional selection of a group of “survivors”. This 
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survival bias arises where death due to HIV occurring prior to initiation of ART 
naturally precludes inclusion within the observed cohort. It is thus directly affected 
by trends in the age of initiation and the immune and disease status at initiation and 
therefore by the prevailing initiation guidelines used.   
All analytic studies included in this review include more than a single guideline 
therefore establishing two subgroups with different expressions of this form of bias. 
Only one study took the guidelines used into account in their analysis however it was 
not found to have any significant associations with the attainment of virological 
suppression at six months (16).  The same  study also discusses the number of infants 
who died prior to inclusion and although these infants are excluded in analysis it is 
an important concern in interpreting the final results and understanding the important 
role of delay in initiation and the impact this can have on virological and mortality 
statistics. 
Confounders 
The measurement and management of confounders varied greatly in the analytic 
studies where a mention of  the consideration of known and unknown confounders in 
analysis was made in some (16, 21) compared to the inclusion of all variables found 
to be significant in the larger adult and child study in another(23, 24).  The possible 
over adjustment for confounding factors as done in the latter could result in an 
inappropriate adjustment for mediating factors and a resulting null association when 
in truth one exists. The failure to measure factors such as comorbid disease, 
socioeconomic variables, feeding and maternal conditions in the majority of these 
studies would result in an inability to adjust for their unknown confounding effects 
and residual confounding (38).  
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Missing Data  
The prevalence of missing data was only described for the infant group in four 
studies (29, 32, 39, 40). KIDS-ART LINC (2008) was the only study which looked at 
factors associated with missing data and identified characteristics associated with 
missingness (younger age and regimen). The management of missing data, where 
reported, largely involved exclusion from multivariate analysis of those participants 
with incomplete data sets (22-24, 41). Of note is the exclusion of over 27% of 
participants by Purchase et al (2012) for incomplete six months outcome data due to 
loss to program (22). The use of complete case analysis may result in a selection bias 
as those with complete data may not represent the total population where this 
missingness is not completely at random (42, 43). The assessment of factors 
associated with missingness such as in the KIDS-ART LINC (2008) study is 
necessary to reassure us as to the effect of this exclusion on bias. Multiple 
imputation, such as used by Fenner et al (2010) (26) is one method which can 
prevent the exclusion of these participants and improve the validity of the findings if 
used appropriately (42, 43). 
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Table 1a.  Quality and Comparability - Analytic Studies                                                                               
Author Year of Publication 
Observation 
Period 
City,  
Country 
Setting Study design 
Infant 
Subgroup  
Infant 
Sample Size 
(% 
total cohort) 
Follow up Time  Inclusion Criteria 
Initiation 
guidelines 
followed 
Bolton–Moore et 
al (2007) 
(23) 
2007 2004-2007 
Zambia, 
Lusaka. 
Primary Care 
Government 
Clinics 
Retrospective 
cohort 
< 18 
months 
291 (9.9%) 
NRI. 
 Infants contributed 213 child-
years. 
Overall: 378a days 
 (138 – 692c)  
NR 
Changed to 
WHO 2006 
in 2006 
Mubiana – 
Mbewe et al 
(2009) 
(24) 
2009 2004-2006 
Lusaka, 
Zambia 
Primary Care 
Government 
Clinics 
Retrospective 
cohort 
< 18 
months 
101 (8%) 
NRI.  
280 daysa 
(110 – 459 c)  
NR 
Changed to 
WHO 2006 
in 2006 
Purchase et al 
(2012) 
(22) 
2011 2005-2008 
Kwazulu 
 Natal,  
South Africa 
Township 
Retrospective 
cohort 
< 12 
months 
94  
(100%) 
NR.  
 Observation up to 18 months post-
initiation 
< 12 months,  
Completed ≥ 6 
months ART,   
2 reliable caregivers 
Similar to 
WHO 2006 
 then stage 2 
or  
CD4<30% 
after 2007 
Feinstein et al 
(2012) 
(41) 
2012 2004-2008 
Johannesburg, 
South Africa, 
Tertiary Facility 
Outpatient 
Paediatric Clinic 
Prospective 
cohort 
<12 
months 
676  
(28.2%) 
Only reported 
for < 2 year 
group 
NR. Administrative end 2 years 
Stunted 
 (HAZ< -2) or 
Underweight  
(WAZ< -2)  
SA national 
guidelines 
changed to 
WHO 2006 
in 2006 
Kay et al (2012) 
 (21) 
2012 2007-2008 
Tororo, 
Uganda 
Rural 
Prospective 
cohort 
< 20 
months 
34 (100%) 
NR. 
Observation up to 18 months post-
initiation 
Nevirapine exposure,  
≥ 1 viral load 
measurement 
WHO 2006 
updated to 
immediate 
start in 2008 
Tukei  et al 
(2013) 
 (16) 
2013 2009-2012 
Kampala, 
Uganda 
Outpatient 
 Non-
governmental 
Free clinic. 
Prospective 
cohort 
< 12 
months 
84 (100%) 
752 daysa   
(531-980 c) 
Living within 20km,  
accept home visits, 
parents or guardians, 
>6 weeks old  
WHO 2006 
(29.8%) 
updated to 
early start  in 
2010 
   NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available ,WHO: World Health Organisation, ART: Antiretroviral therapy, HAZ: Height-for-age z-score, WAZ: Weight-for-age z-score 
   a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
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Table 1b. Quality and Comparability - Descriptive Studies                                                                          
Author 
Year of 
Publication 
Observation 
Period 
City, 
Country 
Setting 
Study 
design 
Infant 
Subgroup 
Infant 
Sample 
Size 
(% total 
cohort) 
Follow-up Time 
Inclusion 
Criteria 
Initiation 
guidelines followed 
Bong et al (2007) 
(33) 
2007 2004-2006 
Mzuzu, 
Malawi 
Free, Hospital 
based 
Retrospective 
cohort 
< 18 
months 
37 
(8%) 
NR. 
Observation up to 6 
months post-initiation 
< 15 yrs, 
6 weeks adherence 
>95%,  no transfers, 
full attendance 
National guidelines 
 
 
KIDS-ART LINC (2008)  
 (39) 
2008 NR-2007 
Multicentre, 
sub-Saharan 
Africa 
Urban 
Retrospective 
cohort 
< 12 
months 
296 (12.3%) 
analysis on 
complete 
data: 
80 (7.6%) 
NRI. 
Overall: 
20.3 monthsa 
(11.7-27.9 c) 
< 15 yrs, ≥3 drugs, 
≥1 day follow up, 
6 months ART. 
Site ≥ 30 children 
NR. 
Fetzer et al (2009) 
(31) 
2009 2004-2006 
Lilongwe, 
Malawi 
Paediatric HIV 
clinic 
Retrospective 
case-cohort 
< 18 
months 
55 
(21.4%) 
NRI. 
Overall: 
196 daysa 
(105-310 c) 
< 18 yrs, ART 
naïve. 
National guidelines 
 
Davies et al (2009) 
 (25) 
2009 1999-2008 
Gauteng, 
Western Cape,  
Kwazulu 
Natal, 
South Africa 
Multicentre 
Retrospective 
cohort 
< 18 
months 
1758 
(29%) 
NRI. 
Overall 
16 monthsa 
(6-29c) 
≤ 16 yrs, ≥3 drugs. 
Sites >25 children 
National guidelines 
Anaky et al (2010) 
(20) 
2009 2004-2007 
Abijan, 
Cote D'Ivoire 
Multicentre, 
NGO program 
urban and 
semi-rural 
Prospective 
cohort 
< 18 
months 
145 
(15%) 
NR ≤15 yrs, ART naïve WHO 2006 
Janssen et al (2010) 
(40) 
2009 2004-2008 
Kwazulu Natal, 
South Africa 
Decentralised, 
rural 
cohort 
< 18 
months 
58 
(12.2%) 
NR. 
732 child-years 
 
≤ 15 yrs 
Regional. Recurrent 
hospitalisation/ 
WHO stage > 1/ 
CD4 ≤ 35% or 
<1500cells/mm3 
 
Fenner et al (2010) 
(26) 2010 1998-2008 
South Africa, 
Malawi, 
Mozambique, 
Zimbabwe 
Multicentre, only 
urban 
cohort 
< 18 
months 
2045 
(24.9%) 
NRI. 
Overall: 
17.3 monthsa 
(8.7-25.7d) 
< 16 yrs, ART 
naïve, 
≥3 drugs. 
Site >100 children 
Site dependent: all 
under 
12 months/ 
immunological and 
clinical criteria 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available , WHO: World Health Organisation, ART: Antiretroviral therapy, NGO: Non-governmental organisation 
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
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Table 1b. Quality and Comparability - Descriptive Studies continued                                                         
Author 
Year of 
Publication 
Observation 
Period 
City, 
Country 
Setting 
Study 
design 
Infant 
Subgroup 
Infant 
Sample 
Size 
(% total 
cohort) 
Follow-up Time 
Inclusion 
Criteria 
Initiation 
guidelines 
followed 
Sauvageot et al (2010) (32) 2010 2002-2008 
Multicentre, 
Sub- Saharan 
Africa, Asia 
MSF 
free care 
centres 
Prospective 
cohort 
< 12 months 
307 
(8.5%) 
NRI. 
Overall 
10.5 monthsa 
(3.7-20.6 c) 
< 5 years 
initiated in 
MSF program 
WHO 2006 
Meyers et al (2011) 
(30) 
2011 2004-2008 
Soweto, 
South Africa 
Government 
clinic, 
township 
Retrospective 
cohort 
< 18 months 
496 
(24%) 
12.3 monthsa 
(3.6-24.8 c) 
 
<15 years 
National 
guidelines 
 
Ekouevi et al (2011) 
(28) 
2011 2000-2007 West Africa 
Multicentre, 
free ART, 
urban. 
Retrospective 
cohort 
< 12 months 
36 
(2%) 
NRI. 
Overall: 
1761 child-years. 
≤ 15 years, 
Triple ART. 
National 
guidelines 
Kabue et al (2012) 
(27) 
2012 2004-2009 
Malawi, 
Lesotho, 
Swaziland 
Multicentre 
Retrospective 
cohort 
< 6 and 6-12 
months 
537 
(23%) 
(119 < 6 
months, 
299 6-12 
months) 
NRI. 
Overall: 
2.3 yearsa 
(1.5–3.1 c) 
< 12  years 
National 
guidelines 
2008–2009 
all < 12 
months. 
 
McNairy et al (2013) 
(36) 
2013 2005-2011 
Kenya, 
Mozambique, 
Rwanda, and 
Tanzania 
Multicentre, 
rural and 
urban 
Retrospective 
cohort 
<12 months 
2151 
(12.1%) 
NRI. 
Overall: 
598 daysa 
(245-1106c) 
< 15 years 
National 
guidelines 
From 2007: 
Unclear. 
suggests all 
< 12 
months 
Omoni et al (2013) 
(29) 
2013 2008-2009 
Abuja and 
Benin, Nigeria, 
Hospital- based 
HIV clinic 
Mixed 
prospective/ 
retrospective 
cohort 
< 12 months 
67 
(44.7%) 
NR. 
Observation up to 
12 months 
post-initiation 
< 36 months WHO 2006 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available, ART: Antiretroviral therapy, MSF: Medecins sans frontiers, WHO: World Health Organisation 
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
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Table 2a. Infant subgroup measurements and Validity – Analytic Studies                    
Author Primary Outcome Other Outcomes Baseline Characteristics 
Predictors assessed for 
primary outcome 
Definition LTFU LTFU procedure Management  LTFU 
Bolton–Moore et al 
(2007) 
(23) 
Mortality rate 
overall, < 90 days, 
≥90 days 
WAZ, 
CD4 (%, count), 
Hb 
Age, sex, WAZ, CD4 (%, count), 
WHO stage, Hb, TB 
CD4%, WAZ, Hb, sex, TB, 
Creatinine, WHO stage, 
regimen, adherence. 
≥ 30 days late & no 
established 
death/transfer 
Electronic Monitoring 
with home visits for 
non-attenders >10days 
Reported at time points. 
Excluded from analysis. 
 
Mubiana – Mbewe et al 
(2009) 
(24) 
Incident clinical 
conditions 
None Sex, WAZ, CD4%,  WHO stage, Hb 
Hb, sex, WAZ, CD4%, 
WHO stage. 
As above As above As above 
Purchase et al (2012) 
(22) 
Completion of 6,12 
and 18 months of 
ART 
WAZ, CD4%, VL, 
Hb, admissions, 
BCG IRIS 
Age,  sex,  WAZ,  CD4%, VL,  WHO 
stage, TB,  admissions, NVP 
exposure, INH prophylaxis, ART 
regimen 
WHO stage, 
CD4%, VL, 
WAZ. 
NR None 
Analysis for predictors of 
loss to 
program 
Feinstein et al (2012) 
(41) 
Weight and Height 
recovery 
LTFU WAZ, HAZ CD4 
Last seen ≥ 
3 months before 
administrative end and 
non- event or death 
NR 
Sensitivity analysis for 
LTFU/death effect 
supported null-associations 
Kay et al (2012) 
(21) 
Virological 
suppression at 18 
months of ART 
CD4%, regimen 
changes 
Age,  sex,  WAZ, CD4%, VL,WHO 
stage, NVP exposure, breastfeeding 
Age, CD4, VL, weight, sex, 
WHO stage, breastfeeding 
NR NR NR 
Tukei et al (2013) 
(16) 
Virological 
suppression at 6 
months of ART 
Mortality rate, 
CD4%, adverse 
events, 
WAZ, HAZ 
Age, sex, WAZ, HAZ, CD4%, VL, 
TB, 
time to start, 
guideline,  regimen 
Age, Sex, CD4%,, WHO 
stage, WAZ, HAZ, WHO 
guidelines, PI regimen 
NR NR Unclear 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available, ART: Antiretroviral therapy, WAZ: Weight-for-age - score, HAZ: Height-for-age z-score, VL: Viral Load,  
TB: Tuberculosis, INH: Isoniazid, Hb: Haemoglobin, LTFU: Loss to follow-up, WHO: World Health Organisation, PI: Protease inhibitor. 
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
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Table 2b. Infant subgroup Measurements and Validity – Descriptive Studies                                    
Author Outcomes Baseline Characteristics Definition LTFU LTFU proceed Management  LTFU 
Bong et al (2007) 
(33) 
Mortality 
cumulative probabilities 
at 3 and 6 months 
Age, sex,  weight-for-height, BMI, 
CD4 
(%, count), WHO stage, orphanhood, 
regimen 
NR NR 
Acknowledge underestimation 
of death 
KIDS-ART 
LINC (2008)  
(39) 
Mortality 
cumulative probabilities 
(graphically), LTFU 
Age,  CD4%, 
disease severity 
(WHO stage and weight  
combined statistic), 
regimen 
Last contact > 6 months before 
database closure, not known death or 
TFO. 
NR 
Sensitivity analysis 
(death combined with LTFU) 
Fetzer  et al 
(2009) 
(31) 
Loss to program NR NR 
No community 
tracing 
Adjustment for associated 
baseline factors only 
reduced precision due to 
sample size. 
Davies  et al 
(2009) 
(25) 
Mortality 
cumulative probabilities  (graphically) 
CD4 (%, count) 
Last contact > 6 months before 
database closure 
Site based death and TFO 
ascertainment 
NR 
Anaky et al 
(2010) 
(20) 
Mortality 
cumulative probabilities and rates at 3 
months and 12 months, LTFU 
Age, sex, WAZ, 
weight,  CD4 (%, count),  WHO 
stage,  Hb, TB treatment active and 
past, cotrimoxazole, 
regimen 
Last contact > 3 months before study 
end. 
 
Phone calls, home visits by 
social workers and supporters 
 
NR 
Janssen et al 
(2010) 
(40) 
Mortality 
rates  overall, 
<90days,>90days , CD4(%, count), VL, 
Hb, LTFU, Albumin, Transfer Out 
Age, sex, WHO stage, 
CD4(%, count), VL, 
WAZ, TB, Hb, 
Albumin 
No drug collection > 3 months 
despite not known to have died or 
TFO. 
Phone calls, home visits 
by nurse tracker 
Sensitivity analysis  
(using maximum  
and minimum mortality in those LTFU) 
 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available , WAZ: Weight-for-age z score, VL: Viral load, TB: Tuberculosis, Hb: Haemoglobin, LTFU: Loss to follow-up,  
WHO: World Health Organisation, BMI: Body Metabolic Index, TFO: Transfer Out 
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Table 2b. Infant subgroup Measurements and Validity – Descriptive continued                      
Author Outcomes Baseline Characteristics Definition LTFU LTFU proceed Management  LTFU 
Fenner  et al 
(2010) 
(26) 
Mortality 
Rate for 12 months rate 
None 
Last contact > 6 months before 
closure date. 
Site dependent: phone calls, 
home visits, counselling 
 
Excluded early defaulters from analysis. 
Sensitivity analysis based on likely mortality in 
those LTFU  
Sauvageot  et al 
(2010)(32) 
Mortality 
cumulative probabilities 
(at 12 and 24 months), 
stage 4 events, drug toxicities 
and retention in care 
Age, sex, WHO 
stage, CD4%, WAZ, TB 
(active and past), 
Hb 
regimen 
Missed scheduled visits for more 
than 2 months 
NR NR 
Meyers et al 
(2011) 
(30) 
Mortality Rate 
overall, <90days,>90days, 
CD4%, VL 
Age, sex, WHO stage, 
CD4% and count, VL, WAZ,HAZ, 
TB, test to 
start interval 
NR 
 
Phone calls, home visits by full 
time on-site defaulter tracer 
NR 
Ekouevi et al 
(2011) 
(28) 
Mortality 
cumulative probabilities 
(6 and 12 months), LTFU, 
Loss to program 
none 
Last contact > 6 months from 
closing date. 
Vital status not ascertained NR 
Kabue et al 
(2012) 
(27) 
Mortality 
cumulative probability 
up to 36 months (graphically only) 
proportion at 12 months, CD4% 
CD4% NR NR 
Assumed to be alive for 
analysis 
McNairy et al 
(2013) 
(36) 
Mortality 
cumulative probabilities reported at 12 
and 24 months, LTFU, retention 
Illness severity as 
defined by WHO stage 
and CD4% 
No clinic visit for more than 6 
months 
NR 
Retention defined as alive 
and attending care. 
Non-retained censored. 
Omoni  et al 
(2013) 
(29) 
CD4% 
CD4%, 
breastfeeding 
NR NR NR 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available , LTFU: Loss to follow-up, WHO: World Health Organisation, WAZ: Weight-for-age z score,  HAZ: Height-for-age z score, 
 VL: Viral Load, TB: Tuberculosis, Hb: Haemoglobin. WAZ: Weight-for-age z-score 
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Results 
Table 2 above summarises those baseline characteristics, outcomes and predictors of 
these outcomes which are reported in the articles identified in this review. Table 3 
below summarises the results of baselines characteristics of infants in the articles in 
this review.  
Baseline Characteristics 
All but three studies reported at least one baseline characteristic specifically for the 
infant population. Immunological measures were the most commonly recorded with 
other frequently reported baseline characteristics being gender, weight-for-age, 
disease stage as per WHO criteria (37), viral load and regimen. Less frequent 
characteristics were previous or current tuberculosis treatment or disease, WHO 
guidelines used for initiation, year of enrolment, Isoniazid prophylaxis, PMTCT 
nevirapine exposure, feeding options, height-for-age, orphanhood, cotrimoxazole 
prophylaxis, albumin and enrolment-to-start time interval.  
Age 
The median or mean ages for the infant subgroup where provided range from 6.2 
months to 14 months (16, 20).  These ages are not comparable to the far younger 
median ages seen in the early initiation arms of experimental studies in Southern 
Africa (CHER median of 7.4 weeks) (4) nor in the developed world (Chiappini et al 
(2006)) median of 3.6 months (7)). The older population arising from these 
observational studies holds several concerns regarding the validity of the findings. 
Most considerable is the concern for survival bias where an older median age 
suggests the existence of a cohort of survivors. This survival effect is particularly 
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important in an infant cohort as not only does early infant HIV-related mortality peak 
at two to three months of age but also those infants perinatally infected have worse 
outcomes with high early mortality in comparison to those infected through 
breastfeeding (21, 44, 45). Furthermore, where maternal PMTCT nevirapine 
exposure occurs, these late seroconverters are more likely to be infected when the 
nevirapine-exposed mother has reverted to wild type virus rather than a resistant 
strain and possibly experience more favourable outcomes on a  non- protease 
inhibitor based regimen (21). The delayed age of initiation of infants seen in these 
studies therefore results in a cohort of those infants who have survived a period of 
extremely high risk of mortality and are therefore likely to be a group significantly 
different to all HIV infected infants.  
Virological   
In keeping with the unavailability of laboratory services and the lack of viral load 
measurement in resource-scarce settings due to high cost  virological measurements 
were not commonly reported and where reported often yielded high proportions of 
missing data of up to 67% of children (40). Where reported viral loads measurement 
ranges from 4.9 to 6.2 log10 copies/ml. 
Immunological  
The vast majority of studies included some measure of immune function - whether 
CD4 percentage, count, both or a summative score of illness combining 
immunological and clinical characteristics (36). Paediatric ART CD4 cell 
percentages are often considered a  more suitable measure of  immunological status 
than absolute counts in the interpretation of  these measures in children of different 
ages due to the age-related variability seen (46). 
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Median absolute CD4 cell counts reported range from 642-861 cells and with median 
or mean percentages ranging from 13% (20) to 20% (16). These results are very 
different to the CHER trial early ART arm where a median CD4% of 35% was 
reported and even more so to the median CD4% of 54% in the infants observed in 
the French Perinatal Cohort study (5). A further four studies provided percentage of 
infants with CD4% below 25% ranging from 82% (21) to over 91% (32). Missing 
CD4 data of up to 50% (29) in the infant group and 65% (36)  for those under the age 
of 5 years were reported. Several other studies that described an overall cohort 
(rather than providing a separate description of infants) reported high prevalence of 
missing CD4 baseline data (20, 25, 28). 
Clinical disease 
Use of the WHO classification of disease status was relatively consistent however 
changes from a three stage to four stage system were applied over the course of 2004 
and 2005 at different sites. Only Davies et al (2009) discuss their management of this 
situation as it pertains to the reporting of their overall cohort, but not infants, and 
label all participants stage three or four under either system as having “clinically 
advanced disease” (25). Severe disease, as defined most commonly as WHO stage 
three or four, was prevalent in over 50% in most studies ranging from 12% in Kay et 
al (2012) (21) to 100% of infants described as being stage four  in Bong et al (2007) 
(33). Kay et al (2012), where only nevirapine exposed infants were included, had a 
very healthy population with 0% recorded as WHO stage four and 79% stage one. In 
view of the immunological and virological markers described for this population 
these results do not seem to be plausible, especially as a significant portion were 
commenced under initiation criteria of WHO stage four or immunological criteria 
and measurement or coding error or missing data needs to be considered. It is a 
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possibility that confusion occurred regarding the previous three stage WHO criteria 
but this does not account for the high proportion of stage one. In Bong et al (2007) 
the high prevalence with wasting in the population might be at least partially 
responsible for the high levels for stage four disease. The general high prevalence of 
severe disease reflects not only the high rates of progression in infants and their high 
risk of mortality but also the limited access to testing and treatment seen in routine 
settings for this group (39).  
The use of “severe clinical status” by KIDS-ART LINC (2008) reflects the quality of 
data as 65.5% of these measures were missing due to incomplete WHO stage or 
weight-for-age z-score information. Missing data for infant WHO stage was reported 
at much lower levels in Janssen et al (2010) (10%) and Sauvageot et al (2010) (13%) 
(32, 40). Anaky et al (2010) and Ekouevi et al (2011) reported high levels of missing 
disease status data for their overall paediatric cohorts but did not specify that for 
infants (20, 28) . 
Growth 
Baseline weight-for-age z-scores (WAZ) of infants varied greatly with median or 
mean values ranging from a WAZ of -1.8 to that of -3.7.  In addition to these 
reported measures Kay et al (2012) seems to have a relatively low prevalence of poor 
nutrition characteristics with only 32% being underweight at WAZ < -2 compared to 
over 62% < -2 in Tukei et al (2013). Of note is that the lower limit seen in Janssen et 
al (2010) represents only 76% of the infant population as data is missing for this 
variable for the remainder. Furthermore Anaky et al (2010), representing the upper 
limit, state an unqualified “high” level of missing data for weight-for-age.   
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Baseline height-for-age z-scores (HAZ) were only provided for in two studies which 
varied quite considerably and weight-for-height z-scores (WFHZ) were measured by 
Tukei et al (2013) with 33.8% WFHZ <-2 and Bong  et al (2007). 
The WHO guidelines of 2010 encourage monthly monitoring of growth and nutrition 
for all HIV positive individuals based not only upon  the appropriateness of weight 
band dosing in children under the age of three years but also as it is a strong indicator 
for the risk of mortality in paediatric studies (37, 47, 48). Identification of high risk 
infants through growth and nutritional assessment is called for in light of the 
metabolic needs, co-morbid infections associated with HIV as well as the effects of 
nutritional deficiency upon the immune system (8, 49). 
PMTCT exposure 
PMTCT exposure, whether maternal, infant or both, was very poorly recorded. 
Beyond Kay et al (2012), where nevirapine exposure was an inclusion criterion, 
reported PMTCT coverage ranges from 65% of infants exposed to maternal or infant 
prophylaxis to over 94% of infants completely ART naïve-including PMTCT 
exposure (32). These are lower proportions compared to the CHER trial where, with 
infants being specifically identified for inclusion through the PMTCT services, only 
16% had had no exposure to PMTCT (4). Davies et al (2009) as a multicentre study 
within South Africa comment on the poor quality of PMTCT recording and found in 
their study that over 50% of infants did not even have a recorded exposure status (25) 
and Kabue et al (2012) report missing PMTCT data for 24% of the overall paediatric 
cohort.  These findings are largely in keeping with global statistics at the time such 
as an estimated coverage of PMTCT (including the no longer supported 
monotherapy) of 48% in 2010 (50). Prendergast et al (2012) in a review of current 
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evidence and its use to inform policy suggest that early infant ART initiation 
guidelines will only show their true impact when the system of antenatal care, 
PMTCT and infant care is strengthened (9). The gaps in recording, reporting and 
actual coverage of PMTCT are considerable and together with the older age at 
initiation, highlight the possibility of poor linkage with maternal antenatal and 
PMTCT services to infant testing and care and a reduced benefit of infant ART. 
Populations of HIV infected infants arising from regions of differing PMTCT 
coverage may also differ regarding outcomes risk as those who seroconvert despite 
PMTCT may represent infants infected by an already resistant strain or under 
conditions of high transmission risk such as high maternal viral loads (21).  
Cotrimoxazole Prophylaxis 
The low frequency of reports on cotrimoxazole coverage despite mention of 
prevailing guidelines and an evident acknowledgement of the importance of this 
prophylactic medication suggest common difficulties in ascertaining its use and 
implementation pre and post-ART. The proportion of missing data for this variable 
was only reported for the overall paediatric cohort by Ekouevi et al (2011) wherein 
one site had a 100% missing data prevalence (28). The benefit of cotrimoxazole as 
established in paediatric experimental studies in Sub-Saharan Africa such as Chintu 
et al (2004) (51) and Mulenga et al (2007) (52) include reduction in death, hospital 
admissions and bacterial infections and thus its use may be responsible for a portion 
of the beneficial response observed in patients on both ART and cotrimoxazole. It 
therefore is an important third variable for which failure to measure may result in 
residual confounding.  
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Tuberculosis 
Prevalence of Tuberculosis and/or treatment thereof differed significantly with 
regards to proportions in initiation cohort and diagnostic methodology. The lowest 
measured prevalence of active tuberculosis in infants was 2.8% in a semi-urban Ivory 
Coast population (20) and the highest prevalence occurred in South Africa with over 
40% of infants on tuberculosis treatment at time of ART initiation in Purchase et al 
(2012) (22).  Purchase et al (2012) comment that this high prevalence is likely to be 
due to the unavailability of diagnostic services and the resulting over diagnosis using 
clinical criteria (22). The high prevalence in infants in these areas with general high 
tuberculosis prevalence may be affected by maternal tuberculosis infection, impaired 
Bacilllus Calmette-Guerin (BCG) response and HIV immune suppression (53).  The 
comparison of proportions of infants diagnosed with tuberculosis and the treatment 
thereof is difficult as the diagnostic resources and thresholds for treatment vary 
considerably between settings (54). 
Regimen 
Protease inhibitors (PI) were available and part of the regular infant regimen in 
several studies, with the majority of these using lopinavir/ritonavir. These studies 
were almost all of South African populations reflecting the increased access to PIs in 
this country. In the Ugandan cohort reported by Tukei et al (2013), the most recent 
study in this review, there was also access to this regimen (16). The use of PI-based 
regimens for infants is supported by anticipated better outcomes than those on 
nevirapine regardless of previous nevirapine exposure (55, 56) particularly in the 
context of PMTCT nevirapine use. Nevirapines’s stability at high temperatures, its 
Outcomes of Infants starting ART in Southern Africa                                                  Literature Review     
29 
 
fixed dose combination formulations and low cost, however, make it an attractive 
alternative (13, 56).  
Initiation delay  
Although time from diagnostic test to start was not provided, the time between 
registration at the care facility and initiation was recorded by a few of the studies. 
Meyers et al (2011) reported a median delay of 4.4 weeks from first visit to initiation 
and comment that this is faster in infants than that observed in their older 
counterparts. Sauvageot et al (2010) reports a median delay of 0.9 months. In Tukei 
et al (2013) a median of 57 days occurred from registration at clinic to start and if 
disaggregated to that under 2006 and 2010 guidelines,these delays are 69 and 33 
days respectively. These delays are not considering the delay in test turnaround time 
and the true unmeasured delay between the first opportunity for identification and 
treatment initiation is probably far greater (57, 58).   
Other Baseline Characteristics 
Baseline haemoglobin levels were reported in several studies with low median levels 
ranging from 9.1 to 9.7 g/dl. Prevalence of missing data was however high with 38% 
reported missing in Janssen et al (2010). Infant feeding was poorly reported and 
definitions unclear and inconsistent with up to 85% infants “breastfeeding” at the 
time of initiation in Kay et al (2012)  and 7% exclusively breastfeeding and 73% 
mixed feeding in the study by Omoni et al (2013) (21, 29). The differences in 
reported feeding practices at initiation would depend on prevalent guidelines as well 
as age at initiation and how well this variable was captured.  
Data on social factors were generally lacking with orphanhood reported for infants 
only by Bong et al (2007) where 11% had lost one parent. Fetzer et al (2009) 
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described 16% of the paediatric cohort as having lost both parents reflecting the 
understandable increased risk of maternal mortality as the child ages (31). 
Orphanhood during infancy may however result in selection bias as it has been found 
to predict delayed access to ART services resulting in a population less likely to be 
orphans than the true HIV positive infant population (34).  
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Table 3a. Baseline Characteristics – Analytic                                                                                    
Author Age  PMTCT 
Cotrimoxazole 
Prophylaxis 
Disease severity CD4 Viral Load WAZ HAZ  Tuberculosis Hb 
Regimen 
(Most common 
for infants) 
Bolton –Moore 
et al (2007) 
(23) 
11amonths 
(7-14c months) 
NR NR 81.6% WHO 3/4 
572a cells/µl 
(268-959c), 
14.7%a 
(10.7-20.5c) 
(35% missing) 
NR 
-2.5a 
(-3.8;-1.1c) 
39.1% < -3 
NR 5.20% 
9.1g/dla 
(8.0-10.3 c) 
AZT or D4T 
+3TC 
+NNRTI 
Mubiana – 
Mbewe et al 
(2007) 
(24) 
NRI, 
Overall 77a 
months 
(39-119 c 
months) 
NR NR 87.1% WHO 3/4 
15.7%a 
(SD 8.2f) 
75% ≤20% 
NR 
- 2.5a   
(2.2f) 
41.3% < - 3 
NR NRI 83.3% > 8.0g/dl 
AZT or D4T 
+3TC 
+NNRTI 
Purchase et al 
(2012) 
(22) 
8.6 months 
(2.1-11.9 c) 
65% NVP 
exposure 
NR 
77.2%  WHO 3/4 
(26.6% stage 3, 
48.9% stage 4) 
15.4%a 
(0.1-43.4 d) 
6.2 log 10 
copies/mla  
(1.4-7.9 d) 
-2.7b 
(1.97f) 
NR 
40.4%  
on treatment at 
ART initiation 
9.7 g/dla 
(7.2-20.2d) 
D4T 
+3TC 
+ Lop/Rit 
(79% of infants) 
Feinstein et al 
(2012) 
(41) 
NRI, 
Overall 4.6a 
years 
(1.7-7.6 c years) 
NR NR NRI NRI NRI NRI NRI NRI NRI 
D4T 
+ 3TC 
+ Lop/Rit 
Kay et al 
(2012) 
(21) 
8.6a months 
(3.2–19.9d) 
All NVP 
exposed 
(maternal, child 
or both) 
NR 
12% WHO 3/4 
(79% stage 1, 
 9 % stage 2,  
12 % stage 3, 
 0 % stage 4) 
19%a 
(9-36 d) 
82% ≤25% 
(15% missing) 
5.8 log 10 
copies/mla 
(3.5-7.0 d) 
32% < -2 WAZ NR NR NR 
AZT 
+ 3TC 
+ NVP 
(PI’s 
unavailable) 
Tukei et al 
(2013) 
(16) 
6.2a months 
(4.04-9.0 c) 
 
NR NR 
55.6% WHO 3/4 
(35.6% Stage 3, 
20% stage 4) 
20%b 
(15-29d) 
56%a 
<750000 
copies/ml 
-2.2a 
(-3.89; -1 c) 
62.7 % ≤ -2  
 
-1.92a 
(-3.05;-1.02 c) 
39.5% ≤-2 
 
11.9% NRI 
AZT or D4T 
+3TC 
+ NVP (±52%) 
or 
Lop/Rit(±35%) 
  
NR: Not reported, NRI: Not reported for infants, WHO: World Health Organisation, NVP: nevirapine, D4T: stavudine, AZT: zidovudine, 3TC: lamivudine, NNRTI: Non-nucleoside reverse transcriptase inhibitor,  
Lop/Rit: lopinavir ritonavir, PI: protease inhibitor, WAZ: Weight-for-age z score, HAZ: Height-for-age z score, PMTCT: Prevention of mother to child transmission of HIV, TB: Tuberculosis, Hb: Haemoglobin.  
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
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Table 3b. Baseline Characteristics – Descriptive                                                                                                
Author Age  PMTCT 
Cotrimoxazole 
Prophylaxis 
Disease severity CD4  Viral Load WAZ HAZ TB Hb 
Regimen 
(Most 
common for 
infants) 
Bong et al 
(2007) 
(33) 
3.6-16.9d 
months 
(12-15.6 c) 
NR NR 
100% 
WHO stage 4 
861 a cells/µl 
(514.7-1373 c) 
15.2 % 
(9.5-20.6 c) 
NR NR NR NR NR 
D4T 
+ 3TC 
+ NVP 
(split adult 
FDC) 
KIDS-ART 
LINC (2008) 
 (39) 
8.4a months 
(2.2-12 c) 
 
NR 
Overall  
35.5% 
67.6% “severe clinical 
status” (WAZ<-3/ 
WHO 3/4) 
(65.5% missing) 
83.6% 
CD4 cells < 25% 
or abs < 1500 
cells/µl 
(16% missing) 
NR 
see baseline 
disease 
severity 
NR Overall 2.5% 
Overall 
 6.3%< 7.5g/dl 
(47% missing) 
AZT or D4T 
+ 2nd NRTI 
+ PI (67%) 
Fetzer et al 
(2009) 
 (31) 
Overall 
5.7 a years 
Overall 13% 
single infant 
dose 
Overall  
19% 
Overall 92% 
WHO stage 3/4 
NR NR NR NR 
Overall 
24% active 
TB, 25% 
history TB 
NR 
D4T 
+ 3TC 
+ NVP 
Davies et al 
(2009) 
(25) 
Overall 
42.7 a 
months 
(14.7-82.5c) 
Overall >50% 
unknown 
exposure 
status 
NR 
Overall 50% 
WHO stage 3/4 
642 cells/µl a 
(280-1132 c) 
16.5% a (10.0-23.6 
c) 
Overall  
5.36 a 
log10copies/ml 
(4.74-5.89 c) 
Overall 
-1.89 a 
(-3.20- -0.93 c) 
Overall -
2.39 
(-3.37- -
1.44) 
NR 
Overall  
12.2%  
Hb < 8 g/dl 
D4T 
+ 3TC + 
+ Lop/Rit 
Anaky et al 
(2010) 
(20) 
14 a months 
(9-16.75c) 
34% maternal 
PMTCT 
program 
involvement 
65.5% prior 
and 88.3%  
with ART 
39.3% 
WHO stage 
3/4 
714 cells/µl a 
(475.5-1182.5c) 
13% a  
(9-15.7c) 
NR 
-3.7 a 
(-5.4; -2.5 c) 
NR 
2.8% active 
TB, 2.1% 
previous 
treatment 
9.2 g/dl a 
(8.3-10 c) 
2NRTI’s 
+ PI 
(nelfinavir) 
(55%) 
Janssen et al 
(2010) 
(40) 
13 a months 
(4-17c) 
NR NR 
63.8% WHO 
stage 3/4 
(10% missing) 
766 a cells/µl 
(464-1130 c) 
19% a  
(11-28 c) 
(33% missing) 
4.9 log 10 
copies/ml a 
(3.4-5.9 c) 
(67% missing) 
-1.8 a 
(-2.8 - -0.9 c) 
(24% missing) 
NR 28.9% 
9.5g/dl a 
(8.4-10.4 c) 
(38% missing) 
D4T 
+3TC 
+ PI 
Fenner et al 
(2010) 
(26) 
Overall 
49 a months 
(16-120c) 
NR NR 
Overall 78.4% 
WHO stage 3/4 
Overall  
11.6% a  
(7-17 c) 
Overall  
5.4 a 
log10copies/ml 
(4.81-5.92 c) 
Overall 
24.6%≤-3 
NR NR 
Overall 
11.6%<8g/dl 
NR 
NR: Not reported, ART: Antiretroviral Therapy, WHO: World Health Organisation, D4T: stavudine, AZT: zidovudine, 3TC: lamivudine, NRTI: Nucleoside transcriptase inhibitor, Lop/Rit: lopinavir/ritonavir,  
PI: Protease inhibitor, WAZ: Weight-for-age z score, HAZ: Height-for-age z score, PMTCT: Prevention of mother to child transmission of HIV, TB: Tuberculosis, Hb: Haemoglobin.  
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
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Table 3b. Baseline Characteristics – Descriptive continued                                                          
Author Age  PMTCT 
Cotrimoxazole 
Prophylaxis 
Disease severity CD4  
Viral 
Load 
 WAZ HAZ  TB  Hb 
Regimen 
(Most common 
for infants) 
Sauvageot et al 
(2010) 
(32) 
0.7 years a 
(0.5-0.9c) 
 
94.5%  
none 
 
NR 
70.7%  
WHO stage  
3 or 4 
(13% missing) 
91.7%  
CD4 <25%, 
10% CD4 < 5% 
(45% missing) 
NR 
-2.6 a 
(-3.6; -1.3 c) 
NR 
3.3% current, 
9.5% prior 
TB 
17.4% a   
< 7.5 g/dl 
AZT or D4T 
+3TC 
+NVP 
(90%) 
Meyers et al 
(2011) 
(30) 
0.75  years a                             
(0.47-1.07c) 
 
NR NR 
88.8% 
WHO stage 
3 or 4 
642 cells/µl a 
(293-1058 c) 
14% (9-19 c) 
6 log 10  
copies/ml                 
(5.4-6.46) 
-3.18 a                            
(-4.52 --1.99 c) 
-3.02 a                             
(-4.03--1.79) 
32.93% NR 
D4T 
+3TC 
+ PI (Lop/Rit) 
Ekouevi et al 
(2011) 
(28) 
Overall 
5 years a  
(2-9c) 
NR 
Overall  
27.2% 
Overall 
19.1% WHO 
stage 4 
Overall 
13% a  (7-19 c) 
NR NR NR NR NR 
Overall 2NRTI 
+1 NNRTI 
Kabue et al 
(2012) 
(27) 
Overall 
3.1 yearsa 
(1.4–7.1 c) 
Overall  
62% none 
NR 
Overall 
69.7% WHO 
stage 3 or 4 
83% CD4< 25% 
or 1500 cells/µl 
NR 
Overall 32.8% 
some 
malnutrition 
NR NR NR 
 
Overall AZT or 
D4T 
+ 3TC 
+ NVP or EFV 
 
McNairy et al 
(2013) 
(36) 
Overall 
4.6 yearsa 
(1.9–8.3 c) 
NR NR 
2006: 56% , 2011: 18% 
CD4<25%/ 1500 
cells/ml3/ WHO stage 4 
Under 5 years: 
15% a  (10-20 c), 
67% CD4<25%/ 
1500 cells/µl 
NR 
Overall 
33% ≤ -2 
NR NR NR 
Overall 2 
NRTI’S 
+ 1 NNRTI 
(95%) 
Omoni et al 
(2013) 
(29) 
Overall 
14.3a months 
(8.3 f) 
NR NR 
Overall 58% 
WHO stage 
3 or 4 
14.9% b (12.4:17.5CI) 
(50% missing) 
NR 
Overall 
50% < -2 
Overall 
64% < -2 
NR NR 
Overall 99.3% 
D4T or AZT 
+ 3TC 
+NVP 
NR: Not reported, WHO: World Health Organisation, D4T: stavudine, AZT: zidovudine, 3TC: lamivudine, NRTI: Nucleoside reverse transcriptase inhibitor, NNRTI: Non-nucleoside reverse transcriptase inhibitor,  
Lop/Rit: lopinavir/ ritonavir, PI: Protease inhibitor, WAZ: Weight-for-age z score, HAZ: Height-for-age z score, PMTCT: Prevention of mother to child transmission of HIV, TB: Tuberculosis, Hb: Haemoglobin.  
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months 
 
Outcomes of Infants starting ART in Southern Africa                                                 Literature Review     
34 
 
Outcomes  
Outcomes measured for infants in the studies included in this review, as in keeping 
with the aims of the mini dissertation, include immunological, virological, clinical, 
growth and program follow-up and retention measures. Table 4 and 5 below 
highlight the results of the main outcomes of these studies.  
Mortality 
Mortality/survival was the most commonly reported outcome and furthermore was 
analysed for predictors in one study (23). It was most commonly presented as a rate 
per 100 child-years or as cumulative probability with Kaplan Meier probabilities for 
given time points. The use of Kaplan Meier cumulative proportions takes into 
account the effect of loss to follow up through censoring at different event-based 
time points and where time to event data involves censoring provides us with a more 
valid statistic than rates (59).  Mortality rates for infants for the overall study period 
as reported in the studies range from 4.09 deaths per 100 observed child years  
(Tukei et al (2013))  to 21.1 deaths per 100 observed child years (Bolton-Moore et al 
(2007)) (16, 23). These two studies not only represent cohorts of different age 
distributions but also significantly different follow-up times with that of the Bolton-
Moore et al (2007) study representing a very short observation time of approximately 
one year and the Tukei et al (2013) study a long observation time of approximately 
two years. This would affect the estimated mortality rates as this rate is not constant 
through time with the majority of infant deaths experienced early such as observed in 
the studies by Anaky et al (2010), Janssen et al (2010), Meyers (2011) and Bolton-
Moore et al (2007) studies where we see a far greater rate of death in this first 90 day 
after initiation of ART(20, 23, 30, 40).  Of interest is that these two extremes closely 
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mimic those mortality rates reported in the CHER trial in the early and deferred 
treatments arms respectively (4). One Malawian observational study not included in 
this review as no infant group data were reported showed a mortality rate of 47 per 
100 child year in children under the age of two years but reported very limited 
information on the age group characteristics (60). Those infants in the Bolton-Moore 
et al (2007) study represented a very ill population with over 80% WHO stage three 
or four and a low median weight-for-age. Furthermore the Tukei et al (2013) study, 
the most recent study in this review, included a high proportion of infants on protease 
inhibitors.  Baseline weight-for-age, CD4 cell measures and WHO stage have each 
been identified as predictors of mortality in those studies within sub-Saharan Africa 
involving a cohort of older children (26-28, 33).  Further still the use of non- 
Protease Inhibitors have been found to be associated with mortality in children on 
ART in experimental studies (55, 56, 61). The distributions of these characteristics in 
the studies may in part be responsible for the differing measures of frequency for 
mortality.   
Cumulative probabilities for mortality by six months range from 8.9% (28) to 24.3% 
(33) and that by 12 months from 10.7% (28) to approximately 17.5% (28). Bong et al 
(2007), with the highest six month probability of death, had a baseline WHO stage 
four  prevalence of 100%. As one of the earlier studies these findings also support 
evidence for a trend over time in HIV outcomes that is dependent not only on 
changing guidelines, access to antiretroviral therapy but also possibly to 
programmatic factors that are more difficult to measure (6, 62).   
Further description of mortality statistics according to age group within infancy (27) 
and year of initiation (36) suggest worse outcomes for those starting prior to six 
months of age compared to those between the ages of six and 12 months and 
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improving 24 month survival between 2005 and 2009. These differences are likely to 
be due to the survival bias discussed earlier and not true worse outcomes. Analyses 
of the strengths of these associations and their predictive power were however not 
reported on.  
Virological Outcomes 
In keeping with the scarcity of baseline virological measures, virological outcomes 
were measured in only five studies and in only two of these (16, 21) were predictors 
for this outcome assessed. In addition to absolute measures of HIV-RNA copies,  
virological outcomes include virological suppression (22, 30), undetectable viral load 
(22) and virological rebound after suppression (30). Definitions were largely 
consistent where virological suppression was considered to be viral load <400 
copies/mL after ART initiation once or twice at different study observation points 
and viral rebound was defined as viral load >1000 copies/mL on two subsequent 
occasions after viral suppression had occurred (30). In the study by Davies et al 
(2009) attainment of viral load < 400 copies/mL led to definition as “undetectable” 
however this variable was not reported for infants specifically(25). Cumulative 
probabilities of achieving virological suppression (viral load <400 copies/ml) varied 
considerably in the two studies it was reported in (16, 21) possibly reflecting the 
younger age group and more severe disease staging in the Tukei et al (2013) study.  
The proportion of infants attaining virological suppression during the study 
observation period is provided by one study (30) and median viral loads at certain 
time points reported for 2 others (22, 40). The considerable difference in the median 
values reported in these two studies may in part be due to the high level of missing 
data in the Janssen et al (2010) study. Not knowing the reason for non-recording or 
measuring of virological data means we cannot exclude the possibility that poor 
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clinical or immunological status may have led to higher likelihood of virological 
assessment for confirmation of treatment failure thus representing a more ill 
population than the rest of the cohort and affected the validity if these results.  
Virological rebound after suppression is reported in two studies with no rebound 
occurring at 12 months after ART initiation in those who suppressed in the Tukei et 
al (2013) study (16) and over 9% of those initially suppressed having virological 
rebound in Meyers et al (2011) (30).  
Immunological Outcomes  
Immunological outcomes were reported far more frequently than virological ones. 
Median/mean CD4 percentages at six months ranged from approximately 23% to 
30%, 12 month percentages from 26% to 33%, 18 month (only described in two 
studies) were 30% and 33% and at 24 months CD4% ranged from 30% to 36%. Kay 
et al (2012) reported on the average increase in CD4% in two groups according to 
attainment of virological suppression (21) and Kabue et al (2012) reported on the 
proportion of infants in whom an increase in over 5% of CD4cells was seen for 
infants under six months and infants six-12 months (27). McNairy et al (2013) used 
the variable “illness severity” as a baseline measure to describe those with 
immunological or disease stage characteristics of a severe nature (36). No study 
looked at predictors of immune status outcome in infants. An improvement in CD4 
cell from baseline measures was consistent in all studies where described and 
statistically significant improvements from baseline measures were reported in 
several studies including Omoni et al (2013) and Tukei et al (2013) (16, 29). 
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Clinical Outcomes 
Disease stage was not used as an outcome measure for infants in any of the studies 
beyond the incidence of stage four events used by Sauvageot et al (2010) (32).  
Mubiana-Mbewe et al (2009) looked particularly at the incidence of clinical 
outcomes including upper and lower respiratory tract infections, mucocutaneous 
infections, malaria and other infections (24). In this study the incident conditions 
were classified clinically due to the unavailability of diagnostic equipment. These 
clinical diagnoses, made by clinical officers (not a nurse or a doctor), were not 
assessed for validity or reliability. In the Mubiana-Mbewe (2009)/Bolton-Moore 
(2007) study with outcomes measured at presentation to the primary facility the 
failure to link the databases of other facilities to that used for the analysis may have 
resulted in an underreporting of severe events as these would present to tertiary 
institutions and not be relayed to the database of the primary facility for capturing. 
Growth Measures 
Five studies provide outcomes pertaining to growth, often only described using 
graphical illustration from which approximate measures were read(23, 30, 41). 
Growth recovery (WAZ and HAZ  > -2) was assessed as the primary outcome by 
Feinstein et al (2012) (41). Other studies looked at weight-for-age and height-for-age 
as descriptive outcomes and consistently used WHO 2006 child growth standards 
and graphs or anthropometric software based thereon for classification (16, 63). The 
US centres for disease control and prevention charts were used by Janssen et al 
(2010) to define baseline growth characteristics as their overall cohort included those 
over the age of 10 years (64). Two studies reported on proportions with WAZ above 
and below the threshold of -2 with six month proportions of underweight children 
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improving from a baseline of 63% to 31% at six months (16). Purchase et al (2012) 
show an improvement from baseline mean weight-for-age z-score of -2.7 to 0.02 at 
18 months (22). The outcome height-for-age was reported in three studies with one 
providing mean values at regular time intervals and the other providing proportions 
on either side of the -2 threshold, with children with HAZ <-2 considered to be 
stunted.   Forty-eight percent and 60% of infants were stunted at six months after 
initiation of ART.  Weight-for-height was only described in one study with 13.7% of 
infants being wasted at six months (16). 
Loss to Follow Up 
Loss to follow up was poorly reported for infants with only six studies reporting on 
it. Those studies providing this measure for our population of interest provide 
cumulative probabilities of being LTFU at six months ranging from 0% at six months 
in Ekouevi et al (2011) to 6-10% depending on immune suppression group in the 
KIDS-ART LINC (2008) study.  At 12 months this probability ranges from 
approximately 11% in the KIDS-ART LINC (2008) study to 30% in McNairy et al 
(2013)(36, 39). In the study by McNairy et al (2013) these probabilities of LTFU are 
further reported as per year of initiation of ART with 12 month probabilities of 
LTFU decreasing from 35% in 2005 to 27% in 2009 and 24 month probabilities from 
39% in 2005 to 37% in 2009.  
Janssen et al (2010) is the only study to provide infant LTFU rates and, as seen in 
mortality outcomes, suggest a high risk period for LTFU in the first 90 days after 
initiation of ART. This trend can also be seen in the Anaky et al (2010) study as it 
provides simple proportions of LTFU within the first three months of ART and then 
in the following nine months with a reduction to over half the proportion of infants 
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lost to follow up in this second period of nine months than the first three months of 
ART.  
These observed differences in LTFU across the different studies may be due to 
several different reasons. For example in the Tukei et al (2013) study a small value 
of a 2% proportion of infants lost to follow up at six months is attributed by the 
authors in part to their strict inclusion criteria, likely to have been imposed for 
purposes of minimising LTFU itself, such as stability and presence of caregivers, 
proximity to the facility and willingness to participate in regular tracing and home 
visits. There exists significant variation in the prevention, reporting, definition and 
management of LTFU.  This reflects different observation periods, retrospective and 
prospective cohort designs, effort and ability to ascertain vital status and statistical 
management in analysis. Of the six studies discussing LTFU only three discussed 
efforts made to trace these participants with phone calls and home visits in 2 (20, 40) 
and the other stating no ascertainment of vital status (28). Only four further studies, 
which did not include LTFU as a reported infant outcome, discuss efforts made to 
elicit vital status and these efforts range from no tracing effort at all (31) to the use of 
a full time dedicated on site defaulter tracer with phone and home visits (30).  
The definitions of LTFU in general ranged from a loss of contact for 30 days to that 
of six months. The effect of use of different definitions of LTFU on the estimation of 
LTFU in ART cohort analysis has been described by Grimsrud et al (2013) as they 
highlight the need to use consistent definitions when comparing this outcome (1).   
The analytic management of LTFU ranged from simple acknowledgement of 
underestimation of death, complete exclusion from analysis, sensitivity analysis and 
the alternative measurement of loss to program. No study used a competing risk 
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analysis for the outcomes of death and LTFU. Overall the Feinstein et al (2012) 
study of growth outcomes provided the most transparency providing detailed 
description of LTFU within different subgroups, the assessment of correlation 
between all covariates with death and LTFU and use of sensitivity analysis to assess 
selection bias due to LTFU or death. This analysis suggested that only extreme 
correlation assumptions would affect the null associations observed in the study (41). 
In comparison Purchase et al (2012) excluded from their study all infants lost to 
program prior to six months of ART resulting in a population of survivors and non-
defaulters – a probable source of selection bias (22). Bias resulting from the 
association between LTFU and underreported mortality is of particular concern in 
infants due to their vulnerabilities, correlation of LTFU with other factors associated 
with poor outcome and the risk of death upon defaulting medication administration 
(18, 65). Maximisation of efforts to ascertain outcomes is therefore important in 
preventing this bias.  
Loss to Program  
Seven studies looked at an outcome which included LTFU (or defaulting care as 
described by Fetzer et al (2009)) and death together as a measure of retention in care 
or program attrition. For example, Fetzer et al (2009), for example, a study with no 
community tracing of defaulters, report a 49% loss to program - a very high 
proportion when we consider the short overall cohort median follow up time. 
Purchase et al (2012) measured “completion of ART” at six, 12 and 18 months and 
reported the predictors thereof (22).  
These outcomes as described in these seven studies can be seen summarised below.  
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Table 4. Loss to Program Outcomes 
Author 
3 
months 
6 
months 
12 
months 
18 
months 
24 
months 
Overall 
Fetzer et al (2009) 
(31) 
     
49% in a median of 196 days 
follow up 
Purchase et al (2012) 
(22) 
 27% 44% 59%   
Tukei et al (2012) 
(16) 
 7%     
Anaky et al (2012) 
(20) 
20% 28% 30% 34%   
Sauvageot et al (2010) 
(32) 
  32%  43%  
Ekouevi et al (2011) 
(28) 
 8.9% 29.8%    
McNairy et al (2013) 
(36) 
  39%  49%  
 
Other  
Other outcomes described for infants were development of BCG Immune 
reconstitution inflammatory syndrome (IRIS) during ART, hospital admissions 
during ART, haemoglobin response, albumin response, drug toxicities or adverse 
events and regimen changes during ART. Drug related outcomes such as adverse 
events, toxicities and regimen change were rarely described for the infant group 
largely due to very small numbers. Tukei et al (2013) for example describes 8.3% 
(N=7) of infants as experiencing adverse treatment events within first six months on 
therapy. This study also described how by 24 months 44 of the 47 participants who 
were still in active care were still on first line treatment. They also state that seven 
children initiated on ART as infants were switched to second line treatment due to 
persistent viraemia. Kay et al (2012) in comparison, a study also having access to 
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virological measures, observed 12% of infants experiencing regimen change but all 
were due to toxicities as the clinical and immunological criteria which were used in 
the study to direct regimen change, were not met by any of these infants. Sauvageot 
et al (2010) focusses specifically on toxicity to different drugs and describe a rate of 
3.8 events per 100 child years for zidovudine and none for nevirapine or stavudine.  
Mubiana-Mbewe et al (2009) describe incident clinical conditions and report a high 
incidence of 68.5 cases of upper respiratory tract infections (URTI) in infants per 100 
child years of observation on ART. Sauvageot et al (2010) also described the 
outcome of new stage four events and in doing so again highlighted the high risk 
period of the first three months after initiation of ART with 10.9 events occurring per 
child year in this period. Purchase et al (2012) describe the change in proportion of 
infants having experienced hospitalisation for any cause in the last six months at six 
month intervals of observation. They compare these values to the 74.5% of infants at 
initiation who had been hospitalised at least once prior to initiation since birth. 
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Table 5a. Outcomes described – Analytic Infant Outcomes                                                          
Author Follow up Time  Mortality Virological 
Immunological 
(CD4%) 
Growth LTFU Other 
Bolton–Moore 
et al (2007) 
(23) 
NRI. 
Overall: 378 
daysa 
 (138 – 692c)  
Total: 21.1/100 CYe  (15.4-28.2CI) 
<90d: 52.2/100 CYe  (35.2-74.5CI) 
>90d: 7.3/100 CYe (4.1-12.0CI) 
 
(reported graphically) 
6m  ±27% a 
12m ±30% a 
24m ±35% a 
WAZ 
(graphically) 
6m&12m: ±-1.25b 
18-24m >-1b 
NRI. 
Overall 13% 
Hb 
(reported graphically) 
12m ±11g/dlb 
24m ± 12g/dlb 
Mubiana – 
Mbewe  et al 
(2009) 
(24) 
NRI.  
280 daysa 
(110 – 459 c)  
    
NRI 
Overall 
13.6/100 CYe 
Incident clinical conditions 
URTI 68.5/100 CYe (48.3-94.5CI) 
LRTI 24.9/100 CYe (14.2- 40.4CI) 
Mucocutaneous:56.5/100CYe(38.3-80.0CI) 
GIT: 53.3/100 CYe (36.2-75.8 CI) 
Purchase et al 
(2012) 
(22) 
NR.  
 Observation up 
to 18 months 
post-initiation 
 
6m 1.4a  log10 copies/ml, 
52%, LDL , 75% < 400 
12m 1.4a  log10 copies/ml, 
57% LDL , 78% < 400 
18m 1.4 a  log10 copies/ml, 
79% UDL 
6m 22.7% a 
(4.7-66.9d) 
12m 30.6% a 
(7.5-48.7d) 
18m 33% a 
(9.7-46d) 
WAZ 
6m -0.51b ±1.39f 
12m -0.05 b ±1.25f 
18m - 0.02 b ± 1.10f 
NR 
Lost to Program 
6m 27%, 12m 44% 
18m 59% 
Hb 6m 11.6g/dl a 
Hospitalisations:  6m24.5%, 12m12.9%, 
18m2.6% 
Regimen change: 3% 
BCG Adenitis <6m13.8% 
Feinstein et al 
(2012) 
(41) 
NR. 
Administrative 
end 2 years 
   
(graphically) 
WAZ (%>-2) 
6m ±40%, 12m ±90% 
18m  ±95% 
HAZ (%> -2) 
6m ±40%, 12m ±55% 
18m ±70% 
NRI. 
Overall 12% 
 
Kay et al 
(2012) 
(21) 
NR. 
Observation up 
to 18 months 
post-initiation 
 
Cum.  Prob. VS* 
6m 45%, 12m 58% 
18m 58% 
Time to VS 
3.7m a  (0.9–8.0 d) 
CD4% increase 
Those with VS*: 
18m: 22% a (12-38d) 
Those without VS*: 
18m: 18% a (-3 to 33d) 
 
NR 
Data suggests 
no LTFU 
Regimen Change: 
12% (toxicity) 
Tukei et al 
(2013) 
(16) 
752 daysa   
(531-980c) 
4.09/100 CYe 
(1.95-8.58CI) 
Cum.  Prob. VS* 
6m 72% (61.6-81.3CI) 
12m 83% (73.8-90.5CI) 
24m 84.1% 
6m 30%b 
12m  33%b 
24m  36%b 
WAZ < -2: 6m 30.8% 
HAZ < -2: 6m 48% 
WHZ<-2: 6m 13.7% 
6m 2% 
Adverse events 
6m: 8.3% 
Active care: 6m 93% 
*VS =virological suppression as determined by HIV-1 RNA<400 copies ml        
 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available, CY: Child years, LDL: lower than detectable limit, LTFU: Loss to Follow-up, ART: Antiretroviral Therapy, WAZ:  
Weight-for-age z score, HAZ: Height-for-age z score, BCG: Bacillus Calmette–Guérin, URTI: Upper Respiratory Tract Infection, LRTI: Lower Respiratory Tract Infection, GIT: Gastrointestinal Urinary, Hb: Haemoglobin 
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: month, d: day  ( Time reference points refer to time since initiation ART ) 
 
 
Outcomes of Infants starting ART in Southern Africa                                                                                                                                                                                           Literature Review 
45 
 
 
Table 5b. Outcomes described- Descriptive infant outcomes                                                             
Author Follow-up Time 
Mortality 
(Cumulative Probabilities) 
Virological 
 
Immunological 
(CD4) 
Loss to Follow Up 
(Cumulative Probabilities) 
Other 
Bong et al 
(2007) 
(33) 
NR. 
(up to 6 months 
post-initiation) 
3m: 18.9% 
6m: 24.3% 
  
NRI 
Overall cohort 9% 
 
 
KIDS-ART 
LINC (2008) 
(39) 
NRI. 
Overall: 
20.3 monthsa 
(11.7-27.9 c) 
(reported graphically) 
6m ± 15% 
12m, 18m, 24m: ± 17.5% 
  
(reported graphically) 
6m: ± 6% - 10%, 12m: ± 11 % 
18m: 14%, 24m: 14%- 20% 
 
Fetzer et al 
(2009) 
 (31) 
NRI. 
Overall: 
196 days a 
(105-310 c) 
   NR Loss to program: 
49% 
Davies et al 
(2009) 
(25) 
NRI. 
Overall 
16 months a 
(6-29c) 
(reported graphically) 
6m ± 13%, 12m ±15% 
18m  ± 16%, 24m ± 16% 
36m ± 17% 
  
NRI 
Overall cohort 12m:2.2%in those 
initiating prior to 2004 and 8.2% in those 
initiating 2006 or later 
Transfer Out: 
Overall 24m: 50% 
of tertiary cohort 
Anaky et al 
(2010) 
(20) 
NR 
6m: 0.14 (0.07-0.21CI) 
12m: 0.16 (0.10-0.22CI) 
18m: 0.16 (0.10-0.22CI) 
Mortality Rates 
Total: 20.9/100 CYe (11.3-30.5CI) 
0-3m: 43.7/100 CYe (19.5-69.0CI) 
4-12m: 9.8/100 CYe (1.8-17.8CI) 
  
Proportions 
Total:15% 
0-3 months:11%, 4-12m: 5.5% 
 
Loss to Program 
3m: 0.20 (0.13-0.27CI) 
6m:  0.28 (0.20-0.36CI) 
12m: 0.30 (0.21-0.39CI) 
18m: 0.34 (0.25-0.43CI) 
 
Janssen et al 
(2010) 
(40) 
NR. 
732 child-years 
 
Mortality Rates 
Total: 76.2/1000 CYe (61.3- 94.3CI) 
<90d:149/1000 CYe (128.3-173.4CI) 
>90d: 61.3/1000 CYe (48.0-77.9CI) 
12m:  
4.7a log10 copies/ml 
(3.4-6.2c) 
(64% missing) 
12m: 26%a (20-30c), 
1077a cells/µl 
(712-1343c) 
(50% missing) 
LTFU  Rates 
Total: 50.8/1000 CYe (38.8-66.2CI) 
< 90d: 74.5/1000 CYe (59.8 -92.5CI) 
>90d: 46.0/1000 CYe (34.6-60.7 CI) 
Albumin: 
12m: 35a (30-36c) (75% missing) 
Transfer Out: 2.5% 
Hb:12m: 10.7a (10.5-11.2c) (97.6% missing) 
Fenner et al 
(2010) 
(26) 
NRI. 
Overall: 
17.3 months a 
(8.7-25.7d) 
12m: 15.3/100 CYe   
NRI 
Overall:12m: 7% 
Transfer out 
Overall: 14.3% 
*VS =virological suppression as determined by HIV-1 RNA<400 copies ml       ** Viral Rebound: > 1000 copies/ml after suppression 
 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available, CY: Child years, LTFU: Loss to Follow-up, Hb: Haemoglobin 
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months, d: day  ( Time reference points refer to time since initiation ART ) 
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Table 5b. Outcomes described- Descriptive infant outcomes continued                                              
Author Follow-up 
Mortality 
(Cumulative Probabilities) 
Virological 
 
Immunological 
(CD4) 
Loss to Follow Up 
(Cumulative Probabilities) 
Other 
Sauvageot et al 
(2010)  
(32) 
NRI. 
Overall 
10.5 monthsa 
(3.7-20.6 c) 
Survival 
12m: 0.85 (0.79-0.89CI) 
24m: 0.80 (0.71- 0.86CI) 
  NR 
Remaining in care 
12m:  0.68 (0.60-0.74CI), 24m: 0.57 (0.47-0.65CI) 
Stage 4 Events0-6m: 10.9 events/ CYe (5.3-20.3CI), 
6-12m: 6.3/CYe (2.0-19.5CI), >12m: 4.7/ CYe (1.2-18.3CI) 
Toxicities: 6m: No events for NVP or D4T. 
AZT: 3.8 events/100 CYe (0.9-15.1CI) 
Meyers et al 
(2011) 
(30) 
12.3 monthsa 
(3.6-24.8 c) 
 
Mortality Rates 
Total: 10.7/100 CYe (8.4-13.7CI)   
<90d: 32.08/100 CYe (23.6-45.7CI) 
>90d: 5.9/100 CYe (4.1-8.5 CI) 
Proportion 
attaining: VS*: 
84.5% 
Viral Rebound** 
9.36% 
(reported graphically) 
6m: ± 23%a 
12m: ± 26.5%a 
18,24 & 36m: ±30%a 
NRI 
Overall Cohort: 6% 
HAZ 
(reported graphically) 
6m: ± 2.75b, 12m: ± -2.5b 
18m: ± -2.4b, 24m: ± -2.2b 
Ekouevi et al 
(2011) 
(28) 
NRI. 
Overall: 
1761 child-years. 
6m: 8.9% (3.4-22.2CI) 
12m: 10.7% (5.0-26.0CI) 
  
6m: 0.00 (0.00-0.00 CI) 
12m: 20.2 (10.2;37.8 CI) 
Loss to Program 
6m:  8.9% (3.4-22.2CI) 
12m: 29.8% (18.0-46.6CI) 
Kabue et al 
(2012) 
(27) 
NRI. 
Overall: 
2.3 yearsa 
(1.5–3.1 c) 
Proportion Deaths 
Age < 6m: 12m: 15.1% 
 Age 6–12m: 12m:  5.7% 
 
 
% with >5% increase 
in CD4% 
Age< 6 m: 
12m: 78.8% 
Age 6-12m: 
12m: 85.5% 
NRI 
Overall Cohort: 9% 
 
McNairy et al 
(2013) 
(36) 
NRI. 
Overall: 
598 daysa 
(245-1106c) 
Total:12m: 13%, 24m: 18% 
2005:6m: 11%, 24m: 21% 
2009 6m: 12%, 24m: 16% 
  
Total:12m: 30%, 24m: 39% 
2005: 12m: 35%, 24m: 39% 
2009: 12m: 27%, 24m: 37% 
Retention in care: 
Total:12m: 61%, 24m: 51% 
2005:12m: 57%, 24m: 48% 
2009:12m: 64%, 24m: 53% 
Omoni et al 
(2013) 
(29) 
NR. 
Up to 
12 months 
post-initiation 
  
12m: 28.9%b 
(24.4-33.4d) 
NRI 
Overall Cohort: 7.3% 
 
*VS =virological suppression as determined by HIV-1 RNA<400 copies ml       ** Viral Rebound: > 1000 copies/ml after suppression 
 
NR: Not reported, NRI: Not reported for infants, overall cohort statistics provided where available, CY: Child years, UDL: Undetectable limit, HAZ: Height-for-age z score  
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months, d: day (Time reference points refer to time since initiation ART)           
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Determinants of infant outcomes  
Within those studies reporting results on the predictors of the primary outcome in 
infants the predictors assessed were largely immunological, virological, clinical, 
growth and regimen baseline characteristics. In addition serum creatinine and 
adherence were assessed as determinants for mortality (24). The results of these 
analyses are presented in Table 6 below. 
Of the six studies providing an analysis of predictors of outcomes specifically for the 
infant subgroup, three did not yield significant results. Predictors were identified for 
mortality and for virological suppression at 18 months. Further analysis of univariate 
association between loss to program at 18 months suggests that mean CD4 cell count 
differs significantly in those that do and do not remain alive and in care to this point 
(22).  In a multivariate Cox proportional hazards regression analysis identifying 
predictors of time to death in 291 infants age below 18 months with a median age of 
six months at ART initiation identified lower categories of weight-for-age and CD4 
cell percentage as being associated with death. The sample on which this analysis 
was done was 157 completed cases. Adjustment for all variables found in the 
univariate analysis to be associated with death at p<0.1 as well as all variables found 
to be significant in the adult and older child cohorts of the overall study. The 
estimates are very large (Hazard ratio (HR) of 19 for an infant with WAZ ≤-3 
compared to >-1 when all other variables are kept constant) but despite non- 
inclusion of the null value have very wide confidence estimates (2.4-150 for this 
estimate). This suggests that the data may have been too few or too varied to attain a 
precise estimate and that uncertainty as to the validity of this estimate exists.  
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Predictors for time to virological suppression were identified in the Kay et al (2012) 
study. These included age in months, viral load and CD4 cell percentage at initiation 
of ART. Again the wide confidence intervals reflect the small sample size - in this 
case 34 infants.  
Tukei et al (2013) provide a logistic regression analysis of factors associated with 
attainment of virological suppression at six months.  This analysis was however 
restricted to those infants remaining on ART for at least six months.  As reported in 
the studies by Anaky et al (2010) and Bolton-Moore et al (2007) we know that this 
early period is a time of extreme risk of death. Exclusion of those infants not 
surviving this period would result in a population with characteristics different to the 
general population initiating ART and excluded a significant portion of infants in 
who the association might have been observed. Additionally it could possibly have 
aggravated an already existing survival bias. Furthermore the use of logistic 
regression where informative censoring has not been considered may have resulted in 
biased estimates. 
The classification of the outcome incident clinical conditions into several groups in 
the Mubiana-Mbewe et al (2009) study may have resulted in the infant population of 
101 participants being further divided into very small subgroups and may have 
contributed to the failure to ascertain a significant association.   
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Table 6. Determinants of infant outcomes 
Author Primary Outcomes  Baseline Predictors assessed  Baseline Predictors identified 
  
Comments 
Bolton–Moore  
et al (2007) 
(23) 
Mortality 
 
Age (months), CD4 %, WAZ, Hb, 
sex, TB, creatinine WHO stage, 
regimen, adherence, 
 
WAZ scores 
WAZ >-1 
WAZ >-2 to -1 
WAZ >-3 to -2   
WAZ ≤-3 
CD4 cell percentage  
CD4 ≥20%:  
CD4 10 to <20%:  
CD4 < 10%:  
 
Crude 
Reference 
HR 1.9 (0.3-11.5 CI) 
HR 6.1 (1.3-27.7 CI) 
HR 9.7 (2.3-40.9 CI) 
 
Reference 
HR 4.7 (1.4-15.7 CI) 
HR 5.2(1.4-18.8 CI) 
 
Adjusted 
Reference 
HR 4.7(0.5-45.9 CI) 
HR 17 (2.0-141 CI) 
HR 19 (2.4-150 CI) 
 
Reference 
HR 16 (2.1-123CI)    
HR 18 (2.1-151CI) 
Cox regression. 
Adjusted for all factors  found in 
univariate analysis to be 
significant the p <0.10 level as 
well as those found significant in 
the adult study. 
Mubiana – 
Mbewe et al 
(2009) 
(24) 
Incident  
clinical  
conditions 
CD4 %, gender, WAZ, WHO stage, 
Hb. None 
Only univariate analysis done for infant subgroup, no significant associations identified. 
Purchase et al 
(2012) 
(22) 
Loss to Program 
at 18 months 
 
Age, gender, NVP exposure, WHO 
stage, TB, CD4%, VL 
CD4 cell percentage  
Those completing 18 months: 
vs 
Those not completing 18 
months: 
 
Mean CD4 cell%: 14%  
 
Mean CD4 cell%: 17.7%  
(p=0.005) 
 
Analysis was only done on those who completed 6 months of 
treatment 
Feinstein et al 
(2012) 
(41) 
Weight recovery 
(WAZ > -2) 
Height recovery 
(HAZ > -2) 
Baseline CD4 None 
Severe immunodeficiency (CD4%<25% ) not found to be associated with weight recovery 
(adjusted HR 1.17 (95%CI 0.69-1.99)) nor height recovery (adjusted HR 1.02 (95%CI 0.56-
1.88)) 
Kay et al 
(2012) 
(21) 
Virological  
suppression* 
 
CD4, VL, gender, WHO stage, 
breastfeeding 
 
Age  
               per 1 month increase 
Viral Load   
< 750 000 
copies/ml 
CD4 cell percentage 
 >25% 
 
Crude 
HR 1.29 (1.14-1.47 CI) 
 
HR 4.95 (1.74-14.1 CI) 
 
HR 5.00 (1.75-14.3 CI) 
 
Adjusted 
HR 1.28  (1.10-1.49 CI) 
 
HR 3.54 (1.13-11.1 CI) 
 
HR 6.0 (1.83-19.6 CI) 
Cox Proportional Hazards 
Regression 
Tukei et al 
(2013) 
(16) 
Virological  
suppression*  
at 6 months 
 
Gender, CD4 %, WHO stage, WAZ, 
HAZ, WHO guidelines, regimen 
None 
 
Analysis was only done on those who completed 6 months of treatment 
Logistic regression  
*Virological suppression as determined by HIV-1 RNA<400 copies ml   
      
ART: Antiretroviral Therapy, WAZ: Weight-for-age z score, HAZ: Height-for-age z score, Hb: Haemoglobin, TB: Tuberculosis, WHO: World Health Organisation, NVP: Nevirapine, VL: Viral load 
a: median, b: mean, c: Interquartile Range, d: Range, e: rate per no. child years, f: Standard Deviation, CI: 95% Confidence Interval, m: months, HR: Hazard Ratio 
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Summary, Interpretation and needs for further research 
The findings of the studies in this review can be summarised in accordance with the 
respective objectives of the review.  
1. To identify all published literature pertaining to studies assessing the 
outcomes (and where available the predictors of these outcomes) of infants 
initiated on ART in routine care in Sub-Saharan Africa, 
Using an electronic database and a keyword search 998 published articles were 
identified, 18 of which satisfied the inclusion and non-exclusion criteria. A further 
article (20), meeting the same inclusion criteria, was identified through examining 
bibliographies of reviews and articles identified.  In keeping with the inclusion 
criteria all reported on outcomes specifically pertaining to an infant group and 6 of 
these provided results from the analysis of predictors for these outcomes.  
2. To consider the evidence provided by the literature regarding all 3 
objectives of the mini-dissertation, and to review and report on the quality 
and results of the studies by critically reading and synthesising the findings 
and evidence regarding the outcomes of these infants,  
Objective 1: To describe the baseline characteristics of infants 
commencing ART in IeDEA sites in Southern Africa.  
Baseline characteristics for an infant group or subgroup were not very well reported 
in the majority of studies. Clinical disease severity (by means of WHO staging) and 
immunological measures (CD4 counts, percentages and prevalence of percentage 
categories) were the most consistently measured and reported measures yet both 
commonly yielded high levels of missing data. PMTCT and cotrimoxazole exposure 
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were the most poorly recorded and reported variables commonly not measured or 
measured with high levels of missing data.  
When considering clinical, immunological, virological and growth measures 
together, as in keeping with the aim of the mini dissertation which this review aims 
to inform, we can identify a few trends amongst the studies with which we can 
identify those studies wherein infants starting ART are either relatively healthy or 
unwell.  
Kay et al (2012) represent a population of infants at a relatively young age with some 
of the most favourable WHO staging, highest CD4 measures, lowest viral loads and 
relatively good weight-for-age measures. They however represent a population 
where PIs were not available and all used a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) based regimen (nevirapine) despite all being nevirapine- exposed 
through PMTCT.  Similarly Janssen et al (2010) represents a population with 
favourable immunological, virological and growth measures but differ in the older 
age, a moderate WHO staging and very high tuberculosis prevalence compared to the 
other studies providing results of these measures in infants.  
In contrast when we look at the study by Meyers et al (2011), observing a relatively 
young population of infants, the measures of these baseline characteristics are 
amongst the worst regarding clinical disease, CD4 count and percentage, viral load 
and weight and height-for-age. Furthermore this group has one of the highest 
prevalence of tuberculosis at initiation making them a significantly unwell 
population of infants in whom we would expect poor outcomes. 
When briefly compared to those characteristics of infants initiating ART in trials in 
the same region of Sub-Saharan Africa we note that the infants in the majority of the 
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observational studies in this review were much older and had higher prevalence of 
characteristics indicating more severe disease severity.  Most notably we see this in 
immunological characteristics largely due to the inclusion criteria e.g CHER (Violari 
et al (2008)) excluding all infants with CD4%<25% (4). Furthermore in 
observational studies conducted in the developed world these characteristics, 
particularly immunological, were at far better levels than any of the studies in this 
review (5).   
Objective 2: To describe and examine the outcomes of infants starting 
ART in Southern Africa. Summary of Outcomes  
These observational studies show that infants initiated on ART improved regarding 
all immunological, virological and growth measures as well as frequency of 
hospitalisations and haemoglobin. This provides supporting evidence to the fact that 
ART is effective in infants beyond the trial setting.  
The magnitude of these improvements and the occurrence of outcomes of death, loss 
to follow up and virological suppression outcomes differed considerably in the 
different studies. Variation appears to reflect in part the distribution of baseline 
characteristics (particularly age at initiation and disease severity) and on definition or 
methods of ascertainment of the outcomes, particularly loss to follow up, as reflected 
in the sections above.  Furthermore programmatic factors such as year of 
observation, prevailing ART initiation guidelines and availability of ART regimens 
may be responsible for a component of the observed differences. Study 
characteristics of length of follow up also appear to considerably affect the estimates 
due to the non-constant nature of risk of these infant outcomes through time. Where 
baseline characteristics reflect those of the chronological, geographical and 
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programmatic situation this information provides us with an understanding of the 
impact of these factors on the cohort profile. Where these characteristics are a result 
of selection process, however, we hold concern as to the validity of these findings 
and specifically to the external validity – its generalizability to our study population.  
Objective 3: To identify and examine predictors for these outcomes.  
Of note is the scarcity of evidence pertaining to the predictors of outcomes of infants. 
Only six studies did such an analysis, only two of which used multivariate statistical 
methods appropriate to the longitudinal nature of the data. The neglect of the issue of 
censoring as done in the other analyses could result in a biased estimate.  
Sample size was of concern in almost all of these analytic studies. Whether a result 
of available participants, categorisation of outcomes or exclusion the resulting 
sample sizes have, even where estimates appear considerable, failed to provide 
certainty.  
Summary of study quality and validity  
Due to the specific inclusion criteria with its chronological, geographical, age and 
routine setting characteristics there was, in general, homogeneity in the populations 
in the articles used in this review. There is variation in the age group however as a 
paucity of literature led to the inclusion of infants up to 19.9 months of age. Sample 
size differs significantly when assessing the infant population with smaller sizes 
being seen in those articles best pertaining to our research objectives with the 
reporting of predictors of outcomes for infants. Median follow up rarely exceeded 
two years and was often not reported for the infant subgroup.  
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The main issues of validity which we have discussed in the previous sections are 
those of selection bias. This includes several issues including survival bias, 
management of missing data (as exclusion in complete case analysis is itself 
selection), LTFU and study exclusion criteria. These biases, all common in cohort 
data, are possibly emphasized in the infant population due to their rapidly changing 
physiology and physical and social vulnerabilities resulting not only in a wide range 
of  disease characteristics but also risk of outcomes, particularly death and loss to 
follow up (10, 66).  
No cohort is thus truly comparable to another and differences in baseline 
characteristics, programmatic factors and their outcomes are inevitable. This 
however, does not necessarily represent invalidity but rather, highlights for us the 
extreme effects of changing guidelines and infant ART programs, resource provision 
and in doing so provides us with a valid description of infants who are initiating ART 
in Southern Africa.  
The ideal study for purposes of fulfilling the objectives of this review would have 
included a sample of infants < 12 months of age which met calculated sample size 
calculations to ascertain the strength of associations in its outcomes and predictors 
thereof. Participants should represent the population which routinely accesses 
standard care in these resource scarce settings and restriction of inclusion 
discouraged as it deters from our aim of assessing routine setting outcomes and 
rather approximates the populations seen in experimental studies.  Focus would be on 
the outcomes of these infants and in so doing allowing for measure of multiple 
outcomes and assessing for the predictors thereof. The observation period should 
have been as long as plausible so as to maximise the opportunity for observing both 
short and long term outcomes particularly in view of the prospect of life-long 
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treatment which these infants have. It would ensure the accurate ascertainment of 
loss to follow up with as much effort as feasible while at the same time not limiting 
inclusion to the extent of decreasing generalizability. Furthermore ascertainment of 
vital status should be done as far as possible and analytic consideration of the effect 
of false assumptions through sensitivity analysis done.  It would have logically, 
based upon existing literature, assessed the role of possible confounders and other 
third variables and correctly managed these. In a similar way transparency for 
occurrence and management of sources of bias such as loss to follow up, censoring 
and missing data should have been provided.  
None of the studies reviewed here fulfil all these criteria. Although providing 
methodologically strong evidence the Feinstein et al (2012) study does not 
adequately apply to our research questions. Tukei et al (2013) and Bolton-Moore et 
al (2007) address the aim of our study most directly however issues of sample size 
and generalizability for Tukei et al (2013) and management of confounders and 
prevention of bias are of concern in the Bolton-Moore et al (2007) study. Despite 
some shortcomings, together these studies provide valuable insight into the 
expression of associations for a range of outcomes and predictors in a resource poor 
setting of sub-Saharan Africa, highlight possible methodological and statistical 
pitfalls and establish a foundation and background upon which the findings of the 
study of this mini-dissertation may be placed. 
3. To synthesise this information and to identify areas where further research 
would be gainful.  
The Drugs for Neglected Disease initiative declared Paediatric HIV as one of the 
globally neglected diseases in 2010 (14). This review highlights that amongst this 
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group stands an even more severely neglected population – HIV infected infants. 
With a severe paucity of evidence, particularly in the lower to middle income 
countries within Southern Africa where the majority of these infants live and die (66, 
67), there exists a large gap in the knowledge of the characteristics and outcomes of 
HIV infected infants initiating ART. 
To attain a generalizable description of baseline characteristics and outcomes with 
certainty in its analysis for predictors for these outcomes we require recent evidence 
from a large sample of multiple cohorts from varied routine settings.   
IeDEA  is an international initiative formed by the pooling of several large data sets 
each comprised of HIV infected individuals attending standard care at participating 
sites (1, 68, 69). The collaboration of IeDEA- SA involves sites from South Africa, 
Zimbabwe, Mozambique, Malawi, Botswana and Zambia all of which have HIV 
adult prevalence rates above 10% (10, 70). The main objectives of IeDEA-SA are “to 
conduct clinical, epidemiological and health services research in order to inform 
HIV/AIDS and tuberculosis service delivery in the region, to increase the capacity 
for delivering ART, and, ultimately, to improve the prognosis of people living with 
HIV and AIDS in Southern Africa.” (70) The IeDEA-SA database is constituted of 
data routinely recorded from participants at every clinic visit and collected on site by 
site investigators using a Data Transfer Protocol (Appendix A). This Data includes 
baseline and follow up visit data using standardised definitions as per the protocol.   
This data therefore offers us the opportunity to address the research objectives. It will 
help us address the research questions of “What are the outcomes of infants starting 
ART in routine care in Southern Africa?” and “What are the predictors of these 
outcomes?”  
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Abstract  
Background: There is limited published data on the outcomes of infants starting 
antiretroviral therapy (ART) in routine care in Southern Africa. This study aimed to 
examine these outcomes together with the baseline characteristics of infants at ART 
initiation.  
Methods: Analysis of prospectively collected cohort data from routine ART initiation 
in infants at 11 sites contributing to the International Epidemiologic Database to 
Evaluate AIDS in Southern African was done. ART naïve HIV-infected infants <12 
months of age at initiation of ≥ three antiretroviral drugs after 2003 were included. 
Kaplan-Meier estimates were calculated for mortality, loss to follow-up (LTFU), 
transfer out and virological suppression. Cox Proportional Hazards models stratified by 
site were used to determine baseline characteristics associated with outcomes mortality 
and virological suppression.  
Results: The median (interquartile range (IQR)) age at ART initiation of 4945 infants 
was 5.9 months (3.7-8.7) with median (IQR) follow-up of 11.2 months (2.8-20.0). At 
ART initiation 87% were severely immunosuppressed (World Health Organisation 
(WHO) 2006 definition) and 77% had WHO clinical stage 3/4 disease.  Three-year 
mortality probability was 15.9% and LTFU 28.9%. Severe immunosuppression, WHO 
stage 3/4, anaemia, being severely underweight and initiation of treatment prior to 2010 
were associated with worse mortality outcomes. At 12 months from ART initiation the 
proportion of infants severely immunosuppressed was 17% and the probability of 
attaining virological suppression was 56.1%.  
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Conclusion: Most infants initiating ART in Southern Africa had severe disease. Infant 
immunological and virological responses were suboptimal and high levels of LTFU and 
mortality were seen.  
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Introduction 
Despite advances in Prevention of Mother to Child Transmission (PMTCT) programs, 
including possible reduction of vertical transmission to as low as 1% 2011 saw over 900 
HIV infected infants born daily, the vast majority in sub-Saharan Africa.1,2 Infants differ 
from older children and adults with respect to rapid physical growth (especially of their 
developing brain), establishment of a functioning immune system and a rapidly 
changing physiology. 3-5 Furthermore infants infected with HIV experience an increased 
vulnerability to the multiple insults of the virus and its complications 6,7 including 
accelerated disease progression and an increased risk of morbidity and mortality. 8-12 
These worsened outcomes, together with age-specific diagnostic, 5,13 treatment and 
monitoring 8 challenges as well as neglect in advances in paediatric HIV  policy, 
pharmaceuticals and testing, make infants a high risk population. 5, 13-15 
2008 saw changes to international guidelines for the initiation of antiretroviral 
therapy (ART) in infants where all infants below 12 months of age, regardless of 
immunological and clinical statuses previously used, were eligible for initiation of 
ART. 16 Subsequently the 2010 and 2013 guidelines were amended to provide ART 
for all children under 2 and under 5 years of age respectively 17,18  These changes 
were largely catalysed by evidence from experimental studies such as the Children 
with Human Immune Deficiency Virus Early Antiretroviral Therapy Trial (CHER). 
This trial, conducted in South Africa, quantified the benefits of early initiation of 
ART before 12 weeks of age in a 76% reduction in early infant mortality and 75% 
reduction in HIV progression when compared to deferring ART until World Health 
Organisation (WHO) 2006 treatment initiation criteria were met. 19,20 
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With an average age at commencement of ART of 7 weeks, availability of 
appropriate laboratory testing and drug regimens including protease inhibitors, 
minimisation of loss to follow up and the exclusion of those with comorbid 
conditions or severe immunosuppression the features of this trial and its participants 
differ considerably from those within the resource-scarce routine care setting of 
Southern Africa. 5,13,15,20-23 
Literature pertaining to the outcomes of infants starting ART in routine care in resource 
scarce settings such as Southern Africa is limited and few studies include large numbers 
of infants starting ART after the WHO 2008 recommendation for immediate ART 
initiation in infants and the implementation thereof. Using data merged from the 
International Epidemiologic Database to Evaluate AIDS in Southern Africa (IeDEA-
SA) sites this study aimed to describe baseline characteristics of infants starting first line 
ART in routine care settings within Southern Africa, their treatment outcomes including 
clinical, immunological and virological responses and to identify the determinants for 
these outcomes. 
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Methods 
Study design and population 
We conducted a retrospective analysis of prospectively collected cohort data of 
infants that initiated ART in routine care settings between January 2004 and 
December 2012 at sites contributing to the IeDEA-SA collaboration.24 Data for this 
collaborative cohort is captured on site by site investigators through the routine 
clinical follow up of infants within the standard treatment and monitoring of HIV 
and ART and anonymised data is then transferred to the central IeDEA-SA 
datacenter using a Data Transfer Protocol.  
This analysis included 11 sites from South Africa, Zimbabwe, Malawi and Zambia. 
Site inclusion required the initiation of infants on ART both before and after 1 
January 2010 so as to as to ensure that each cohort captured a portion of infants 
initiated after the release of the WHO 2010 guidelines for early initiation. 25 HIV–
infected (recorded Polymerase chain reaction (PCR) diagnosis or presumptive 
diagnosis); ART-naive (except for PMTCT exposure) infants with a recorded date of 
initiation of at least 3 antiretroviral drugs before the age of 12 months were eligible 
for inclusion. Participants with missing data for date of initiation of ART, age and 
gender were excluded from the analysis as were those infants identified as being 
virologically suppressed (HIV-Ribonucleic Acid (RNA) <400 copies/ml) due to the 
suggestion of possible non-naivety to ART. Eligibility for ART initiation was site 
specific and would reflect the country’s guidelines at the time and the level of 
implementation of such guidelines. 26 
Each site has institutional ethical approval for contribution of data to IeDEA-SA 
Ethical approval for the database and this analysis was obtained from the Health 
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Sciences Human Research Ethics Committee of the University of Cape Town, South 
Africa.  
Key cohort characteristics and outcomes 
Characteristics of infants at initiation of ART included demographic details, 
anthropometric measures, haemoglobin (Hb), clinical (WHO clinical staging) 27 
,immunological and virological markers of disease severity and information 
pertaining to medicines administered including PMTCT therapy. These 
characteristics are presented overall and according to time period (before or after 1 
January 2010) of initiation. P values are reported as per significance testing for the 
differences between medians (Wilcoxon Sum Rank Test) and differences between 
proportions.  
Where not recorded for day of initiation the measurements from the closest date to 
initiation within an interval 6 months prior and 1 week post initiation was used for 
laboratory baseline characteristics and 3 months prior and up to day of initiation for 
anthropometric characteristics. Age at ART initiation was categorised as <3 months, 
3-6 months and 6-12 months. Severe anaemia was defined using the Division of 
AIDS (DAIDS) guidelines 2 Hb <10g/dL where age in days was ≤ 21; <8g/dL for 
those 22-35 days and Hb <7g/dL for those age 36-56 days and <7.5g/dl for those age 
≥57days. Weight and height measures were converted to age and gender specific z-
scores (weight-for-age z-score (WAZ), height-for-age z-score (HAZ) and weight–
for-height (WFHZ) using the 2007 WHO growth reference standards 29 WAZ and 
HAZ were further each categorised as <-3, -3 to -2 and >-2. Severe immune 
suppression was defined where the lowest of the CD4 absolute cell count or 
percentage met classification as the as per the WHO criteria. 27 Virological 
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suppression was defined on the first date of a recorded viral load <400 copies/ml. 
Year of initiation was defined before 2010 or 2010 and after so as to reflect the 2010 
WHO changes to guidelines for initiation of ART 25 and a time where the 2008 
WHO guidelines were implemented at national levels.  
Death, transfer out (TFO), loss to follow-up (LTFU) and virological suppression 
were assessed as outcomes. LTFU was defined where the last visit recorded was 
more than 9 months prior to site database closure with the date of LTFU being the 
date of the last visit. Response variables included CD4 absolute cell count and 
percentage, viral load and anthropometric measures (WAZ and HAZ).  
Statistical methods 
Descriptive analyses of baseline characteristics of infants at initiation of ART and 
responses over time are provided in accordance with the variable format and 
distribution. Immunological, virological and anthropometric responses over time on 
ART were examined in those infants who remained in care for a minimum of 12 
months. This was done so as to approximate a true change in averages by minimising 
the effect of loss (through death, LTFU) of the sicker infants on these averages.  
Survival Analysis using the Kaplan-Meier method was used to assess time to event 
data for outcomes of mortality, TFO, LTFU and virological suppression. Competing 
Risk Analysis provided Cumulative Incidence Functions considering death, TFO and 
LTFU. Cox Proportional Hazards models stratified by site were used to determine 
baseline characteristics associated with mortality with a separate model including 
estimates for baseline virological characteristics within South African sites. This was 
done due to the high levels of missing virological data from sites outside South 
Africa. Cox Proportional Hazards models stratified by site were used to determine 
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baseline characteristics associated with time to virological suppression in a cohort 
comprised only of infants from South African sites whom had a baseline viral load 
and at least 1 other follow up viral load measurement recorded.  
Missing baseline data for CD4 count and percent, Hb, WAZ and HAZ and WHO 
stage were modelled using multiple imputation. The imputation model, with the 
assumption of data missing at random, included all baseline characteristics including 
site, age and year of initiation, outcomes of mortality, LTFU and TFO and follow-up 
time. Five imputation sets were generated and reported estimates representing pooled 
imputed data estimates were calculated using Rubin’s Rules. 30 
Independent variable for inclusion in the models were selected a priori and are 
complemented by a post-imputation model selection method using Variable 
Importance (VI) and an estimate weighted according to both frequency and strength 
of association in the augmented datasets. 31  
All statistical analysis was done using STATA 12.0 32 with multiple imputation done 
using ICE.  
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Results 
Cohort characteristics 
The median (Interquartile range (IQR)) age at ART initiation of 4945 infants was 5.9 
months (3.7;8.7) with median follow-up of 11.2 months (IQR 2.8;20.0). Amongst the 
11 sites represented in this cohort, together demonstrating all levels of care, 8 South 
African sites contributed 3473 (70%) of infants. 26% of the total cohort represented 
infants initiating ART after 2009.  
Baseline Characteristics 
At ART initiation 76.5% of infants were classified as WHO clinical stage 3/4 and 87.2% 
met the 2006 WHO definition of severe immunosuppression (Table 1). Approximately 
60% of infants were either moderately of severely underweight and approximately 60% 
were either moderately or severely stunted at initiation. A baseline viral load measure 
was only recorded for 41.3% of infants in the total cohort, with median viral load of 
5.99 log 10 copies/ml (IQR 5.41;6.45).  
Infants initiating ART after 2009 were generally younger and less severley ill than those 
initiating in 2009 and before suggesting that a proportion of infants started on ART after 
2009 were started without severe disease (Table1).  
Missing data of baseline characteristics was seen in all anthropometric and laboratory 
measures with the highest prevalence seen in virological data (Table 1).  
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Table 1. Baseline characteristics of infants initiating ART, 2004-2012 
Characteristics N Overall* 2004-2009 2010-2012 p value 
Age  (months),  
median (IQR) 
4945 
5.98 
(3.68;8.74) 
6.11 
(3.81;8.87) 
5.42 
( 3.35; 8.38) 
0.0000 
Female,  
n(%) 
4945 
2546 
(51.49%) 
1845 
(50.69%) 
701 
(53.72%) 
0.0603 
WHO stage 3 or 4,  
n (%) 
4347 
3327 
(76.54%) 
2605 
(81.18%) 
722 
(63.44%) 
0.0000 
Absolute CD4,   
median (IQR) 
3417 
765 
(347;1334) 
724 
( 324;1274) 
887 
(440;1535) 
0.0000 
CD4 Percentage,   
median (IQR) 
3244 
18.45 
(12;26) 
18 
(11.5;24.9) 
20.7 
(13.6;28.4) 
0.0000 
Severe Immunosuppression  
(WHO 2006), n (%) 
3514 
3063 
(87.17%) 
2336 
(89.16%) 
727 
(81.32%) 
0.0000 
Viral Load ≥1 000 000,  
n (%) 
2042 
1012 
(49.56%) 
815 
(49.54%) 
197 
(49.62%) 
0.9777 
Severe Anaemia (DAIDS 
2009), n (%) 
2813 
248 
(8.82%) 
176 
(8.74%) 
72 
(9.01%) 
0.8182 
Weight-for-age z – score 
(WAZ), median (IQR) 
3795 
-2.53 
(-3.96;-1.16) 
-2.69 
(-4.12; -1.34) 
-2.12 
(-3.45;-0.84) 
0.0000 
WAZ category, n (%) 3795 
 
   
WAZ > -2 
 
1523 
(40.13%) 
1.037 
(37.13%) 
486 
(48.31%) 
0.0000 
WAZ ≤ -2 to > -3 
 
686 
(18.08%) 
510 
(18.29%) 
176 
(17.50%) 
0.5762 
WAZ ≤ -3 
 
1586 
(41.79%) 
1242 
(44.53%) 
344 
(34.19%) 
0.0000 
Height–for–age z-score 
(HAZ),  median (IQR) 
2919 
-2.50 
(-3.90;-1.12) 
-2.64 
(-4.01;-1.28) 
-2.16 
(-3.54;-0.77) 
0.0000 
HAZ category, n (%) 2919 
 
   
HAZ  > -2 
 
1177 
(40.32%) 
844 
(38.59%) 
333 
(45.49%) 
0.0010 
HAZ  ≤ -2 to > -3 
 
538 
(18.43%) 
392 
(17.92%) 
146 
(19.95%) 
0.2222 
HAZ  ≤ -3 
 
1204 
(41.25%) 
951 
(43.48%) 
253 
(34.56%) 
0.0000 
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Table 1 Baseline characteristics of infants initiating ART, 2004-2012 Continued 
First Line Regimen, n (%) 4653 
 
D4T + 3TC + 
lopinavir/ritonavir  
2068 (44.44%) 
D4T + 3TC +  nevirapine 
 
971 
 (20.87%) 
ABC + 3TC + 
lopinavir/ritonavir  
598 
 (12.85%) 
AZT + 3TC + nevirapine 
 
343 
(7.37%) 
AZT + 3TC + 
lopinavir/ritonavir 
 
286 
 (6.15%) 
Other  
387  
(8.32%) 
3rd ART drug, n (%) 4659 
 
lopinavir/ritonavir 
 
2957 (63.47%) 
ritonavir 
 
214 
 (4.59%) 
nevirapine 
 
1399 (30.03%) 
efavirenz  
89 
 (1.91%) 
PMTCT exposure, n (%) 1637 
 
Exposed 
 
948 
 (57.91%) 
D4T: stavudine, 3TC:lamivudine, ABC: abacavir, AZT: zidovudine 
*Proportions represent proportion of non-missing (N) observations 
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Mortality and programmatic outcomes 
Mortality was highest in the few months after ART initiation with 6 and 12 month 
cumulative probabilities of 10.1% (95% Confidence Interval (CI) 9.3-11.1) and 
13.2% (95% CI 12.1-14.3) respectively (Figure1a). Cumulative probabilities of being 
LTFU showed a considerable loss in the first year with 6 and 12 months probabilities 
of 13.7% (95% CI  12.7-14.7) and 18.8% (95% CI 17.6-20.1) respectively 
(Figure1a). Transfer out from a higher level of care to another facility occurred 
throughout follow-up with the 36 month probability being 34.2% (95% CI 32.3-36.1) 
(Figure1a). Analysis of these outcomes using the cumulative incidence functions 
from a competing risk analysis provided a 12 month probability of mortality 
(competing with LTFU and TFO) of 11.3% (95% CI 10.4-12.2) (Figure 1b). The 
correlating probabilities of being alive and in care at 6 and 12 months were 71.5% 
(95% CI 70.2-72.7) and 59.6% (95% CI 58.2-61.0) respectively.  
Unadjusted assessment of the outcome mortality according to time period of 
initiation suggested improved mortality in those initiating ART in the year 2010 and 
onwards (Log-rank test for equality of survivor functions p= 0.0005). The apparent 
lower mortality from 2010 onwards was unlikely to be due to lower ascertainment of 
deaths in the later period, as there was a trend towards lower LTFU from 2010 
onwards in comparison to the preceding years (Log-rank test for equality of survivor 
functions for LTFU between time period prior to 2010 and period 2010 onwards 
p=0.0567) (Figure 1c and 1d).
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Figure 1. Kaplan-Meier failure functions and competing risk cumulative 
incidence functions of time to outcomes of death, LTFU and TFO over time on 
ART including in graphs (c) and (d) failure functions of death and LTFU by 
time period of initiation.  
Baseline Characteristics associated with mortality 
Severe immunosuppression (adjusted Hazard ratio (aHR) 2.19, 95% CI 1.44-3.33), 
WHO stage 3/4 (aHR 1.36, 95% CI 1.04-1.78), lower weight-for-age z-score and 
initiation of ART in 2010 or after were each found to be independently associated 
with mortality (Table 2).  Compared to having a WAZ of >-2 those infants with 
WAZ <-3 at baseline had a 2.23 fold (aHR, 95% CI 1.78-2.80) increase in the hazard 
of an earlier time to death. After adjusting for factors of disease severity at baseline, 
infants initiating ART in 2010 or later had a reduced risk of death compared to those 
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(a) Kaplan-Meier estimates for outcomes of 
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(b) Competing Risks Analysis for outcomes of 
infants initiating ART in Southern Africa
Loss to Follow Up
Transfer Out
Death
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0 1 2 3 4 5 6 7 8 9 10 11 12
Months on ART
(d) Kaplan-Meier estimates for Loss to Follow-up 
by time period of initiation
Initiation 2010 onwards
Initiation prior to 2010
F
ai
lu
re
 F
un
ct
io
n
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0 1 2 3 4 5 6 7 8 9 10 11 12
Initiation prior to 2010
Initiation 2010 onwards
(c) Kaplan-Meier estimates for Mortality
by time period of initiation
Months on ART
F
ai
lu
re
 F
un
ct
io
n
Outcomes of Infants starting ART in Southern Africa                                                            Manuscript 
15 
 
initiated before 2010 (aHR 0.75, 95% CI 0.59-0.94). No evidence was found 
supporting an effect on mortality of infant age group.  Overall estimates from the 
imputed datasets using Rubin’s Rules provided similar estimates to those of the 
complete case analysis (Supplementary table 1 and 2).  
In an analysis restricted to infants from SA sites, there was no association between 
baseline viral load category and death after adjustment for other disease severity 
characteristics at baseline (Supplementary Table 2).  
Table 2. Survival Analysis of imputed data: Cox regression for predictors of 
mortality stratified by cohort 
 Univariate Multivariate* Model Selection 
¥ 
Variable HR P value 95% CI HR P value 95% CI HR 95% CI VI 
Female gender 0.97 0.716 0.83-1.14 - - - - - 0.31 
Age at  
Initiation 
0-3 months reference reference reference 
3-6 months 0.90 0.417 0.71-1.15 0.87 0.268 0.68-1.11 - - 0.22 
6-12 months 0.98 0.898 0.78-1.25 0.84 0.161 0.66-1.07 - - - 
Severe Immune 
suppression (WHO 2006) 
2.51 0.000 1.66-3.79 2.19 0.000 1.44-3.33 2.15 1.42-3.27 1 
WHO stage 3 or 4 1.89 0.000 1.47-2.45 1.36 0.023 1.04-1.78 1.35 1.04-1.77 0.87 
Severe Anaemia  
(DAIDS 2009) 
1.57 0.003 1.18-2.10 1.34 0.062 0.98-1.82 1.29 0.82-2.05 0.79 
Weight-for-Age  
(Z-score) 
> -2 reference reference reference 
-2 to -
3 
1.40 0.015 1.07-1.84 1.29 0.063 0.99-1.71 1.29 0.99-1.71 1 
< -3 2.55 0.000 2.04-3.19 2.23 0.000 1.78-2.80 2.22 1.78-2.79 - 
ART Initiated 2010 and 
after 
0.65 0.000 0.52-0.83 0.75 0.015 0.59-0.94 0.75 0.59-0.95 0.88 
*** Viral Load > 1 
million 
1.30 0.045 1.01-1.68 1.17 0.267 0.88-1.56 1.14 0.79-1.62 0.56 
 
*Adjusted for age, weight-for-age category, severe immunosuppression, WHO stage 3/4, severe anaemia and initiation after 
2009 
***modelled on a subset of infants from South African cohorts, adjusted for variables as above  
¥ Using AIC and Variable Importance (VI) 
 
HR: Hazard Ratio 
 
CI: Confidence Interval 
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Months on ART 0 6 12 18 24 30 36 42 48
Weight-for-age
n 1775 1920 1871 1572 1252 984 791 603 465
Median -2.40 -0.97 -0.63 -0.59 -0.64 -0.64 -0.71 -0.77 -0.77
IQR -3.85;-1.02 -2.06;0.01 -1.55;0.29 -1.53;0.27 -1.51;0.16 -1.46;0.07 -1.44;-0.06 -1.47;-0.04 -1.45;-0.08
Height-for-age
n 1418 1700 1649 1385 1106 858 694 518 397
Median -2.34 -2.13 -1.97 -1.92 -1.88 -1.93 -1.76 -1.63 -1.41
IQR -3.76;-1.02 -3.37;-1.04 -3.09;-0.99 -2.96;-0.96 -2.83;-0.88 -2.67;-0.93 -2.55;-0.90 -2.41;-.077 -2.32;-0.60
Weight-for-height
n 1412 1696 1648 1385 1102 856 691 514 391
Median -1.26 0.12 0.36 0.36 0.37 0.35 0.29 0.13 0.09
IQR -2.73;0.15 -1.01;1.13 -0.56 ;1.31 -0.51;1.29 -0.45;1.22 -0.41;1.15 -0.52;1.06 -0.52;1.06 -0.68;1.06
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Median anthropometric z-scores over time
Response on ART for infants remaining in care for a minimum of 12 
months 
Anthropometric Response 
Weight-for-age showed rapid improvement in the first 6 months of therapy with an 
increase from a median WAZ of -2.40 to -0.97 (Figure 2). Height-for-age showed a 
slower progression reaching a median HAZ of -1.97 from a baseline of -2.34 after 1 
year on ART.   
Figure 2. Growth response on ART over time for infants remaining in care for 
at least 1 year. 
Outcomes of Infants starting ART in Southern Africa                                                            Manuscript 
17 
 
Immunological Response 
Absolute CD4 count showed a rapid increase in the first year after initiation with a 
12 month median CD4 cell count of  1573 cells/mL being almost double that seen at 
baseline (Figure 3a).  As expected CD4 percentages, a measure adjusting more 
appropriately for age-related immunological changes, showed a similar initial trend 
but with a sustained increase in median values only reaching a plateau at 36 months 
(Figure 3b). These combined effects can be seen in the change in the proportion of 
infants meeting the WHO criteria for severe immune suppression with a change from 
87.1% (95% CI 85.5-88.7) at baseline to 16.6%  (95% CI 14.8-18.4) at 12 months 
and 3.0% (95% CI 1.8-4.3) at 36 months.  
Haemoglobin 
Median (IQR) haemoglobin increased from a baseline of 9.7 g/dL to 11 g/dL (10.2; 
12.0) at 6 months (Figure 3c).  
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(a) Median (IQR) Absolute CD4 cell counts over time
n 1661 1603 1519 1205 999 836 686 528 425
Median 783 1431 1573 1545 1466 1401 1374 1292 1244
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(b) Median (IQR) CD4 cell percentage over time                    
n 1582 1638 1545 1213 980 823 664 520 422
Median 18.2 26.2 30 31 31.7 32.7 33.55 32.75 33.05
IQR 12;26 19.9;33.2 23.8;36 25.4;37 26.1;36.9 27.2;37.9 28.2;37.5 27.7;37.9 28.1;38.3
0.
00
0.
25
0.
50
0.
75
1.
00
0 6 12 18 24 30 36 42 48
Months on ART
(d) Kaplan-Meier failure estimates for time to 
Virological Suppression 
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(c) Median (IQR) Haemoglobin over time
n 1254 1256 1209 946 765 619 491 392 321
Median 9.8 11 11.2 11.3 11.5 11.6 11.8 12 12
IQR 8.8;10.9 10.2;12 10.3;12 10.5;12.1 10.7;12.2 10.9;12.3 11;12.4 11.2;12.8 11.3;12.7
Figure 3. Responses over time on ART of a) Changes in median CD4 Absolute 
Cell counts , b) Changes in median CD4 Percentage, c)changes in median 
Haemoglobin over time and d) Kaplan-Meier estimates for outcome of 
Virological suppression in a subset if South African infants with s minimum of a 
baseline and one other viral load measurement. 
Virological response 
Amongst a subset of infants from South African sites who had a minimum of a 
baseline and one other viral load measurement the probabilities of attaining 
virological suppression at 6 and 12 months were found to be 28.1% (95% CI 25.6-
30.7) and 56.1% (95% CI 53.2-59.1) respectively (Figure 3d). The only independent 
predictor of failure to suppress was a viral load of 1 million copies/ml or above at 
ART start (aHR 0.78, 95%CI 0.68-0.89) (Supplementary table 3).  
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Discussion 
Principle findings  
In this study we found that infants initiating ART in Southern Africa between 2004 
and 2012 had a high median age and a high predominance of severe baseline disease 
severity, with some improvement after 2009. Within this cohort we noted that despite 
considerable early responses to ART and a reduction in the prevalence of severe 
disease characteristics, infants remaining in care experienced suboptimal 
immunological, anthropometric and virological responses. Furthermore mortality, 
particularly in the initial stage after ART initiation, was high and loss to follow-up 
was substantial throughout the observation period. Analysis of those factors 
independently associated with mortality identified baseline immunological, clinical 
and anthropometric characteristics together with the time period of initiation of ART, 
where initiation after 2009 was found to have a protective effect.  
Strengths and Limitations of findings 
To our knowledge this is the largest study of infant ART outcomes in Sub-Saharan 
Africa to date. Observing HIV infected infants over a period of time of considerable 
guideline changes this study includes infants from several Southern African sites, each 
representing the routine provision of HIV care and together representing all levels of 
health care.  The levels of missing data were most noted in virological measures. This 
was due to the unavailability of these measures beyond South Africa and the use of 
virological measures for confirmation of HIV diagnosis within South Africa.  
The use of multiple imputation in the management of missing baseline data has 
resulted in avoidance of bias associated with complete case analysis. 33,34 
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The advanced age at initiation observed in this study, although representing the 
reality of the routine care setting, is likely to have resulted in survival bias through 
the formation of a cohort of survivors. This survival effect, worse in older infants by 
virtue of having survived longer, would result in a reduction of any potential benefit 
of starting ART at a younger age and may be responsible for failure to observe an 
age effect in this study.  
Beyond inability  to observe associations for variables such as comorbidities, infant 
feeding practices, PMTCT, cotrimoxazole prophylaxis and socio-economic factors 
which were poorly collected or absent, lack of data on these variables may have 
resulted in residual confounding. Furthermore associations between regimen and 
outcomes were not examined due to a near perfect correlation with site/country of 
origin. Concern also exists pertaining to the possibility of the under-ascertainment of 
mortality in view of the high proportion of infants lost to follow-up. An increased 
rate of loss to follow-up was not observed for the period after 2009 and suggests 
differential loss to follow-up (with regards to year of initiation) did not affect the 
validity of the association between year of initiation and mortality.  
Electronic data capturing procedures necessary for site inclusion in the IeDEA-SA 
databases may have resulted in a reduction in data representivity for all routine care 
sites within Southern Africa.  
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Interpretation  
The CHER trial, possibly the most significant contributor for evidence for the early 
initiation of ART in infants, showed the benefits of early ART in a cohort of infants 
with a very young age and complete absence of severe immunosuppression at 
baseline. 20 The low likelihood of fully achieving these benefits within the South 
African routine care setting due to suboptimal coverage of early infant HIV diagnosis 
was highlighted by Johnson et al (2012) in a model-based analysis examining the 
effect of early ART provision.35 Our study has confirmed through observation what 
this analysis suggested – that within the context of delayed initiation infant ART 
outcomes are suboptimal. The predominance of severe baseline disease and failure to 
attain levels of normality in immunological, anthropometric and virological 
responses as well as high levels of mortality and loss to follow-up are cause for 
considerable concern. Furthermore with an estimated 45% of in utero-infected and 
22% of intrapartum-infected infants dying or lost to follow-up by 14 weeks of age 
our concern is extended to the uncaptured pre-ART losses seen with delayed 
initiation. 36 
This study has briefly described the improvements in delay in initiation over time, a 
trend seen in comparing earlier observational studies from Sub-Saharan Africa to 
more recent studies. These observed improvements over time include a reduction in 
age at initiation,21,37 baseline disease severity and outcomes of mortality.9,21 Our 
results are also comparable to those observed in more recent studies pertaining to 
immunological 38,39 and anthropometric responses 21,40  and mortality 41 in infants on 
ART within sub-Saharan Africa.  Our findings relating to virological suppression 
vary considerably to those of  previous studies such as Kay et al (2012) who 
described a 45% 12 month probability of virological suppression (defined as two 
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consecutive viral load <400copies/ml) and to Tukei et al (2013) who described a 12 
month probability of virological suppression of 72% in a cohort of infants with  
minimum of 6 months of ART.21,42 These differences are likely to be largely due to 
the population and treatment program dissimilarities in these studies. 
Beyond the change in characteristics over time our study has identified the effect of 
initiation of ART from 2010 onwards  (when early initiation was implemented on a 
national scale) – with  improved outcomes of mortality over and above that expected 
to be associated with improvements in age and baseline characteristics. This 
highlights the role of an uncaptured element of improved baseline disease severity 
and programmatic advances and suggests that the implementation of the guidelines 
for early initiation may have resulted in an improvement in the outcomes of these 
infants through a greater urgency and attention toward infant ART initiation.  
Recommendations  
Ongoing attention to the initiation and continued management of ART in infants is 
required for the optimisation of care and outcomes of these infants. Efforts towards 
approximation of the early initiation standards set by the trials upon whose evidence 
guidelines for early initiation were based could reduce the currently persisting 
vulnerability of infants on ART. Research is therefore necessary to identify how to 
overcome barriers to early initiation and optimal care of HIV infected infants 
including issues of PMTCT linkage, birth testing, infant ART initiation and 
maintenance, and the reduction of loss to follow-up.   
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Conclusion 
In a large cohort of HIV infected infants within the routine care setting of Southern 
Africa we observed improvements in disease severity characteristics at ART 
initiation and outcomes on ART. While there has clearly been progress with regard 
to timely initiation of infants on ART and consequently improved outcomes, this 
remains inadequate as delayed initiation results in severe baseline illness and the 
persistence of a vulnerability of infants despite the administration of ART.  
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Figure Legend 
Figure 1. a. Kaplan-Meier estimates for outcomes of initiating ART in Southern 
Africa.   
 b. Competing Risk Analysis Cumulative Incidence Functions for outcomes 
of initiating ART in Southern Africa.   
 c Kaplan-Meier estimates for outcome of mortality by time period of 
initiation 
 d Kaplan-Meier estimates for outcome of loss to follow-up by time period 
of initiation 
Figure 2.  Growth response on ART over time for infants remaining in care for at 
least 1 year. 
Figure 3. a. Changes in median Absolute CD4 cell count over time on ART for infants 
remaining in care for a minimum of 12 months.  
 b. Changes in median CD4 percent over time on ART for infants remaining 
in care for a minimum of 12 months.  
 c.  Changes in median Haemoglobin over time on ART for infants remaining 
in care for a minimum of 12 months. 
 d. Kaplan-Meier estimates of time to virological suppression. 
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Introduction 
General remarks 
 This document provides guidance on the preparation of data tables for the transfer of 
data for the IeDEA Southern Africa Collaboration. 
 It is requested that each clinic prepares ten separate tables with the new data, as 
described in detail below. While 6 of these tables should be submitted by all sites, 
tables 7 -10 will only be applicable to certain sites (see below).  
 The tables can be sent in the format that is most convenient for the site, including 
MS Excel, MS Access, and ASCII etc. Please contact the IeDEA data manager if 
you have any queries.  
 It is appreciated that for some clinics it may be easier to send their data as they stand 
(for example in Excel) and to leave the data management and preparation of the ten 
tables to the data centre. This is not a problem, but it is requested that a separate 
document be included with a list of the variables in the dataset and brief 
descriptions/definitions.  
 It is accepted that there will be missing data for some patients, and even entire 
missing tables from some sites who simply do not have that data in electronic 
format.  
 It is requested that for security purposes, data tables be encrypted and compressed 
with WinZip 9 or higher using the AES encryption algorithm prior to sending.  The 
encryption password (minimum of 10 characters long, including upper/lower case, 
numbers and special characters) should be communicated to the relevant data centre 
contact person by fax or by telephone.   
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 The use of UCT’s Vula site is encouraged; this is an open-source tool allowing for 
the secure transfers of data from sites to the Data Centre.  Vula is open and 
accessible 24 hours a day, 7 days a week.   
 Please ensure that the dataset has been stripped of personal identifying information 
prior to sending. 
 Please include a unique anonymous identifier for each patient (PATIENT) for cross-
reference with your own database. It can be the identifier you are using or a special 
identifier you create for IeDEA Southern Africa. This anonymisation key must be 
maintained by the site under secure conditions.  
 Sites treating children should please send the date at which they changed from using 
the WHO 3-stage clinical staging system to the 4-stage clinical staging system. 
 Thank you very much for your contribution to this collaborative project! 
Inclusion criteria for patients 
Please include all patients with the following characteristics:  
 Documented HIV-1 infection  
 Patients in care at the facility for whom the date of first visit at the facility is known 
exactly.  
Notes: 
 Where possible, it is intended that data be transferred on HIV-infected patients 
followed-up at the facility irrespective of whether or not they received highly active 
antiretroviral therapy (HAART). 
 When transferring data just on patients who received HAART, it is preferable to 
include patients irrespective of whether or not they were exposed to antiretrovirals 
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before the recorded HAART start date. In other words treatment-naïve and 
treatment-experienced patients are included.  
 Sites should send all information on all patients (adults and/or children) in a single 
dataset. For adult patients (those whose first visit at your facility was after their 
16th birthday) the paediatric specific fields (highlighted in blue) do not need to be 
completed (i.e. enter code 88 – not applicable). Paediatric specific fields must be 
entered as completely as possible for all patients whose first visit at your facility is 
before their 16th birthday even if their follow-up extends beyond the age of 16 
years.  
 Some patients will have been in care at another facility prior to commencing care at 
your facility. These patients should be included in the dataset, noting against the 
relevant field that they have been transferred in. All treatment and opportunistic 
infection (OI) history prior to commencing care at the facility should be 
reconstructed as far as possible and entered in the appropriate tables, with unknown 
codes for dates of start and end date of OIs/antiretroviral drugs where necessary. 
Dates 
 The term baseline will not be used as this creates confusion. We will rather make use 
of a set of key dates that will be entered into the first table, the PATIENT table. 
These are: 
Variable name Definition of key date 
FRSVIS_DMY Date of first visit at your facility 
HIVP_DMY  
(HIVP_Y (year) and HIVP_M (month) if 
exact date unknown) 
Date of first positive HIV-1 test 
HAART_DMY Date of HAART initiation 
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 For all fields that require a date, the precise date should be entered in the format  
dd-mm-yyyy if it is known. If the precise date is not known, the month and year 
should be entered separately as far as possible in the separate dedicated fields 
provided for these, and the precise date field should be left blank.  
 If month or both the year and month are unknown, the precise date field should be 
left blank and unknown codes should be entered into the year field (9999) and the 
month field (99) as appropriate.   
 For certain date fields a precise date is obligatory e.g. date of first visit at your 
facility (FRSVIS_DMY) and date of HAART initiation (HAART_DMY). In 
patients who commenced HAART at another facility, if the precise date of start of 
HAART cannot be estimated reasonably accurately, the patient should be entered as 
treatment experienced and the date of first visit at your facility will be regarded as 
the date of start of HAART. 
Definitions  
 HAART is defined as treatment with a combination of at least three drugs from any 
class or classes.  
 “Treatment experienced” is defined as previous exposure to any antiretroviral drug 
for at least 30 days, excluding exposure for prevention of mother to child 
transmission (PMTCT) or post-exposure prophylaxis (PEP). 
Standard codes 
Certain codes will appear repeatedly in a number of lists for coded fields. In this instance, 
the same codes/coding format will be used in all fields where these codes appear as follows: 
Codes Description 
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0 No 
1 Yes 
90 Other 
95 Not ascertained/Not collected at this facility 
99 Unknown despite attempting ascertainment  
88 Not applicable 
Data tables 
For each clinic, the following five to ten data tables or files should be prepared, depending 
on data availability.  
 Tables 1 to 5 are required by all sites.  
 Table 6 (LINKAGE DATA) is required only for sites that record information on 
families 
 Table 7 (PREGNANCY) is required only for sites that record information on 
pregnancy electronically.  
 Table 8 (PAR HEALTH) is required only for patients who commence care before 
their 16th birthday.  
 Table 9 (TB) is required only from sites that record detailed information on episodes 
of tuberculosis electronically.  
 Table 10 (TRIAL) is required only for sites where patients may be enrolled on 
clinical trials or research studies apart from cohort analyses of routinely collected 
data.  
 In addition, a table summarising with information on the overall cohort or “meta-
data” for the transfer, should be included with all transfers. 
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1. PAT (Patient data): A table containing socio-demographic data on patients, clinical 
characteristics at start of HAART in HAART-treated patients, as well as information 
on the outcomes of patients. One line will correspond to one patient. In other words, 
each patient will appear only once in this table. We propose that this table is called 
PAT.   
2. LAB (Laboratory data at baseline and follow-up): This is a single table 
containing all laboratory data: CD4, HIV viral load, and all other laboratory tests.  
One line will correspond to one laboratory result. In other words, most patients will 
have multiple records in this table. We propose that this table is called LAB.  
3. ART (Antiretroviral treatments): A table with the data on all antiretroviral drugs 
that a patient has received or been exposed to including PMTCT (both exposure to 
mother as well as infant peri- or post-natal) or post-exposure prophylaxis. This 
includes treatment received at your facility and at other facilities.  The table will 
contain one line for each separate drug, with different fields for the drug name 
(code), the prescription start dates and stop dates.  Most patients will have numerous 
records in this table.  The drug history of patients who commence care at your 
facility but have previously been treated at another facility should be reconstructed 
and entered into this table as far as possible. We propose that this table be called 
ART. 
4. OI (Opportunistic Events): A table with the information on all opportunistic 
infections or incident HIV-associated diagnoses. One line will correspond to one 
clinical event with different fields for the event type (code), the start dates and stop 
dates. It is anticipated that stop dates will often not be known. In other words, some 
patients will have more than one record in this table and some may have no records 
in this table. History of opportunistic events occurring prior to commencing care at 
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your facility should be reconstructed as far as possible.  We propose that this table 
be called OI. 
5. VIS (Visit data): A table containing information on all clinical visits (including the 
first visit at your facility). One line will correspond to one visit.  Most patients will 
have more than one record in this table. We propose that this table be called VIS. 
6. LINK (Linkage data): A table containing information on family members (partners, 
children and siblings) also receiving HIV care either within your cohort or at another 
site. All family members receiving HIV care should be included whether they are 
receiving care at an IeDEA collaborative site or at a non-IeDEA site. One line will 
correspond to one family member receiving HIV care. In other words, some patients 
will have more than one record in this table and some may have no records in this 
table. We propose that this table is called LINK.  
7. PREGNANCY (Pregnancy data): A table containing information on all 
pregnancies, including spontaneous abortions/miscarriages and terminated 
pregnancies, and their outcomes. One line will correspond to one pregnancy. 
Multiple pregnancies will each have a record in the table, with the outcome of the 
relevant foetus recorded. Some patients will have more than one record in this table, 
while others (including all males and children less than 10 years) will have no 
records in this table. We propose that this table be called PREGNANCY. 
8. PAR_HEALTH (Parental health): A table with information on parental health 
status. This table is only required for sites sending data on patients 15 years old and 
younger at their first visit to the facility.  This table is linked to the visit table, so 
ideally there is an update on parental health status at every visit. Alternatively, this 
table should be filled in at least once, either for the first visit at your facility or the 
date of start of HAART.  
Outcomes of Infants starting ART in Southern Africa                                                           Appendices                 
 
9 
 
9. TUBERCULOSIS (Tuberculosis data): A table with information on all episodes 
of tuberculosis (TB). This table is only for sites that record detailed information on 
TB episodes. Sites that do not collect detailed information on TB episodes should 
enter the TB episodes in the OI table. One line will correspond to one TB episode. In 
other words, some patients will have more than one record in this table and some 
may have no records in this table. We propose that this table be called TB. 
10. TRIAL (Enrolment in trials): A table with information on any trial or research 
study (apart from cohort analysis of routinely collected data) on which a patient is 
enrolled.  This table is only for sites running trials or research studies. One line will 
correspond to one trial/research study on which the patient is enrolled. In other 
words, some patients will have more than one record in this table and some may 
have no records in this table. We propose that this table be called TRIAL. 
11. OUTCOME_REVISED: (Death registry linkage data) A table with information 
on updated death status following linkage to registry systems. 
12. MET (Meta-data):  A table comprising key characteristics of the data that is 
transferred. 
Variables to be included in core tables 
Socio-demographic characteristics and outcomes (PAT table) 
Table 1 below details the data that should be included in PAT table.  
The patient identification variable (PATIENT) must be unique, and it cannot be missing in 
any of the tables. This field must contain a unique and anonymous patient identifier; the field 
must NOT contain their name or any other identifying information. It is up to the local 
collaborator to maintain the key for linking the unique patient identifier with the patient. 
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Table 1 – Variables to be included in PAT table 
Name Format and definitions Description 
PATIENT 
Text & numeric 
characters  
(based on 
cohort/site/patient 
identifier - FS) 
Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
FACILITY Text 
Text field identifying particular clinic 
within cohort, if more than facility 
within the cohort 
BIRTH_DMY DATE (dd-mm-yyyy) 
Date of birth  
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
BIRTH_Y 
Numeric (for example 
1960) 
9995 = Not ascertained 
9999 = Unknown 
despite attempting 
ascertainment 
 
Year of birth 
BIRTH_M 
Numeric (for example 
8) 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
Month of birth 
GENDER 
Numeric with codes: 
1 = Male 
2 = Female 
95 = Not ascertained 
99 = Unknown despite 
attempting 
Sex / gender of patient 
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ascertainment 
FRSVIS_DMY DATE (dd-mm-yyyy) 
Date of first visit at facility  
(Note: This date must be entered 
exactly) 
ENTRY 
Numeric with codes 
(see List 1) 
Mode of entry to your facility 
ENTRY_OTHER Text 
Details of other mode of entry not 
listed in List 1 
MODE 
Numeric with codes 
(see List 2) 
Most probable mode of  HIV 
transmission  
Name Format and definitions Description 
HIV_TYPE 
Numeric (for example 
1) 
1 = HIV-1 
2 = HIV-2 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
Field to distinguish HIV-1 from HIV-2 
HIVP_DMY DATE (dd-mm-yyyy) 
Date of first positive HIV test 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
HIVP_Y 
Numeric (for example 
2001) 
9995 = Not ascertained 
9999 = Unknown 
despite attempting 
ascertainment 
Year of first positive HIV-1 test 
HIVP_M 
Numeric (for example 
8) 
95 = Not ascertained  
99 = Unknown despite 
attempting 
ascertainment 
Month of first positive HIV-1 test 
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HIV_TEST 
Numeric with codes 
(IeDEA SA codes) 
1 = Presumptive 
diagnosis 
2 = Serology 
3 = PCR 
4 = P24 
5 = Rapid test 
90 = Other 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
Type of test used for diagnosis  
HAART 
Numeric 
0 =  Never started 
HAART 
1 =  Started HAART  
Conditional: 
If 1 then go to HAART_DMY 
HAART_DMY DATE (dd-mm-yyyy 
Date of HAART initiation 
(minimum 3 drugs together) 
Note: This date must be entered 
exactly. If patient commenced 
HAART at another facility and the 
exact date is not known, the patient 
should be entered as “Treatment 
experienced” in the EXP_Y field 
below and the first visit at your facility 
will be used as the start of HAART 
date. 
 
Name Format and definitions Description 
FHV_STAGE_WHO 
Numeric with codes: 
1 = Stage I 
2 = Stage II 
Clinical WHO stage (I to IV) at time of 
starting HAART 
 
(Enter 88 patients who have not 
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3 = Stage III 
4 = Stage IV 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
commenced HAART) 
FHV_SDI_1 
Text (for example PCP 
- see List 3) 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
Stage defining illness-1 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
Note: At least FHV_S_SDI_1 should 
be completed in patients commencing 
HAART; A maximum of 4 stage 
defining illness can be entered in the 4 
fields provided. There is no specific 
ordering to the entering of stage 
defining illnesses.  
FHV_SDI_2 
Text (for example PCP 
- see List 3) 
0 = No further stage 
defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
Stage defining illness-2 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
 
FHV_SDI_3 
Text (for example PCP 
- see List 3)  
0 = No further stage 
defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
Stage defining illness-3 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
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ascertainment 
 
FHV_SDI_4 
Text (for example PCP 
- see List 3)  
0 = No further stage 
defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
 
 
Stage defining illness-4 at time of 
starting HAART. 
(Enter 88 patients who have not 
commenced HAART) 
Name Format and definitions Description 
EXP_Y 
Numeric with codes: 
0 = No (No previous 
ARV experience ) 
1 = Yes (Treatment 
experienced, drug 
history known and 
recorded in ART table) 
2 = Yes (Treatment 
experienced, drug 
history not known)  
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
Patient is treatment experienced prior 
to starting HAART (HAART_DMY) ?   
Experienced = Any ARV drug for at 
least 30 days before starting HAART 
(PMTCT regimen and PEP excluded)  
This should be entered for all patients 
even those who have not commenced 
HAART.  
MTCT_Y 
Numeric with codes: 
0 = No (No MTCT 
exposure ) 
1 = Yes (MTCT 
exposed, drug history 
reconstructed  and 
Patient exposed to MTCT drugs (either 
mother during pregnancy or infant 
peri- or post-natally) prior to start of 
HAART (HAART_DMY)? 
This should be entered for all patients 
even those who have not commenced 
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recorded in ART table) 
2 = Yes (MTCT 
exposed, drug history 
not reconstructable)   
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
HAART. 
PEP_Y 
Numeric with codes: 
0 = No (No PEP 
exposure) 
1 = Yes (PEP exposed, 
drug history 
reconstructed  and 
recorded in ART table) 
2 =Yes (PEP exposed, 
drug history not 
reconstructable)   
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
Patient exposed to post-exposure 
prophylaxis (PEP) drugs prior to start 
of HAART (HAART_DMY)? 
This should be entered for all patients 
even those who have not commenced 
HAART. 
TB_FHV 
Numeric with codes 
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
Patient was on treatment for TB at start 
of HAART (HAART_DMY) 
(Enter 88 patients who have not 
commenced HAART) 
WKS_TB_FHV 
Numeric (for example 
8) 
88=Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
Duration in weeks since start of TB 
treatment when HAART was 
commenced in  patients with TB at 
start of HAART  
(Enter 88 for patients who have not 
commenced HAART or who did not 
have TB at start of HAART) 
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ascertainment  
 
Name Format and definitions Description 
PREG_FHV 
Numeric with codes  
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
 
Pregnant at start of HAART 
(Enter 88 for men and children <10 
years old AND all patients who have 
not commenced HAART) 
LAST_CONTACT_DMY DATE (dd-mm-yyyy) 
Date of last contact 
Note: This date must be entered 
exactly. 
LAST_CONTACT_T 
Numeric with codes 
(See List 4) 
Type of last contact 
OUTCOME 
Numeric with codes 
(See List 5) 
Outcome including death and loss to 
follow-up 
OUTCOME_DMY DATE (dd-mm-yyyy) 
Date of outcome  
(Leave blank if outcome is Alive [in 
care] or  
Alive [not in care])  
OUTCOME_Y 
Numeric (e.g. 2004) 
8888 = Not applicable 
or exact date of 
outcome entered above 
9995 = Not ascertained  
9999 = Unknown 
despite attempting 
ascertainment 
 
Year of outcome 
Enter 8888 for patients who have not 
died, or if exact date of outcome 
entered above. 
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OUTCOME_M 
Numeric (e.g.12) 
88 = Not applicable or 
exact date of outcome 
entered above 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
Month of outcome 
Enter 88 for patients who have not 
died, or if exact date of outcome 
entered above. 
 
DEATH_C1 
Numeric with codes 
(see List 6)   
Cause of death : 
Enter 88 for patients who have not 
died 
Note : There are 3 fields for 3 causes 
of death to be entered in no specific 
order. If an HIV-related cause of death 
is recorded, please ensure that the 
condition is recorded appropriately in 
the OI table.   
 
Nature of contribution of cause: 
For each cause of death, please 
characterise the contribution of the 
specific cause. 
 
DEATH_N1 
Text with following 
codes: 
I = Immediate cause 
U = Underlying 
cause/condition 
C = Contributing cause 
N = Not available 
DEATH_C2 
Numeric with codes 
(see List 6) 
DEATH_N2 
Text with following 
codes: 
I = Immediate cause 
U = Underlying 
cause/condition 
C = Contributing cause 
N = Not available 
 
Name Format and definitions Description 
DEATH_C3 
Numeric with codes 
(see List 6) 
 
DEATH_N3 
Text with following 
codes: 
I = Immediate cause 
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U = Underlying 
cause/condition 
C = Contributing cause 
N = Not available 
 
CAREG 
Numeric with codes 
(see List 7) 
Primary caregiver at start of HAART 
(HAART_DMY) 
(paediatric patients only – enter 88 for 
adult patients) 
DISCL_CG 
Numeric with codes 
(see List 8) 
Person informed of the HIV status of 
the child 
(paediatric patients only – enter 88 for 
adult patients) 
DISCL_CHILD 
Numeric with codes 
0 = No 
1 = Yes 
2 = In process 
88 = Not applicable 
(adult patient) 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
Was the child informed of his/her 
status at HAART_DMY? 
(paediatric patients only - enter 88 for 
adult patients) 
DELIV_M 
Numeric with codes 
10 = Vaginal, 
spontaneous 
11 = Vaginal, forceps 
12 = Vaginal, vacuum 
20 = Caesarean section 
– primary/elective 
(before onset of labour 
and rupture of 
membranes) 
21 = Caesarean section 
Mode of delivery  
(paediatric patients only - enter 88 for 
adult patients) 
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– emergency 
22 = Caesarean section 
– type unknown 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
WEIGHT_BIRTH 
Numeric (e.g 3.20) 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
 
 
Weight at birth in kg  
(paediatric patients only - enter 88 for 
adult patients) 
Name Format and definitions Description 
BRSTFD 
Numeric with codes 
10 = breastfeeding, 
exclusive 
11 = breast-feeding, 
exclusivity unknown  
12 = mixed feeding 
20 = Formula feeding 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown, despite 
attempting 
ascertainment 
Main infant feeding option after birth 
(paediatric patients only - enter 88 for 
adult patients) 
BRSTFD_ED DATE (dd-mm-yy)  
Date of cessation of breast feeding if 
applicable 
Leave blank if not applicable, child 
still being breastfed, date not known, 
Outcomes of Infants starting ART in Southern Africa                                                           Appendices                 
 
20 
 
or child not breastfed at all. 
BRSTFD_EST_DUR 
Numeric (e.g. 2) 
77 = still breast-
feeding, ED unknown 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting 
ascertainment 
Estimated duration of breastfeeding in 
months in children who are exclusively 
breastfed or mixed fed. 
(paediatric patients only - enter 88 for 
adult patients) 
Enter 88 if child still being breastfed or 
child not breastfed at all. 
 
List 1 - Codes for mode of entry (ENTRY)  
Code source: IeDEA SA codes 
Table name: LU :PAT :ENTRY 
Codes Mode of entry 
1 PMTCT program 
2 Diagnosis testing during hospitalization 
3 Diagnosis testing during consultation 
4 Orphans programs 
5 Family diagnosis 
6 TB program 
7 General HIV service clinic 
8 Self-referral with known diagnosis 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
List 2 - Codes for mode of infection (MODE) 
Code source: Based on HICDEP codes; new codes denoted by * 
Table name: LU_mode 
Codes Mode of infection 
1 Homo/bisexual man  
2 Injecting drug user 
3 Homo/bisexual man + injecting drug user (1 + 2) 
4 Haemophiliac 
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5 Transfusion, non-haemophilia related 
6 Heterosexual contact 
6.1 Presumed heterosexual 
7 Heterosexual contact + Injecting drug user (6 + 2) 
8 Perinatal 
90 Other 
95*  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 3 - Disease codes for FHV_SDI (PAT table) and OI_ID (OI table)  
Code source: Based on HICDEP codes; new codes denoted by * 
Table name: LU:DIS 
Note that this is a common list of HIV-associated conditions for capturing incident 
opportunistic infections and HIV-associated conditions, as well as stage-defining conditions 
in adults and children.  Where duration or recurrence is required for a condition to be stage 
defining, the event columns have a zero to exclude them from lookups of incident 
conditions. Where conditions are not stage defining, the stage-defining columns for children 
and adults have zeros to exclude them from lookups of stage-defining conditions. 
Codes Description WHO 
stage 
(Adult) 
WHO 
stage 
(Paed) 
Event 
(Adult) 
Event 
(Paed) 
SDI 
(Adult) 
SDI 
(Paed) 
ANGC* Angular cheilitis 2 2 1 1 1 1 
BCGD BCG disease – disseminated 4 4 1 1 1 1 
BCGL* BCG Lymphadenitis 
(localised to R axilla) 
88 88 1 1 0 0 
BCGP* BCG Pulmonary 88 88 1 1 0 0 
BCIR* Recurrent severe presumed 
bacterial infection 
(excluding pneumonia)  
4 4 0 0 1 1 
BCIS* Severe presumed bacterial 
infection – single episode 
(excluding pneumonia) 
88 88 1 1 0 0 
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BCNE Bacterial pneumonia, 
recurrent (>2 episodes 
within 1 year) 
4 3 0 0 1 1 
BCNS* Severe presumed bacterial 
pneumonia (single episode) 
88 88 1 1 0 0 
BLD* Unexplained anaemia 
(<8g/dl), and or neutropaenia 
(<500/mm3 – 2; <1000/mm3 
- children), and or 
thrombocytopaenia 
(<50000/mm3) > 1 month 
3 3 0 0 1 1 
CANM* Candidiasis (oral) (outside 
neonatal period)  
3 3 1 1 1 1 
CANO Candidiasis oesophogeal 4 4 1 1 1 1 
CANT* Candidiasis (trachea, bronchi 
or lungs) 
4 4 1 1 1 1 
CLD* Chronic HIV-associated lung 
disease 
88 3 0 1 0 1 
CMO* HIV-associated 
cardiomyopathy 
88 4 1 1 0 1 
Codes Description WHO 
stage 
(Adult) 
WHO 
stage 
(Paed) 
Event 
(Adult) 
Event 
(Paed) 
SDI 
(Adult) 
SDI 
(Paed) 
CMVO Cytomegalovirus other 
location (site other than 
liver, spleen or lymph nodes) 
(onset at age>1month) 
4 4 1 1 1 1 
CMVR Cytomegalovirus (CMV) 
chorioretinitis (onset at 
age>1month) 
4 4 1 1 1 1 
CRCO Cryptococcosis 
extrapulmonary 
4 4 1 1 1 1 
CRSP Cryptosporidiosis (duration 
> 1 month) 
4 4 0 0 1 1 
CRSPS* Cryptosporidiosis ? 88 88 1 1 0 0 
CRVC Cervical cancer (invasive) 4 88 1 1 1 0 
DEM AIDS dementia complex 4 88 1 0 1 0 
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DIAC* Unexplained chronic 
diarrhoea (> 1month for 
adults; >14 days for 
children) 
3 3 0 0 1 1 
DIAS Diarrhoea (duration <1 
month - adults; <14 days - 
children) 
88 88 1 1 0 0 
ENC* HIV encephalopathy 4 4 1 1 1 1 
FBLS Focal brain lesion 88 88 1 1 0 0 
FEVC* Unexplained persistent fever 
(> 1 month) 
3 3 0 0 1 1 
FNID* Fungal nail infections 
(fingers or toes) 
88 2 0 1 0 1 
FNIF* Fungal nail infections of 
fingers 
2 88 1 0 1 0 
HERP Herpes simplex virus ulcers 
(duration > 1 month)  
4 4 0 0 1 1 
HERPS* Herpes simplex virus ulcers 88 88 1 1 0 0 
HERPV* Visceral herpes simplex 
infection 
4 4 1 1 1 1 
HG Hodgkins Lymphoma 88 88 1 1 0 0 
HIST Histoplasmosis extrapulm. 4 4 1 1 1 1 
HPVE* Extensive human papilloma 
virus infection  
88 2 1 1 0 1 
HSM* Hepatosplenomegaly 88 2 0 0 0 1 
HZ* Herpes zoster (not specified) 88 88 1 1 1 1 
HZM* Herpes zoster (more than 
one dermatome) 
88 88 1 1 0 0 
HZS* Herpes zoster (single 
dermatome)  
2 2 1 1 1 1 
ISDI Isosporiasis diarrhoea 
(duration > 1 month) 
4 4 0 0 1 1 
ISDS* Isosporiasis diarrhoea 88 88 1 1 0 0 
KS Kaposi Sarcoma 4 4 1 1 1 1 
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LEIS Leishmaniasis visceral 4 88 1 1 1 0 
LEU Progressive multifocal 
leucoencephalopathy 
4 4 1 1 1 1 
LGE* Lineal gingival erythema 88 2 1 1 0 1 
LIP* Lymphoid interstitial 
pneumonitis 
88 3 0 1 0 1 
MC Mycobacterium avium 
complex (MAC) or Kanasii 
extrapulm. 
4 4 1 1 1 1 
MCDI Microsporidosis diarrhoea 
(duration > 1 month) 
4 4 0 0 1 1 
MCDS* Microsporidosis diarrhoea 88 88 1 1 0 0 
MCI* Mycobacterium Immune 
reconstitution syndrome 
88 88 1 1 0 0 
MCP Mycobacterium tuberculosis 
pulmonary 
3 3 1 1 1 1 
MCPO Mycobacterium pulmonary 
other (excluding BCG in 
children) 
88 88 1 1 0 0 
MCX Mycobacterium tuberculosis 
extrapulmonary 
4 4 1 1 1 1 
MCXO Mycobacterium extrapulm. 
other (excluding BCG in 
children) 
4 4 1 1 1 1 
MNUM* Moderate unexplained 
malnutrition (60-80% 
EWFA) 
88 3 0 1 0 1 
MNUS* Unexplained severe wasting 
or malnutrition (<60% 
EWFA) 
88 4 0 1 0 1 
Codes Description WHO 
stage 
(Adult) 
WHO 
stage 
(Paed) 
Event 
(Adult) 
Event 
(Paed) 
SDI 
(Adult) 
SDI 
(Paed) 
MOLC* Extensive molluscum 
contagiosum 
88 2 1 1 0 1 
MYCD* Any disseminated mycosis 4 4 1 1 1 1 
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NHG Non-Hodgkin Lymphoma, 
not specified 
88 88 1 1 0 0 
NHGB Non-Hodgkin Lymphoma, 
Burkitt (classical or atypical) 
88 88 1 1 0 0 
NHGI Non-Hodgkin Lymphoma, 
diffuse large B-cell 
lymphoma (immunoblasti or 
centroblastic) 
4 4 1 1 1 1 
NHGP Non-Hodgkin Lymphoma 
primary brain lymphoma 
4 4 1 1 1 1 
NHGU Non-Hodgkin Lymphoma 
unknown/other histology 
88 88 1 1 0 0 
NPO* HIV-associated nephropathy 88 4 1 1 0 1 
NUS* Acute necrotising ulcerative 
stomatitis, gingivitis or 
periodontitis 
3 3 1 1 1 1 
OHLP* Oral hairy leukoplakia 3 3 1 1 1 1 
ORUL* Recurrent oral ulcerations 2 2 0 0 1 1 
PARE* Parotid enlargement 88 2 1 1 0 1 
PCP Pneumocystis carinii 
pneumonia  
4 4 1 1 1 1 
PGL* Persistent Generalized 
Lymphadenopathy 
1 1 0 0 1 1 
PPE* Papular pruritic eruptions 2 2 1 1 1 1 
RTIL* Lower respiratory tract 
infection (other than 
presumed pneumonia) ? 
88 88 1 1 0 0 
RTIR* Recurrent or chronic 
respiratory tract infection 
(RTIs, sinusitis, bronchitis, 
otitis media, otorrhea, 
pharyngitis) 
2 2 0 0 1 1 
RTIU* Upper respiratory tract 
infection 
88 88 1 1 0 0 
RVF* Acquired HIV-associated 
recto-vaginal fistula 
88 4 1 1 0 1 
SAME Salmonella bacteraemia 
(non-typhoid) (single 
88 88 1 1 0 0 
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episode) 
SAM Salmonella bacteraemia 
(non-typhoid) recurrent 
4 88 0 0 1 0 
SEBD* Seborrheic dermatitis 2 2 1 1 1 1 
TOX Toxoplasmosis brain 
(outside neonatal period) 
4 4 1 1 1 1 
WAST HIV Wasting Syndrome 4 88 1 0 1 0 
WTLM* Moderate unexplained 
weight loss (<10% of body 
weight) 
2 88 1 0 1 0 
WTLS* Severe unexplained weight 
loss (>10% of body weight) 
3 88 1 0 1 0 
List 4 - Codes for last contact (LAST_CONTACT_T) 
Code source: IeDEA SA codes 
Table name: LU :PAT :LAST_CONTACT_T 
Codes Last contact type 
1 Visit in the facility 
2 Phone call 
3 Home visit 
4 Hospitalisation 
5 Drug pick-up only 
6 Visit in another facility 
7 Laboratory test received 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 5 - Codes for outcome (OUTCOME) 
 Code source: IeDEA SA codes 
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Table name: LU :PAT :OUTCOME 
Codes Mode of Outcome 
10 Death (HIV-related) 
11 Death (HIV relationship unknown) 
12 Death (not HIV-related) 
20 Alive and in care at your facility 
21 Known to be alive and in care at another facility  
22 Known to be alive and patient is not in care  
23 Known to be alive but not known whether patient is in care 
30 Transfer out within the same service, vital status after transfer out unknown 
31 Transfer out to a different service, vital status after transfer out unknown 
40 Loss to follow-up despite active tracing attempted 
41 Loss to follow-up (not actively traced) 
90 Other 
95 Not ascertained 
 
List 6 - Codes for cause of death (DEATH_C1 – 3) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :PAT :DEATH_C 
For HIV-related and Aids defining events (8.*), it is expected that the associated event will 
be recorded in the OI table. 
Codes  Cause of Death  
1  Myocardial Infarction  
2  Stroke  
3  Other cardiovascular diseases  
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4  Symptoms caused by mitochondrial toxicity  
4.1  Lactic acidosis  
5  Complications due to diabetes mellitus  
6  Pancreatitis  
7  Complications due to hepatitis  
7.1  Hepatitis related  
7.2  Liver failure not related to hepatitis or mitochondrial toxicity  
8  HIV-related  
8.1  AIDS defining event  
8.2  Invasive bacterial infection  
9  Renal failure  
10  Bleeding (haemophilia) 
20  Non AIDS defining cancer  
88* Not applicable 
90  Other  
91  Suicide 
92  Drug Overdose  
93 Accident 
95* Not ascertained 
99 Unknown, Fatal case with no information 
 
List 7 - Codes for primary caregiver (CAREG)  
Code source: IeDEA SA codes 
Table name: LU :PAT :CAREG 
Codes Primary caregiver 
1 Mother 
2 Father 
3 Grandmother 
Outcomes of Infants starting ART in Southern Africa                                                           Appendices                 
 
29 
 
4 Other family member 
5 Institution 
6 None 
90 Other 
88 Not applicable 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 8 - Codes for person informed of the HIV status of the child (DISCL_CG)  
Code source: IeDEA SA codes 
Table name: LU :PAT :DISCL_CG 
Codes Disclosure to caregiver 
1 Mother 
2 Father 
12 Both parents 
3 Grandmother 
4 Other primary caregiver 
90 Other 
88 Not applicable  
95 Not ascertained 
99 Unknown despite attempting ascertainment 
Laboratory data (LAB table) 
Table 2 details the laboratory data that should be included in the LAB table.  All available 
data from the date of first visit should be included.   
Notes: 
 Results of laboratory tests must be provided in the units specified 
 Results of laboratory tests can be entered in one of two fields – a numeric field (LAB_V) and 
a coded text field (LAB_T) (for very high and/or undetectable viral loads, and for TB 
microscopy and culture results). 
 TB microscopy and culture results should only be entered in the coded result field (LAB_T) 
as follows, and not in the numeric field (LAB_V): 
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 For viral loads, there is an additional field to indicate the lower limit of detection of the assay 
used. This field should be entered as not-applicable (Code = -88) for other laboratory results.  
 For TB sensitivity results, there are 2 additional fields. The first (TB_DRUG) where the drug 
to which sensitivity testing has been done is entered, and the second (SENS), where the 
sensitivity is recorded using the standard yes/no format. These fields should be entered as 
not-applicable (Code = 88) for other laboratory results.  
 Both CD4 percentage and absolute count should be included on paediatric patients until they 
are 16 years old. 
 There is no code for unknown values of for laboratory test results as tests of which the result 
is unknown should not be included in the dataset.  
 Only dates in the DMY format are permissible in this table 
Table 2 – Variables to be included in the table LAB 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
LAB_DMY Date (for example dd/mm/yy) 
 
Date when specimen was taken 
LAB_ID Text (see List 9) 
Code representing the measurement 
 
LAB_V Numeric (for example 44) 
Numeric value of measurement 
Leave blank if result entered as code 
(LAB_C) 
 
Name Format Description 
LAB_T 
Text  
Lower than limit of detection for 
viral loads should be entered as 
Text result 
 eg. “> 6 000 000” or “P+++” 
Leave blank if result entered as number 
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“LDL” 
TB microscopy and culture results 
should be entered as follows: 
-  
Paucibacillary 
1+ 
2+ 
3+ 
Unknown + 
(LAB_V) 
RNA_L 
Numeric 
-88 = Not applicable 
-99 = Unknown 
Lower limit of detection of RNA assay 
(Enter -88 for laboratory tests other than 
viral load) 
TB_DRUG 
Text with codes: 
INH_L = Isoniazid low dose 
INH_H = Isoniazid high dose 
INH_U = Isoniazid – dose 
unspecified 
PZA = Pyrazinamide 
RIF = Rifampicin 
ETN = Ethionamide 
ETB = Ethambutol 
STREP = Streptomycin 
QUI = Quinolone 
88 = Not applicable 
TB Drug against which sensitivity has 
been tested.  
(Enter 88 for laboratory tests other than 
viral load) 
DRUG_RES 
Numeric with codes: 
0 = No (Sensitive) 
1 = Yes (Resistant) 
88 = Not applicable 
Is Mycobacterium TB cultured 
RESISTANT to drug in TB-DRUG 
field? 
(Enter 88 for laboratory tests other than 
viral load)  
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List 9: Codes for measurement type (LAB_ID) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :LAB :LAB_ID 
 
 
Antiretroviral drug variables (ART table) 
Table 3 details the data on antiretroviral treatment that should be included in the ART table. 
As previously mentioned, preferably we will receive one line per drug, each with its 
prescription, start and stop date.   
Notes: 
All antiretroviral drugs to which a patient has been exposed (including PMTCT exposure of 
both pregnant women and infants peri-  or postnatally) and PEP should be included with 
either the dates of starting and stopping the individual drugs, OR the number of doses OR 
the duration of treatment.  
Codes Measurement 
ALB Albumin (g/L) 
ALT Alanine-Aminotransferase (UI/L) 
AST Aspartate aminotransferase (UI/L) 
CD4A* CD4 absolute cell count (cells/μl) 
CD4P* CD4 percentage (%) 
CHOL Cholesterol (mmol/L) 
CRE Creatinine (μmol/L) 
HAEM Haemoglobin (g/dl) 
LACT Lactate (mmol/L) 
LYMP Total lymphocyte count (cells/µl) 
NEUT Neutrophil count (x1000/mm3) 
PLT Platelets (cells/μl) 
RNA* HIV-RNA measurement value (copies/ml) 
TBC* TB culture 
TBM* TB microscopy 
TBS* TB sensitivity 
TG Triglycerides (mmol/L) 
URE Urea (mmol/L) 
WBC White cell count (x1000/ mm3) 
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 History of exposure to antiretroviral drugs prior to commencing care at the reporting 
facility should be reconstructed as far as possible and included in this table, making 
use of appropriate drug codes for unknown regimens and date/time codes for 
unknown start and stop dates or unknown durations.  
Table 3 – Variables to be included in ART table 
Name Format Description 
PATIENT 
Free (numerical or 
alphanumerical) 
Unique patient identifier 
ART_ID ATC (for example NVP – see 
List 10) 
Type of antiretroviral drug 
ART_SD_DMY Date(dd-mm-yyyy) Date of starting each antiretroviral drug 
(start date). 
Enter exact date in this field if known. 
 If unknown leave blank and enter month 
and year as far as possible in fields 
below. 
Name Format Description 
ART_SD_Y Numeric (e.g. 2003) 
8888 = Exact start date entered 
in appropriate field 
9999 = Unknown despite 
attempting ascertainment 
9995 = Not ascertained 
Year of starting drug 
ART_SD_M Numeric (e.g. 7) 
88 = Exact start date entered in 
appropriate field 
99 = Unknown despite 
attempting ascertainment 
95 = Not ascertained 
Month of starting drug 
ART_RS Numeric with codes  
(See List 11) 
Reason for receiving ART  
ART_FORM Numeric with codes  Type of formulation 
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1 = Tablet/capsule 
2 = Syrup/Suspension 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
ART_COMB Numeric with codes  
1 = Individual drug 
2 = Part of a fixed dose 
combination  
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Is drug part of a fixed dose combination? 
ART_ED_DMY Date(dd-mm-yyyy) Date of stopping each antiretroviral drug 
(end date) 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
EITHER month and year as far as 
possible in fields below OR number of 
doses OR duration in weeks in the 
appropriate fields.  
ART_ED_Y Numeric (e.g. 2004) 
8888 = exact end date or 
number of doses or duration in 
weeks entered in appropriate 
fields 
9999 = Unknown despite 
attempting ascertainment 
9995 = Not ascertained 
Year of stopping drug 
ART_ED_M Numeric (e.g. 7) 
88 = exact end date or number 
of doses or duration in weeks 
entered in appropriate fields 
99 = Unknown despite 
attempting ascertainment 
95 = Not ascertained 
Month of stopping drug 
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Name Format Description 
NO_DOSES Numeric (e.g. 1) 
888 = end date or duration in 
weeks entered in appropriate 
fields 
999 = Unknown despite 
attempting ascertainment 
995 = Not ascertained 
Number of doses of drug e.g. 1 for single 
dose Nevirapine 
NO_WEEKS Numeric (e.g. 12) 
888 = end date or number of 
doses entered in appropriate 
fields 
999 = Unknown despite 
attempting ascertainment 
995 = Not ascertained 
Number of weeks of receiving drug  
e.g. 12 for AZT from 28 weeks of 
pregnancy delivering at term 
ART_END_RS Numeric with codes  
(See List 12) 
Reason for stopping antiretroviral drug 
INFO_SOURCE Numeric with codes  
1 = Clinical records at this 
facility 
2 = Clinical records/letter from 
      another facility 
3 = Patient/caregiver report 
4 = Likely protocol in use 
90 = Other 
99 = Unknown 
Source of information about ART 
 
List 10: Anti-retroviral drugs :  (ART_ID) 
Code source: ATC classification: Anatomical Therapeutic Chemical 
Table name: LU :ART :ART_ID 
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ATC codes Antiretroviral treatment 
J05A  Drug unspecified (i.e. single drug, totally unknown) 
J05A-BEV Beviramat 
J05AE  PI unspecified  
J05AE01  Saquinavir (gel, not specified)  
J05AE01-SQH  Saquinavir hard gel (INVIRASE)  
J05AE01-SQS  Saquinavir soft gel (FORTOVASE)  
J05AE02  Indinavir (CRIXIVAN)  
J05AE03  Ritonavir (NORVIR) 
J05AE03-H  Ritonavir high dose (NORVIR)  
J05AE03-L  Ritonavir low dose (NORVIR)  
J05AE04  Nelfinavir(VIRACEPT) 
J05AE05  Amprenavir (141W94) (AGENERASE)  
J05AE06  Lopinavir/Ritonavir (ABT-378/r, Kaletra)  
J05AE07  Fosamprenavir  
J05AE-ATV  Atazanavir (ZRIVADA) 
J05AE-GW4  GW433908/VX-275 (Drug phase III) (PROGENERASE)  
J05AE-TMC  TMC 114 (Tibotec)  
J05AE-TPR  Tipranavir (trial drug)  
J05AF  NRTI unspecified 
ATC codes Antiretroviral treatment 
J05AF01  Zidovudine (AZT, RETROVIR)  
J05AF02  Didanosine (ddI) (VIDEX)  
J05AF03  Zalcitabine (ddC) (HIVID)  
J05AF04  Stavudine (d4T) (ZERIT)  
J05AF05  Lamivudine (3TC, EPIVIR)  
J05AF06  Abacavir (1592U89) (ZIAGEN)  
J05AF07  Tenofovir (TDF, VIREAD)  
J05AF08  Adefovir (PREVEON)  
J05AF09  Emtricitabine (FTC, EMTRIVA)  
J05AF10  Entecavir  
J05AF30-KIV  Kivexa  
J05AF30-TZV  Trizivir  
J05AF-FOZ  Fozivudinetidoxi 
J05AF-LDN  Lodenosine (trialdrug)  
J05AG  NNRTIunspecified  
J05AG01  Nevirapine (VIRAMUNE)  
J05AG01-SD  Nevirapine (VIRAMUNE) single dose 
J05AG02  Delavirdine (U-90152) (RESCRIPTOR)  
J05AG03  Efavirenz (DMP-266) (STOCRIN, SUSTIVA)  
J05AG-CPV Capravirine 
 
 
J05AG-ETV Etavirine 
J05AG-CPV Capravirine 
J05AG-LOV  Loviride  
J05AG-RPV Rilpivirine 
J05AG-TMC  TMC 125 (Tibotec)  
J05A-PBT  Participant in Blinded Trial  
J05AR* ART regimen and drug unspecified (i.e. both number and names of drugs 
totally unknown) J05AX07  Enfurvirtide (FUZEON, T-20/Ro 29-9800)  
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J05AX08 Raltegravir 
JO5AX09 Maraviroc 
J05AX-VIC Vicriviroc 
L01XX05  Hydroxyurea/Hydroxycarbamid (LITALIR)  
 
List 11: Codes for reason for receiving ART (ART_RS)  
Code source: IeDEA SA codes  
Table name: LU :ART :ART_RS 
Codes Reason 
10 MTCT – antenatal (mother) 
11 MTCT – peripartum (mother) 
12 MTCT – postpartum (mother) 
13 MTCT – timing unknown (mother) 
20 MTCT – peripartum (infant) 
21 MTCT – postpartum (infant) 
22 MTCT – timing unknown (infant) 
30 ARV as treatment 
 
40 PEP 
95 Not ascertained 
99 Unknown despite attempting ascertainment 
List 12: Reason for treatment discontinuation (ART_END_RS)  
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :ART :ART_END_RS 
 
Note: Reasons for stopping treatment are grouped by similarity. The broad reason is 
indicated by the integer, while subcategories of that reason are denoted by figures to the right 
of the decimal point. Reasons should therefore be coded to the greatest level of detail that the 
data permits.  
For example, if a drug was stopped because of treatment failure determined by a declining 
CD4 count, the stop reason should be coded as 1.3; however if the reason for stopping is 
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simply “treatment failure” with the means of determining this not specified, the stop reason 
should be coded as 1. 
Old Code Code* Reason for treatment discontinuation AE CI FL Other 
1 1 
Treatment failure (i.e. virological, 
immunological, and /or clinical failure)    1   
1.1 1.1 Virological failure    1   
1.2 1.2 Partial virological failure    1   
1.3 1.3 Immunological failure – CD4 drop    1   
1.4 1.4 Clinical progression    1   
2 2 Abnormal fat redistribution 1       
3 3 Concern of cardiovascular disease 1       
3.1 3.1 Dyslipidaemia 1       
3.2 3.2 Cardiovascular disease 1       
4 4 Hypersensitivity reaction 1       
5 5 
Toxicity, predominantly from abdomen/G-I 
tract 1       
5.1 5.1 Toxicity – GI tract 1       
5.2 5.2 Toxicity – Liver (ALT/Hepatitis) 1       
5.3 5.3 Toxicity – Pancreas 1       
6 6 Toxicity, predominantly from nervous system 1       
6.1 6.1 Toxicity - peripheral neuropathy 1       
 6.2 Toxicity - neuropsychiatric 1       
 6.3 Toxicity - headache 1       
7 7 Toxicity, predominantly from kidneys 1       
8 8 
Toxicity, predominantly from endocrine 
system 1       
8.1 8.1 Diabetes 1       
9 9 Haematological toxicity (anemia …etc.) 1       
10 10 Hyperlactataemia/lactic acidosis 1       
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91 11.9 Toxicity – other (not mentioned above) 1       
 11.99 Toxicity - unspecified 1       
90.1 12 Comorbidity  1     
92.3 13 Drug interaction  1     
92.4 13.1 
Drug interaction - commencing TB/BCG 
treatment  1     
92.5 13.2 Drug interaction - ended TB/BCG treatment      1 
96 14 Pregnancy  1     
 14.1 Pregnancy intended  1     
96.2 14.2 Pregnancy ended      1 
 15 Social contra-indication   1     
Old Code Code* Reason for treatment discontinuation AE CI FL Other 
 16.9 Contra-indication - other  1     
 16.99 Contra-indication unspecified  1     
96.1 17 MTCT regimen completed       1 
94.1 18.1 Non-compliance       1 
 18.2 Defaulter       1 
 19 
Change in treatment not due to side-effects, 
failure, poor adherence or contra-indication       1 
92 19.1 More effective treatment available       1 
92.1 19.2 Simplified treatment available       1 
92.2 19.21 Treatment to complex       1 
 19.3 
Change in eligibility criteria (e.g. child old 
enough for tablets; refrigerator no longer 
available)       1 
 19.4 Protocol change       1 
97 19.51 Study treatment commenced       1 
 19.52 Study treatment completed       1 
 19.6 Drug not available       1 
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93 19.7 Structured Treatment Interruption (STI)       1 
93.1 19.71 
Structured Treatment Interruption (STI)-at 
high CD4       1 
94 19.8 Patient's wish/ decision, not specified above       1 
95 19.9 
Physician’s decision, not specified above (note 
overlap with standard code       1 
95.1 20 Contra-indication expired       1 
88 88 Death (note overlap with N/A in other lists)       1 
90 90 Side effect - any of the above not mentioned 1      
99.5 95 Not ascertained       1 
98 98 Other causes, not specified above       1 
99 99 Unknown despite attempting ascertainment       1 
*Second merge should only utilise this field. The old code has been given for lookup 
reference purposed for previously supplied data. 
Opportunistic events (OI table) 
Table 4 below details the data on opportunistic events or HIV associated conditions 
diagnosed during follow up that should be included in table OI. 
History of opportunistic events prior to commencing care at the reporting facility should be 
reconstructed as far as possible and included in this table, making use of appropriate 
date/time codes for unknown start and end dates. It is anticipated that the end date of OIs 
will frequently be unknown.  
Table 4 – Variables to be included in OI table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
OI_ID 
Text (for example PCP - see List 3 
– Disease codes – under PAT 
table)  
Type of opportunistic event 
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OI_SD_DMY Date(dd-mm-yyyy) 
Date of start of each opportunistic 
event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
OI_SD_Y 
Numeric (e.g. 2001) 
 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite 
attempting ascertainment 
Year of start of event 
OI_SD_M 
Numeric (e.g. 11) 
 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of start of event 
OI_ED_DMY Date(dd-mm-yyyy) 
Date of end of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below 
If OI is ongoing (has not yet ended) 
leave blank and enter appropriate code 
in field below 
Name Format Description 
OI_ED_Y 
Numeric (e.g. 2001) 
 
8885 = Ongoing 
Year of end of event 
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8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite 
attempting ascertainment 
OI_ED_M 
Numeric (e.g. 11) 
 
85 = Ongoing 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of end of event 
DIAG_METH Numeric (see List 13 ) Method of diagnosis 
 
List 13: Diagnosis Method of Opportunistic Event (DIAG_METH)  
Code source: IeDEA SA codes 
Table name: LU :OI :DIAG_METH 
Codes Diagnosis Method 
10 clinical only 
11 clinical & radiology 
12 clinical and endoscopy 
20 microscopy for infectious agent 
21 culture of infectious agent 
30 blood antibody test 
31 site specimen (non-blood) antibody test 
40 tissue histology 
90 other 
95 Not ascertained 
99 Unknown despite attempting ascertainment 
 
Follow-up clinic visits (VIS table) 
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Table 5 below details the information to be included in the VIS table. Please include all 
visits for each patient since the first visit at the reporting facility, and where possible visits at 
previous facilities. Weight, height and head circumference left blank will be assumed to have 
not been ascertained. 
Table 5 – Variables to be included in VIS table  
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
VISIT_DMY Date (for example dd/mm/yy) Date of visit patient 
VISIT_FAC 
Numeric with codes 
1 = Visit at this cohort’s facility 
2 = Visit at another facility 
99 = Site of visit unknown 
Facility at which visit took place 
WEIGHT Numeric (for example 75) Weight in kilos (kg) 
HEIGHT Numeric (for example 75) Height in centimeters (cm) 
CTX 
Numeric with codes : 
1 = yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment  
Cotrimoxazole status 
INH 
Numeric with codes : 
1 = Yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Isoniazid status 
FLU 
Numeric with codes : 
1 = Yes 
Fluconazole status 
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0 = No 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
HEADC Numeric (for example 75) 
Head circumference in centimeters 
(cm) 
SCHOOL_Y 
Numeric with codes 
 
0 = No school 
1 = At school 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Schooling for children >5 years.  
For adults and children less than 5 
years,  
enter 88. 
Variables to be included in additional tables 
Family and partner linkages (LINK table) 
Table 6 details the information on family members (partners, children and siblings) that 
should be included in the LINK table. 
All family members receiving HIV care should be listed. This includes those receiving care 
within the reporting cohort as well as those receiving care at other sites. 
The cohort-specific identifiers of family members receiving HIV care at the reporting site 
should be included.  
Table 6 – Variables to be included in the table LINK 
Name Format Description 
PATIENT 
Free (numerical or 
alphanumerical) 
Unique patient identifier 
LINK_REL Numeric with codes (See List 14) 
 
Relationship of family member to 
patient 
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LINK_COHORT Text with codes (See List 15) 
Cohort within which family member 
is receiving HIV care 
LINK_ID 
Free (numerical or 
alphanumerical) 
-88 = Not applicable 
-95 = Not ascertained 
-99 = Unknown despite 
attempting ascertainment 
Unique patient identifier of family 
member 
Enter -88 if family member in care at 
non-IeDEA site. 
 
List 14 - Codes for relationship of family member to patient (LINK_REL)  
Code source: IeDEA SA codes 
Table name: LU :LINK :LINK_REL 
Codes Relationship 
1 Mother 
2 Father 
3 Child 
4 Sibling 
5 Spouse/partner 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 15 - Cohort where family member is receiving care (LINK_COHORT)  
Code source: To be created by transferring site 
Table name: LU :LINK :LINK_COHORT 
Codes Cohort 
Cohort ID Cohort description 
Pregnancy information (PREGNANCY table)  
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Table 7 details information to be included in the PREGNANCY table. This table contains 
information on all pregnancies since the patient was known to be HIV-infected, including 
spontaneous abortions/ miscarriages and terminated pregnancies, and their outcomes.  
Table 7 – Variables to be included in PREGNANCY table 
Name Format Description 
PATIENT 
Free (numerical or 
alphanumerical) 
Unique patient identifier for patient 
PREG_DIAG_DMY 
Date (dd-mm-yyyy) 
Exact date when patient first 
presents as pregnant 
PREG_DUR_DIAG Numeric (e.g. 12) 
 
99 = Unknown 
Estimated duration of pregnancy in 
weeks when patient first presents as 
pregnant 
PREG_END_DMY Date (dd-mm-yyyy) Exact date of delivery, spontaneous 
abortion or termination 
Enter exact date in this field if 
known. 
 If unknown leave blank and enter 
month and year as far as possible in 
fields below. 
PREG_END_Y Numeric (e.g. 2003) 
 
8888 = Not applicable 
(Exact date entered in field 
above) 
9995 = Not ascertained 
9999 = Unknown despite 
attempting ascertainment 
Year of delivery, spontaneous 
abortion or termination 
PREG_END_M Numeric (e.g. 9) 
88 = Not applicable 
(Exact date entered in field 
above) 
Month of delivery, spontaneous 
abortion or termination 
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95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
PREG_ED Numeric (e.g. 36) 
 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Estimated duration of entire 
pregnancy in weeks 
PREG_OUTCOME Numeric with codes  
1 = Live birth 
2 = Still birth 
3 = Termination of 
pregnancy 
4= Spontaneous abortion  
     (miscarriage) 
95 = Not ascertained 
99 = Unknown despite 
attempting  
        ascertainment 
Outcome of pregnancy 
Name Format Description 
INF_WT Numeric (e.g. 2.9) 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Weight of delivered infant. 
If spontaneous abortion or 
termination, enter 88 
NEONATAL_DEATH Numeric with codes 
0 = No 
1 = Yes  
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Did delivered live infant die within 1 
month of birth? 
If stillbirth, spontaneous abortion or 
termination, enter 88 
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BIRTH DEFECT_Y Numeric with codes 
0 = No 
1 = Yes  
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Did fœtus or infant have any 
congenital malformations? 
BIRTH_DEFECT_TYPE Text Free text description of 
malformations 
 
Parental Health (PAR_HEALTH table)  
Table 8 details variables to be included in the table PAR_HEALTH. This table contains 
information on parental health status.  
This table is linked to the visit table, so ideally there is an update on parental health status at 
every visit. Alternatively, this table should be filled in at least once, either for the first visit at 
your facility or the date of start of HAART.  
For patients over 16 years of age, no entries are required into this table (i.e. this table is not 
required at all for sites that have only patients over 16 years of age in their care).  
While information on parental health is very valuable, it is acknowledged that many sites do 
not collect this information. If only information at the child’s first visit or at the start of 
HAART is collected, this should be included with the appropriate visit date. If no 
information on parental health is collected, this table can be omitted.   
Table 8: Variables to be included in the PAR_HEALTH table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) 
Unique patient identifier for 
patient 
VIS_DMY Date (dd/mm/yy) Date of parental health 
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evaluation  
(probably same as clinic visit 
date) 
MAT_DEATH Numeric with codes 
0 = No (Alive) 
1 = Yes (Dead) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Maternal status: Mother 
deceased? 
MAT_HIV Numeric with codes 
0 = Negative 
1 = Positive 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Mother’s HIV status if 
available 
MAT_TTT Numeric with codes 
0 = No treatment 
1 = CMX only 
2 = HAART only 
12 = CMX and HAART 
88 = Not applicable (mother HIV negative or 
deceased) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Mother’s treatment if 
available 
PAT_DEATH Numeric with codes 
0 = No (Alive) 
1 = Yes (Dead) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Paternal status: Father 
deceased? 
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PAT_HIV Numeric with codes 
0 = Negative 
1 = Positive 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Father’s HIV status if 
available 
PAT_TTT Numeric with codes 
0 = No treatment 
1 = CMX only 
2 = HAART only 
12 = CMX and HAART 
88 = Not applicable (father HIV negative or 
deceased) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Father’s treatment if 
available 
 
Tuberculosis information (TB table) 
This table is for capturing details of the TB episodes during HIV follow-up.  Tests related to 
TB can be included in the LAB table.  Where possible this data can be derived from the 
electronic TB register. 
Table 9 – Variables to be included in the table TB 
Name Format Description 
PATIENT 
Free (numerical or 
alphanumerical) 
Unique patient identifier 
REG_DMY Date (dd/mm/yy) 
 
 
Date registered with TB 
REGID 
Text (eg. 2272007) 
-95 = Not ascertained 
-99 = Unknown despite 
attempting ascertainment 
 
 
TB register number 
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RAD 
Numeric with codes 
0 – Not done 
1 – Normal 
20 – Abnormal 
unspecified 
21 – Abnormal - not 
consistent with current TB 
22 – Abnormal - 
consistent with current TB 
unspecified 
23 – Abnormal – 
consistent with current TB 
–  
Cavity on right 
24 - Abnormal – 
consistent with current TB 
–  
Cavity on left 
25 - Abnormal – 
consistent with current TB 
– 
Bilateral cavities 
26 - Abnormal – 
consistent with current TB 
-  
No cavities 
99 = Unknown despite 
attempting ascertainment 
Radiography findings if done 
RESISTANT 
Numeric with codes 
0 – No 
1 – MDR 
2 – XDR 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Resistance data based on sensitivities 
Note: Exact results of sensitivities should 
be record in the LAB table.  Code as MDR 
if … to more than one drug and XDR if… 
Categories MDR and XDR should be for 
the worst resistance status during the 
episode.  
  
TB_START_DMY Date (dd/mm/yy) Date starting TB treatment 
TB_END_DMY Date (dd/mm/yy) 
Date ending TB treatment or date of 
outcome 
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CAT 
Numeric with codes 
1 – Newly diagnosed for 
the first time 
2 – After relapse 
3 – After default 
4 – After failure 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
 
TB Category 
Name Format Description 
CLASS 
Numeric with codes 
1 - Pulmonary 
2 – Extra-pulmonary 
3 – Both pulmonary and 
extra-pulmonary 
4 - Primary 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Classification of episode 
SITE 
Numeric with codes 
1 – Bones/Joints (A18.0) 
2 – Lymph nodes (A16.3) 
3 – Meningitis (A17.0) 
4 – Miliary (A19.9) 
5 – Pleura (A16.5) 
9 – Other sites (A18.8) 
88 – Not applicable as 
pulmonary or primary 
only 
Site of disease if extra-pulmonary 
component diagnosed 
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95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
REGIMEN 
Numeric with codes 
1 – 2HRZE 4HR - 
Regimen 1 
2 –2HRZES 1HRZE 
5HRE - Regimen 2 
3 – 2HRZ 4HR - Regimen 
3 
4 –Other Regimen 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
TB treatment regimen  
REG_OTHER Text 
Text field for other regimen not included in 
codes for REGIMEN field above 
TB_OUTCOME 
Numeric with codes 
1 – Completed 
2 – Cured 
3 – Failed 
4 – Interrupted 
5 – Defaulted 
6 – Treatment ongoing 
7 - Died 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Outcome of TB episode 
 
Trial/research study enrolment information (TRIAL table) 
Table 10 details the data that should be included in the TRIAL table.  This table is only for 
sites running trials or research studies. Any trial/research study (apart from cohort analysis of 
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routine data) on which a patient has been enrolled should be entered together with the dates 
of entering and leaving each trial. Sites should send an additional coding table of the trials 
running at their site.  
 
Table 10 – Variables to be included in the table TRIAL 
Name Format Description 
PATIENT 
Free (numerical or 
alphanumerical) 
Unique patient identifier 
TRIAL_START_DMY 
Date (for example 
dd/mm/yy) 
Date of enrolment onto trial 
TRIAL_END_DMY 
Date (for example 
dd/mm/yy) 
Date of completion/ disenrolment  
Leave blank if patient is still enrolled 
on trial 
TRIAL_ID 
Free (numeric or text) 
codes (See List 16) 
Name of trial on which patient is 
enrolled 
Each site to send their own List with 
coding and description of trial 
List 16: Example of codes for trial name (TRIAL_ID)  
Code source: Site to supply own codes 
Table name: LU :TRIAL :TRIAL_ID 
Codes  
(Text or 
Numeric) 
Trial name (text 
field) 
Short description of trial (Memo field) 
INH INH trial Trial of thrice weekly vs daily INH prophylaxis in 
HIV-infected children 
TB TB treatment 
duration trial 
Trial of 6 month vs 9 month chemotherapy in HIV-
infected children 
Revised Death (Outcome) data 
This table contains information about death linkage data. 
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 Table 11 – Variables to be included in the table OUTCOME_REV 
Name Format Description 
PATIENT 
Text  (numerical or 
alphanumerical) 
Unique patient identifier 
COHORT Text Name of the cohort  
REVISED OUTCOME 
Numeric with codes (See 
List 5) 
Revised outcome of death 
REVISED OUTCOME 
_DMY 
Date (for example 
dd/mm/yy) 
Date of revised outcome 
REVISION_DMY 
Date (for example 
dd/mm/yy) 
Date revision took place 
MATCHABLE_FIELD Text Field used to match data 
SOURCE Text 
Source of information update i.e. 
death registry 
 
 
Meta-data 
This table contains information about the data transfer itself. 
Table 12 – Variables to be included in the table META 
Name Format Description 
COHORT Text Name of the cohort  
ENROLS_DMY 
Date (for example 
dd/mm/yy) 
Date of start of enrolment 
ENROLE_DMY 
Date (for example 
dd/mm/yy) 
Date of end of enrolment 
FU_CLOSE_DMY 
Date (for example 
dd/mm/yy) 
Date of last possible follow-up 
ASC_DMY 
Date (for example 
dd/mm/yy) 
Date of last possible outcome ascertainment 
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LTF_DEF Numeric 
For patients classified by the site as LTF, the 
number of days used to define LTF 
REPORTER Text Name of person responsible for data transfer 
TRANSFER_DMY 
Date (for example 
dd/mm/yy) 
Date extracted 
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Appendix B: IeDEA –SA Concept Sheet for Proposed Analysis  
The International Epidemiologic Databases to Evaluate AIDS Southern Africa 
(IeDEA-SA) 
Proposed analysis: Outcomes of infants starting ART in Southern Africa 
 
CONCEPT SHEET FOR NEW ANALYSES 
Title: Outcomes of infants starting ART in Southern Africa 
Lead author: Mireille Porter 
IeDEA senior 
investigator: 
Brian Eley 
Collaborators: Mary-Ann Davies, James Nuttall, representative from each 
collaborating site 
Statisticians: Mireille Porter 
Data 
manager: 
Nicky Maxwell and Fritz Kaeser 
Where will 
statistical 
analyses be 
done? 
University of Cape Town 
Has funding 
been 
requested? 
Yes/No ? 
If yes, please 
give details: 
 
Required 
variables: 
 
Target 
journal: 
PIDJ/JAIDS/AIDS  
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Milestones: Circulation of concept sheet: <date> 
Circulation of early draft paper: <date> 
Circulation of mature draft paper: <date> 
Submission to target journal: <date> 
Abstract: 
 
Advances in evidence of the benefits of early initiation of ART in 
infants have resulted in international treatment guidelines changes 
and an increase in velocity and coverage of infant ART provision.  
However there is limited published data on the outcomes of infants 
starting ART in routine care in Southern Africa. Using data merged 
from IeDEA sites in Southern Africa we aim to describe infant 
diagnostic and treatment practices at participating sites, baseline 
characteristics of infants starting first line ART, treatment outcomes 
including clinical, immunological and virological responses and 
identify the determinants for these outcomes.  
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Outline:  
 
1. Background 
 
In 2010 a global estimate of 1.49 million infants were born to mothers 
living with HIV with over 1000 newly infected infants born daily.1,2 
Without ART provision it is estimated that up to 30% of HIV positive 
infants will die before reaching one year of age and 50% by the age of 
two years.3 In addition, untreated HIV infection in infancy is associated 
with serious morbidity from opportunistic infections and associated 
organ damage including HIV encephalopathy. 4  
 
A 2007 cohort study showed that 85% of infants would require ART by 
6 months of age according to the 2006 WHO 5 immunological criteria 
for ART initiation in infants of CD4< 25%.  In keeping with previous 
studies, 6, 7 this highlighted the possible clinical and immunological 
benefits that immediate ART initiation in infants might provide.8 
Subsequently the Children with Human Immune Deficiency Virus Early 
Antiretroviral Therapy Trial (CHER) done in South Africa provided 
clear evidence supporting early treatment of infants. HIV ART 
commencement before 12 weeks of age reduced mortality by 76% and 
disease progression by 75% in comparison to deferring ART until WHO 
2006 treatment initiation criteria were met.9 Further substudy analyses 
showed specific benefits of early initiation regarding short-term 
neurodevelopmental outcomes10, nutrition and growth 11. These findings 
resulted in changes to national and global infant ART guidelines with 
WHO 2010 guidelines calling for all HIV infected infants under the age 
of 2 years to be commenced on ART regardless of clinical or 
immunological factors.3 
 
The CHER trial showed the benefits of early ART start in a controlled 
trial environment. There is however limited data on the outcomes of 
ART initiation in infants from routine settings. Previously published 
studies lack power due to very small sample sizes and having been 
designed for other specific outcomes such as resistance.  6,7,12,13 
 
The use of the IeDEA Southern Africa infant ART cohort will provide 
us the opportunity to examine the extent of implementation  of WHO 
2010 guidelines as well as the outcomes of infants starting ART and 
predictors of these outcomes. 
2. Objectives and hypotheses 
4. To describe infant diagnostic and treatment initiation practices at 
IeDEA sites in Southern Africa.  
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5. To describe the baseline characteristics of infants commencing ART 
in IeDEA sites in Southern Africa. 
6. To describe and examine the outcomes of initiation of ART in 
infancy in Southern Africa and their determinants. 
 
3. Study design    
3.1 Eligibility criteria 
A retrospective cohort analysis of data collated from participating 
IeDEA Southern Africa sites 
 Sites included require provision of ART for infants (<1 year old) (at 
least 25 infants <1 year of old initiated ART since 1 January 2010) 
 Infants who are HIV infected (recorded PCR diagnosis or 
presumptive diagnosis) and ART naïve (except for PMTCT exposure)  
 Infants require initiation of a minimum of 3 antiretroviral drugs and 
a recorded date of initiation before their first birthday.  
A brief standardised survey at participating sites will be done to attain 
data on infant testing and initiation practices. 
 
3.2 Key variables and definitions 
3.2.1 Brief Description of infant HIV testing and ART initiation 
practices   
These will be determined through a brief questionnaire to site 
investigators. Variables will include: 
 Main points of entry for infants to ART services 
 Linkage with PMTCT services 
 Protocol and practice of identification of HIV positive 
infants  
 Availability of PCR diagnostic and laboratory services 
 Protocol and practice once identified to start including test-
to-start interval 
 Main clinical providers of infant HIV care 
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 First line infant regimen used and availability 
 
3.2.2  Infant and program characteristics at baseline initiation of ART 
These will include: 
 Age (Date of birth) and Gender. 
 Birth weight and gestational age. 
 PMTCT exposure. 
 Level of care / facility. 
 Measures of disease severity.   
o Clinical Disease measures  
 WHO stage 
 Stage defining illnesses 
 Opportunistic infections 
 Nutritional and Growth markers  
(weight and height - age and sex-adjusted z-scores 
 Immunological and Virological markers  
(CD4 count or percentage, Viral Load if available) 
 Tuberculosis diagnosis and treatment duration 
 Date of initiation ART. 
 First-line regimen used. 
 Primary Caregiver if available. 
 
3.3 Outcomes  
These will include: 
 Probability of Death, Loss to Follow-Up(LTFU), Transfer out 
(TFO). LTFU will be defined as no clinic attendance for more 
than 6 months before the date of closure of the site 
database and with the date of LTFU being the date of the 
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last visit. 
 Immunological, Virological and Growth longitudinal 
response characteristics for those remaining in care. 
 Opportunistic Infections, emphasis on Tuberculosis 
diagnosis and treatment. ( if available) 
 
3.4  Statistical methods 
Analysis of pooled data from infant ART sites using the agreed IeDEA 
Southern Africa format. For all analyses, techniques will be used that 
account for between cohort variation and the hierarchical structure of 
the data. 
 Site based testing and initiation practices will be described 
 Baseline characteristics of infants starting ARV’s will be described 
using medians (IQR) and proportions as appropriate. 
 Estimation of median time from ART start in an HIV-infected infant 
to death, LTFU and virological suppression will be done using the 
Kaplan-Meier method. 
 Crude and adjusted associations between baseline characteristics 
and ART outcomes will be done using Cox Proportional Hazards 
models 
 Immunological and growth response and their determinants will be 
assessed using longitudinal analysis taking into account repeated 
measures in individual patients. 
 
3.5 Sample size considerations 
 
All infants meeting eligibility criteria will be included in the study 
therefore no sample size calculation done.  
 
3.6  Ethical considerations 
The data to be used for this analysis are anonymised and will be 
obtained from individual IeDEA sites each of which has existing IRB 
approval for contribution of data to IeDEA collaborative analyses.  
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Appendix D: Official letter of ethical approval from University of Cape 
Town Faculty of Health Sciences Research Ethics Committee for parent 
project by IeDEA (previously OASIS). 
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Appendix E: Annual Progress Report/Renewal by Human Research 
Ethics Committee 
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Appendix F: Instructions for Authors: The Pediatric Infectious Disease 
Journal (PIDJ) 
The Pediatric Infectious Disease 
Journal (PIDJ) 
Online Submission and Review System 
SCOPE 
The Pediatric Infectious Disease Journal is a 
peer-reviewed, multidisciplinary journal 
directed to physicians and other health care 
professionals who manage infectious diseases 
of childhood.  
Instructions for Authors (this page) 
Copyright Transfer & Disclosure (PDF)  
Reprint Ordering  
Permissions Requests  
Reprints  
 
Ethical/Legal Considerations  
A submitted manuscript must be an original contribution not previously published (except 
as an abstract or preliminary report), must not be under consideration for publication 
elsewhere, and, if accepted, must not be published elsewhere in similar form, in any 
language, without the consent of Lippincott Williams & Wilkins. Each person listed as an 
author is expected to have participated in the study to a significant extent. Although the 
editors and referees make every effort to ensure the validity of published manuscripts, the 
final responsibility rests with the authors, not with the journal, its editors, or the publisher. 
All manuscripts must be submitted on-line through the journal's web site at 
http://pidj.edmgr.com/. See submission instructions under "Online manuscript 
submission."  
Patient anonymity and informed consent: It is the author's responsibility to ensure that a 
patient's anonymity be carefully protected and to verify that any experimental investigation 
with human subjects reported in the manuscript was performed with informed consent and 
following all the guidelines for experimental investigation with human subjects required by 
the institution(s) with which all the authors are affiliated. Authors should mask patients' 
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eyes or, if the eye area is the focus of the illustration, the patient's nose and mouth, and 
they should remove patients' names from figures unless written consent obtained from the 
patients is submitted with the manuscript.  
Copyright: All authors must sign a copy of the journal's "Authorship Responsibility, Financial 
Disclosures, and Copyright Transfer" form and submit it at the time of manuscript 
submission.  
Conflicts of interest: Authors must state all possible conflicts of interest in the manuscript, 
including financial, consultant, institutional and other relationships that might lead to bias 
or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated 
as none declared. All sources of funding should be acknowledged in the manuscript. All 
relevant conflicts of interest and sources of funding should be included on the title page of 
the manuscript with the heading “Conflicts of Interest and Source of Funding:”. For 
example:  
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is 
currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for 
Organization X – the CME organizers for Company A. For the remaining authors none were 
declared.  
In addition, each author must complete and submit the journal’s copyright transfer 
agreement, which includes a section on the disclosure of potential conflicts of interest 
based on the recommendations of the International Committee of Medical Journal Editors, 
“Uniform Requirements for Manuscripts Submitted to Biomedical Journals” 
(www.icmje.org/update.html). The form is readily available on the manuscript submission 
page www.editorialmanager.com/pidj/ can be completed and submitted electronically. 
Please note that authors may sign the copyright transfer agreement form electronically. For 
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additional information about electronically signing this form, go to 
http://links.lww.com/ZUAT/A106.  
Compliance with NIH and Other Research Funding Agency Accessibility Requirements 
A number of research funding agencies now require or request authors to submit the post-
print (the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
will identify to the National Library of Medicine (NLM) articles that require deposit and will 
transmit the post-print of an article based on research funded in whole or in part by the 
National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other 
funding agencies to PubMed Central. The revised Copyright Transfer Agreement provides 
the mechanism. 
Permissions: Authors must submit written permission from the copyright owner (usually 
the publisher) to use direct quotations, tables, or illustrations that have appeared in 
copyrighted form elsewhere, along with complete details about the source. Any 
permissions fees that might be required by the copyright owner are the responsibility of 
the authors requesting use of the borrowed material, not the responsibility of Lippincott 
Williams & Wilkins.  
Preparation of Manuscript  
Manuscripts that do not adhere to the following instructions are returned to the 
corresponding author for technical revision before undergoing peer review. Also, to 
streamline the review process, on reviewing newly submitted manuscripts, we will identify 
those that do not meet the mission of the journal, provide no new information or insights 
into management of infectious diseases or are of more local importance and better suited 
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for a regional journal and return them immediately to the authors to allow them to submit 
their work elsewhere in a timely fashion.  
New Article Types  
Research Reports This section comprises manuscripts on all aspects of the molecular 
pathogenesis and immunologic mechanisms of bacterial, viral, fungal and other infections 
in infants, children and adolescents. The emphasis will be on manuscripts that present data 
that are clinically applicable and provide a more thorough understanding of the 
pathophysiologic basis of infections in children and that could impact eventual treatment 
and prevention. The manuscripts can be formatted as original studies or brief reports and 
will be peer reviewed.  
HIV Reports The section comprises of high-quality, high-impact original articles and brief 
reports of epidemiologic, clinical, translational and implementation science studies 
pertaining to the prevention, treatment and outcomes of HIV infection in infants, children, 
and adolescents. 
 
Vaccine Reports Articles that present data from Vaccine Phase II-IV studies will appear in 
this section. These manuscripts receive the same peer review as articles submitted as 
Original Studies. The universal open access fee for all accepted manuscripts in this category 
is: $1500.00 US, plus an additional per-page fee with 2 options: 1) $50 per page for print 
and online publication; or 2) $25 per page for online only publication. All articles in this 
series will be available online by free access. For manuscripts in this category, authors 
should refer to the “Guidelines for collection, analysis and presentation of vaccine safety 
data in pre- and post-licensure clinical studies” published in Vaccine (2009, vol. 27; pp 2282-
8) and use case definitions as developed by The Brighton Collaboration 
(www.brightoncollaboration.org) whenever possible.  
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Manuscript Submission  
Online manuscript submission: All manuscripts must be submitted on-line through the new 
web site at http://pidj.edmgr.com/. First-time users: Please click the Register button from 
the menu above and enter the requested information. On successful registration, you will 
be sent an E-mail indicating your user name and password. Print a copy of this information 
for future reference. Note: If you have received an E-mail from us with an assigned user ID 
and password, or if you are a repeat user, do not register again. Just log in. Once you have 
an assigned ID and password, you do not have to re-register, even if your status changes 
(that is, author, reviewer, or editor). If you experience any problems, please contact Amy 
Newman, Journal Manager, at PIDJournal@yahoo.com, Ph 830-865-1249, Fax 214-710-
2175.  
Authors: Please click the log-in- button from the menu at the top of the page and on the 
next screen log into the system as an Author. Submit your manuscript according to the 
author instructions. You will be able to track the progress of your manuscript through the 
system. If you experience any problems, please contact Amy Newman, Journal Manager, at 
PIDJournal@yahoo.com, Ph 830-865-1249, Fax 214-710-2175. Requests for help and other 
questions will be addressed in the order received. To submit a completed manuscript, the 
following documents are required: Cover Letter, Title Page, Abstract, and Manuscript. 
Tables and figures are optional. Each portion of the manuscript must be submitted as 
separate documents (i.e. cover letter, title page, abstract, manuscript, tables and figures all 
saved as separate files). The text documents, cover letter, title page, abstract and 
manuscript are to be uploaded as Microsoft Word documents. Tables are to be created in 
Microsoft Word also. Excel tables will not load properly. All figures should be TIFF, EPS or 
PowerPoint files.  
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General format: Submit manuscripts in English. Double space all copy, including legends, 
footnotes, tables, and references. Use a common font such as Arial or Times Roman in size 
12. Enumerate all pages of the manuscript, beginning with the Title Page as page 1, and 
follow in sequence to the abstract, manuscript and all other attachments. If you are 
unfamiliar with numbering, you can search HELP while in Microsoft Word, and it will show 
in detail how to number all pages.  
Title page: Title page must be submitted as a separate file. Include on the title page: (a) 
complete manuscript title; (b) authors' full names, highest academic degrees, and 
affiliations; (c) name and address for correspondence, including Fax number, telephone 
number, and E-mail address; (d) address for reprints if different from that of corresponding 
author (indicate whether reprints are available); and (e) all sources of support, including 
pharmaceutical and industry support, that require acknowledgment; (f) list three to five key 
words for indexing; (g) an abbreviated title of 55 characters or less used for the cover of the 
journal; (h) a running head title of 44 characters or less including spaces used for page 
headings on the pages in which your article is published.  
The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard 
Hughes Medical Institute (HHMI); and other(s).  
Structured abstract for Original Studies and Supplement Articles: Abstracts must be 
submitted as a separate file. Limit the abstract to 250 words. Do not cite references in the 
abstract. Limit the use of abbreviations and acronyms. Use the following subheads: 
Background, Methods, Results, and Conclusions (others may be added as needed).  
Unstructured abstract for Instructive Cases and Brief Reports: Abstract must be submitted 
as a separate file. Limit the abstract to 60 words. It must be factual and comprehensive. 
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Limit the use of abbreviations and acronyms, and avoid general statements (e.g. "the 
significance of the results is discussed").  
Text: Organize the manuscript into four main headings, Introduction, Materials and 
Methods, Results, and Discussion. If a brand name is cited, supply the manufacturer's name 
and address (city and state/country).  
Abbreviations: For a list of standard abbreviations, consult the American Medical 
Association Manual of Style, 9th edition, or other standard sources. Write out the full term 
for each abbreviation at its first use unless it is a standard unit of measure. Abbreviations 
are allowed only if used three times or more in text.  
References: The authors are responsible for the accuracy of the references. Key the 
references (double-spaced) at the end of the manuscript. Cite the references in text in the 
order of appearance, including those references cited in tables and figure legends at the 
chronological citation of the tables and figures in text. Cite unpublished data, such as 
papers submitted but not yet accepted for publication or personal communications, in 
parentheses in the text. If there are more than six authors, name only the first three 
authors and then use et al. Refer to the List of Journals Indexed in Index Medicus for 
abbreviations of journal names, or access the list at http://www.nlm.nih.gov/tsd/ 
serials/lji.html. Sample references are given below.  
Journal article 
1. Trujillo M, Correa N, Olsen K, et al. Cefprozil concentrations in middle ear fluid. Pediatr 
Infect Dis J. 2000;19:268 –270.  
Book chapter  
2. Grose C. Bacterial myositis and pyomyositis. In: Feigin RD, Cherry JD, eds. Textbook of 
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Pediatric Infectious Diseases. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1998:704 
– 708.  
Entire book  
3. Nelson JD, Bradley JS. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 14th ed. 
Philadelphia: Lippincott Williams & Wilkins; 2000.  
Proceedings  
4. Harrigan PR, Dong W, Weber AE, et al. Highly mutated RT and protease [Abstract I-115]. 
In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 
CA, September 24 to 27, 1998. Washington, DC: American Society for Microbiology; 1998.  
 
Online journals  
5. Friedman SA. Preeclampsia. Obstet Gynecol. [serial online]. January 1988;71:22–37. 
Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990.  
World Wide Web  
6. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. Available at: 
http://www.ama-assn.org/ special/hiv/ethics. Accessed June 26, 1997.  
Figures:  
A) Creating Digital Artwork  
1. Learn about the publication requirements for Digital Artwork: 
http://links.lww.com/ES/A42  
2. Create, Scan and Save your artwork and compare your final figure to the Digital 
Artwork Guideline Checklist (below).  
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3. Upload each figure to Editorial Manager in conjunction with your manuscript text 
and tables.  
B) Digital Artwork Guideline Checklist 
Here are the basics to have in place before submitting your digital artwork:  
 Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High 
resolution PDF files are also acceptable.  
 Crop out any white or black space surrounding the image.  
 Diagrams, drawings, graphs, and other line art must be vector or saved at a 
resolution of at least 1200 dpi. If created in an MS Office program, send the native 
(DOC, PPT, XLS) file.  
 Photographs, radiographs and other halftone images must be saved at a resolution 
of at least 300 dpi.  
 Photographs and radiographs with text must be saved as postscript or at a 
resolution of at least 600 dpi.  
 Each figure must be saved and submitted as a separate file. Figures should not be 
embedded in the manuscript text file.  
Remember:  
 Cite figures consecutively in your manuscript.  
 Number figures in the figure legend in the order in which they are discussed.  
 Upload figures consecutively to the Editorial Manager web site and enter figure 
numbers consecutively in the Description field when uploading the files.  
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Figure legends: Include legends for all figures. They should be brief and specific, and they 
should appear on a separate manuscript page after the references. Legends should be part 
of the manuscript file on the disk. Use scale markers in the image for electron micrographs, 
and indicate the type of stain used.  
Color figures: The journal accepts for publication color figures that enhance an article. 
Authors who submit color figures receive an estimate of the cost for color reproduction. If 
they decide not to pay for color reproduction, they can request that the figures be 
converted to black and white at no charge.  
Supplemental Digital Content  
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to 
LWW journals that enhance their article's text to be considered for online posting. SDC may 
include standard media such as text documents, graphs, audio, video, etc. On the Attach 
Files page of the submission process, please select Supplemental Audio, Video, or Data for 
your uploaded file as the Submission Item. All SDC files should be uploaded as the author 
would like them presented in the final article. If an article with SDC is accepted, our 
production staff will create a URL with the SDC file. The URL will be placed in the call-out 
within the article. SDC files are not copyedited by LWW staff, they will be presented 
digitally as submitted. For SDC documents, any labels or legends should be included in the 
original SDC file when submitted. For a list of all available file types and detailed 
instructions, please visit http://links.lww.com/A142.  
SDC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript. Citations should include the type of material submitted (Audio, Figure, Table, 
etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list 
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number, and provide a description of the supplemental content. All descriptive text should 
be included in the call-out as it will not appear elsewhere in the article.  
Example:  
We performed many tests on the degrees of flexibility in the elbow (see Video, 
Supplemental Digital Content 1, which demonstrates elbow flexibility) and found our results 
inconclusive.  
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the manuscript 
file. Include the SDC number and file type of the Supplemental Digital Content. This text will 
be removed by our production staff and not be published. 
Example: 
Supplemental Digital Content 1. wmv  
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 
10 MBs, authors should first query the journal office for approval. For a list of all available 
file types and detailed instructions, please visit http://links.lww.com/A142.  
Tables: Create tables using the table creating and editing feature of your word processing 
software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. 
Provide a separate document for each table. Cite tables consecutively in the text, and 
number them in that order. Key each on a separate sheet, and include the table title, 
appropriate column heads, and explanatory legends (including definitions of any 
abbreviation not already defined in the text). Do not embed tables within the body of the 
manuscript. They should be self-explanatory and should supplement, rather than duplicate, 
the material in the text. In each table, the genus of each genus-species must be written out 
at its first appearance.  
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Style: Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate 
Dictionary (10th edition) should be used as standard references. Refer to drugs and 
therapeutic agents by their accepted generic or chemical names, and do not abbreviate 
them. Use code numbers only when a generic name is not yet available. Capitalize the trade 
names of drugs and place them in parentheses after the generic names. To comply with 
trademark law, include the name and location (city and state/country) of the manufacturer 
of any drug, supply, or equipment mentioned in the manuscript. Use the metric system to 
express units of measure and degrees Celsius or degrees Fahrenheit consistently 
throughout the manuscript to express temperatures, and use SI units rather than 
conventional units. Abbreviate "liter" in such forms as "3 units/L" and "5 mL"; write out 
when used alone (10 liters; 0.5-liter gavage). See also Day RA, ed. How to Write and Publish 
a Scientific Paper. 5th ed. Phoenix, AZ: The Oryx Press, 1998.  
Brief Reports: Papers for this section should be no longer than 5–6 double-spaced typed 
manuscript pages (fewer than 1500 words), 10 references and 1 figure or table. Word count 
does not include Title Page or Unstructured Abstract.  
Letters to the Editors: Letters to the Editors should pertain to articles published within the 
Pediatric Infectious Disease Journal or highlight important new clinical or laboratory 
insights. Text should contain 500 words or fewer and less than 5 references.  
Financial disclosure: In the cover letter, indicate all affiliations with or financial involvement 
in any organization or entity with a direct financial interest in the subject matter or 
materials of the research discussed in the manuscript (e.g. employment, consultancies, 
stock ownership). All such information will be held in confidence during the review process. 
Should the manuscript be accepted, the Chief Editors will discuss with the author the extent 
of disclosure appropriate for publication.  
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After Acceptance  
Open access  
LWW’s hybrid open access option is offered to authors whose articles have been accepted 
for publication. With this choice, articles are made freely available online immediately upon 
publication. Authors may take advantage of the open access option at the point of 
acceptance to ensure that this choice has no influence on the peer review and acceptance 
process. These articles are subject to the journal’s standard peer-review process and will be 
accepted or rejected based on their own merit.  
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for The Pediatric Infectious Disease Journal is 
$3,000. The article processing charge for authors funded by the Research Councils UK 
(RCUK) is $3,800. The publication fee is charged on acceptance of the article and should be 
paid within 30 days by credit card by the author, funding agency or institution. Payment 
must be received in full for the article to be published open access.  
Authors retain copyright: Authors retain their copyright for all articles they opt to publish 
open access. Authors grant LWW a license to publish the article and identify itself as the 
original publisher.  
Creative Commons license: Articles opting for open access will be freely available to read, 
download and share from the time of publication. Articles are published under the terms of 
the Creative Commons License Attribution-NonCommerical No Derivative 3.0 which allows 
readers to disseminate and reuse the article, as well as share and reuse of the scientific 
material. It does not permit commercial exploitation or the creation of derivative works 
without specific permission. To view a copy of this license visit: 
http://creativecommons.org/licenses/by-nc-nd/3.0.  
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Compliance with NIH, RCUK and other research funding agency accessibility requirements: 
A number of research funding agencies now require or request authors to submit the post-
print (the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
identifies to the National Library of Medicine (NLM) articles that require deposit and 
transmits the post-print of an article based on research funded in whole or in part by the 
National Institutes of Health, Howard Hughes Medical Institute, or other funding agencies 
to PubMed Central. The revised Copyright Transfer Agreement provides the mechanism. 
LWW ensures that authors can fully comply with the public access requirements of major 
funding bodies worldwide. Additionally, all authors who choose the open access option will 
have their final published article deposited into PubMed Central.  
RCUK funded authors can choose to publish their paper as open access with the payment of 
an article process charge, or opt for their accepted manuscript to be deposited (green 
route) into PMC with an embargo.  
With both the gold and green open access options, the author will continue to sign the 
Copyright Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that 
the author is fully compliant with the requirements. After signature of the CTA, the author 
will then sign a License to Publish where they will then own the copyright.  
It is the responsibility of the author to inform the Editorial Office and/or LWW that they 
have RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the 
author has not completed the proper forms.  
FAQ for open access: http://links.lww.com/LWW-ES/A48  
Page proofs and corrections: Corresponding authors receive page proofs to check the 
copyedited and typeset article before publication. Portable document format (PDF) files of 
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the typeset pages and support documents (e.g., reprint order form) are sent to the 
corresponding author by E-mail. Complete instructions are provided with the E-mail for 
downloading and printing the files and for faxing the corrected page proofs to the 
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Appendix G: Supplementary tables and figures for journal ready manuscript 
Supplementary Table 1: Estimates from Survival Analysis (including imputed data and complete case analysis) for the outcome of mortality 
Survival Analysis Estimates for outcome of mortality: Cox Regression stratified by cohort n=4945 
  
  
Imputed Data Complete Data 
Univariate Multivariate* Model Selection ¥ Univariate Multivariate* 
Variable HR P value 95% CI HR P value 95% CI HR 95% CI VI HR P value 95% CI HR P value 95% CI 
Female gender 0.97 0.716 0.83-1.14  - - - - - 0.31 0.97 0.716 0.82-1.14 - - - 
Age at Initiation 
0-3 months reference reference reference reference reference 
3-6 months 0.90 0.417 0.71-1.15 0.87 0.268 0.68-1.11 - - 0.22 0.90 0.417 0.71-1.15 0.92 0.619 0.66-1.29 
6-12 months 0.98 0.898 0.78-1.25 0.84 0.161 0.66-1.07 - - - 0.98 0.898 0.78-1.25 0.82 0.268 0.57-1.17 
Severe Immune suppression (WHO 2006) 2.51 0.000 1.66-3.79 2.19 0.000 1.44-3.33 2.15 1.42-3.27 1 2.61 0.000 1.73-3.95 2.13 0.002 1.33-3.40 
WHO stage 3 or 4 1.89 0.000 1.47-2.45 1.36 0.023 1.04-1.78 1.35 1.04-1.77 0.87 1.91 0.000 1.49-2.44 1.39 0.040 1.02-1.90 
Severe Anaemia (DAIDS 2009) 1.57 0.003 1.18-2.10 1.34 0.062 0.98-1.82 1.29 0.82-2.05 0.79 1.56 0.003 1.17-2.10 1.37 0.070 0.97-1.92 
Weight-for-Age  
(Z-score) 
> -2 reference reference reference reference reference 
-2 to -3 1.40 0.015 1.07-1.84 1.29 0.063 0.99-1.71 1.29 0.99-1.71 1 1.46 0.009 1.09-1.93 1.68 0.003 1.19-2.36 
< -3 2.55 0.000 2.04-3.19 2.23 0.000 1.78-2.80 2.22 1.78-2.79 - 2.55 0.000 2.06-3.15 2.44 0.000 1.85-3.22 
ART Initiated 2010 and after 0.65 0.000 0.52-0.83 0.75 0.015 0.59-0.94 0.75 0.59-0.95 0.88 0.65 0.000 0.52-0.83 0.80 0.161 0.59-1.09 
*Adjusted for age, weight-for-age category, severe immunosuppression,  WHO stage 3 or 4, severe anaemia and initiation in 2010 and after  
¥ Using AIC and Variable Importance (VI) 
      
  
HR: Hazard Ratio 
      
  
CI: Confidence Interval 
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Supplementary Table 2: Estimates from Survival Analysis (including imputed data and complete case analysis) for the outcomes of mortality in a 
subset of infants from South African sites including analysis of the associations of baseline viral load category therewith. 
Survival Analysis looking at South African sites and the association of viral load with mortality:  Cox Regression stratified by site n=3473 
 
  
  
Imputed Data Complete Data 
Univariate Multivariate* Model Selection¥ Univariate Multivariate* 
Variable HR P value 95% CI HR P value 95% CI HR 95% CI VI HR P value 95% CI HR P value 95% CI 
Female gender 1.01 0.912 0.82-1.24 - - - - - 0.3 1.01 0.912 0.82-1.24 - -- - 
Age at Initiation 
0-3 months reference reference reference reference reference 
3-6 months 0.83 0.192 0.63-1.09 0.75 0.042 0.57-0.99 0.79 0.52-1.19 0.53 0.83 0.192 0.63-1.09 0.77 0.204 0.51-1.15 
6-12 months 0.87 0.341 0.66-1.15 0.76 0.059 0.57-1.01 0.80 0.54-1.20 - 0.87 0.341 0.66-1.15 0.80 0.353 0.51-1.27 
Severe Immune suppression (WHO 2006) 2.63 0.003 1.41-4.91 2.28 0.013 1.21-4.29 2.17 1.07-4.40 0.97 2.62 0.000 1.53-4.49 2.02 0.059 0.97-4.19 
WHO stage 3 or 4 1.98 0.002 1.28-3.06 1.46 0.101 0.93-2.31 1.48 0.94-2.31 0.69 2.09 0.001 1.33-3.27 1.72 0.126 0.86-3.47 
Severe Anaemia (DAIDS 2009) 1.43 0.099 0.93-2.21 1.34 0.188 0.86-2.07 1.18 0.60-2.32 0.60 1.44 0.078 0.96-2.18 1.69 0.036 1.03-2.75 
Viral Load ≥ 1 million copies/ml 1.30 0.045 1.01-1.68 1.17 0.267 0.88-1.56 1.14 0.79-1.62 0.56 1.37 0.019 1.05-1.79 1.39 0.068 0.98-1.98 
Weight-for-Age  
(Z-score) 
> -2 reference reference reference reference reference 
-2 to -3 1.10 0.665 0.69-1.75 1.01 0.956 0.64-1.59 1.02 0.64-1.61 1 1.14 0.542 0.75-1.72 0.93 0.788 0.53-1.62 
< -3 2.28 0.000 1.66-3.13 1.97 0.000 1.43-2.73 1.99 1.44-2.75 - 2.32 0.000 1.71-3.15 1.72 0.012 1.13-2.62 
ART Initiated 2010 and after 0.47 0.000 0.32-0.67 0.51 0.000 0.35-0.74 0.51 0.35-0.74 1 0.47 0.000 0.32-0.67 0.57 0.08 0.30-1.07 
*Adjusted for age, weight-for-age z-score category, severe immunosuppression,  WHO stage 3 or 4, severe anaemia, viral load category and initiation in 2010 and after   
¥ Using AIC and Variable Importance (VI)  
HR: Hazard Ratio, CI: Confidence Interval  
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Supplementary Table 3: Estimates from Survival Analysis (including imputed and complete case analysis) for the outcomes of virological 
suppression in a subset of infants from South African sites with a minimum of a baseline and one other virological measure 
Survival Analysis looking at South African sites and the association of viral load with time to virological suppression:  Cox Regression stratified by site n=1364 
  
  
  
Imputed Data  Complete Data 
Univariate Multivariate* Univariate Multivariate* 
Variable HR P value 95% CI HR P value 95% CI HR P value 95% CI HR P value 95% CI 
Female gender 1.01 0.877 0.88-1.15 - - - 1.01 0.880 0.88-1.15 - - - 
Age at Initiation 
0-3 months reference reference reference reference 
3-6 months 0.82 0.053 0.67-1.02 0.87 0.165 0.71-1.06 0.82 0.053 0.67-1.00 0.83 0.150 0.64-1.07 
6-12 months 0.87 0.170 0.71-1.06 0.91 0.382 0.75-1.12 0.87 0.170 0.71-1.06 0.89 0.418 0.68-1.18 
Severe Immune suppression (WHO 2006) 0.88 0.236 0.72-1.08 0.97 0.793 0.79-1.19 0.88 0.214 0.72-1.08 0.99 0.976 0.76-1.30 
WHO stage 3 or 4 0.78 0.011 0.64-0.94 0.84 0.105 0.69-1.04 0.77 0.013 0.63-0.95 0.71 0.010 00.55-0.92 
Severe Anaemia (DAIDS 2009) 1.14 0.384 0.84-1.56 1.17 0.312 0.86-1.59 1.21 0.205 0.90-1.62 1.07 0.689 0.76-1.51 
Viral Load ≥ 1 million copies/ml 0.76 0.000 0.67-0.87 0.78 0.001 0.68-0.89 0.76 0.000 0.67-0.87 0.81 0.025 0.67-0.97 
Weight-for-Age  
(Z-score) 
> -2 reference reference reference reference 
-2 to -3 0.85 0.126 0.69-1.05 0.88 0.233 0.71-1.09 0.94 0.611 0.74-1.19 1.01 0.956 0.73-1.39 
< -3 0.85 0.067 0.72-1.01 0.90 0.283 0.75-1.09 0.87 0.133 0.72-1.04 0.86 0.232 0.66-1.10 
ART Initiated 2010 and after 1.23 0.044 1.01-1.49 1.16 0.167 0.94-1.42 1.23 0.044 1.01-1.49 1.09 0.483 0.84-1.43 
*Adjusted for age, weight-for-age z-score category, severe immunosuppression,  WHO stage 3 or 4, severe anaemia, viral load category and initiation in 2010 and after   
HR: Hazard Ratio  
CI: Confidence Interval  
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